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Angiogenesis, i.e., sprouting from pre-existent vasculature, 
contributes to the growth of atherosclerotic plaques and solid 
tumors by providing conduits for transport of nutrients and oxygen. 
Advanced atherosclerotic plaques are characterized by an extensive 
network of microvessels mostly originating from the vasa vasorum 
that reside within the arterial wall,1 whereas solid tumors are 
provided with an internal and peripheral microvascular network.2 
Methods for visualization and quantification of neo-vasculature 
and angiogenic activity would provide insight in the development 
of these pathologies and could potentially be an entrance point 
for therapy. In this thesis, two-photon laser scanning microscopy 
(TPLSM) and magnetic resonance imaging (MRI) were utilized to 
visualize and quantify neo-vascular morphology and angiogenic 
activity in mouse models of atherosclerosis and cancer.
Demarcation of microvasculature from surrounding tissue may 
be achieved by contrast agents that track with blood plasma3,4 or 
interact with the microvascular endothelium.5 Both allow assessment 
of microvessel diameter, length, and density. Under conditions 
of for instance angiogenesis, the endothelium reacts to blood-
borne mechanical and chemical stimuli by expressing biologically 
functional epitopes.6-8 These epitopes may be specifically targeted by 
contrast agents for molecular imaging of angiogenic activity5,9 or other 
functional expressions of endothelial cells. Bi-modal contrast agents 
offer the ability to visualize neo-vasculature with two complementary 
imaging modalities, e.g., TPLSM and MRI.5,10 TPLSM offers a high 
spatial resolution within a limited sampling volume; MRI allows 
whole-body imaging with limited spatial resolution.
Atherosclerosis is a chronic inflammatory disease of the large 
arteries, characterized by the accumulation of inflammatory cells 
and lipids in the vascular wall.11 In The Netherlands, cardiovascular 
complications, including myocardial infarction and stroke, 
contributed to about 31% of overall mortality in 2007, a number that 
has decreased from 46% over the preceding 12 years (www.cbs.nl). 
Atherosclerotic lesions develop from initial fatty streaks to complex 
structures with high inflammatory content, intraplaque hemorrhage, 
and a thin fibrous cap.12-14 Plaque progression is accompanied by an 
increase in vasa vasorum density1 and the formation of intraplaque 
microvasculature.15 These features are believed to affect plaque 
stability,16 thereby rendering the plaque prone to rupture and 
thromboembolic complications.17 
Cancer can be defined as the uncontrolled growth, invasion or 
metastasis of a group of cells.18 In 2007, cancer accounted for about 
31% of all deaths in The Netherlands and has recently overtaken 
cardiovascular disease as primary cause of death (www.cbs.nl). 
Solid tumors require a microvascular network to provide the highly 
proliferative cancer cells with nutrients and oxygen and remove 
waste products and metabolites. The rate at which local microvessel 
density increases is a prognostic indicator of malignancy in 
various, but not all, tumor types and is the rate-limiting step in solid 
tumor growth.19-21 Tumor microvasculature is highly tortuous and 
morphologically heterogeneous.22
TPLSM is a fluorescence technique that allows optical sectioning 
of intact biological tissue to a depth of up to several hundreds of 
micrometers.23 It offers several advantages over histological tissue 
characterization, including preservation of tissue integrity during 
preparation.24 However, tissue sampling volumes are relatively 
small (< 1 mm3) and in vivo measurements suffer from artifacts due 
to cardiac and respiratory movement. Hence, TPLSM measurements 
have been predominantly performed ex vivo.25 The three-dimensional 
sub-micrometer resolution ensures visualization of sub-cellular 
events, e.g., interaction between fluorophore-conjugated ligands 
and biological epitopes,10 and allows unprecedented visualization 
and quantification of microvascular morphology.26
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MRI is a non-invasive imaging modality that allows functional 
and anatomical characterization of live organisms. Endogenous 
contrast enables discrimination between pathological and healthy 
soft tissue, while contrast may be increased by high-relaxivity 
exogenous contrast agents.27 The sub-millimeter spatial resolution 
of MRI precludes visualization of individual microvessels with 
diameters smaller than 200 μm. However, MRI enables localization 
and quantification of effects of contrast agents. This allows 
assessment of measures for microvessel density, dimensions, 
and flow, which may serve as surrogate markers for detecting 
angiogenesis. In addition, targeted contrast agents allow molecular 
imaging of angiogenic activity.28 Validation of MRI results requires 
higher resolution imaging techniques.29
As introductory chapter to the experimental sections, chapter 
2 provides an overview on the role of microvasculature in athero- 
and carcinogenesis. In addition, various MRI and TPLSM methods 
are presented that are used to visualize and quantify neo-vascular 
characteristics and angiogenic activity.
Chapter 3 provides a review of five recently developed contrast-
enhancing nanoparticles and targeting ligands for optical and potentially 
bi-modal molecular imaging of atherosclerosis. One particular 
nanoparticle, the quantum dot, has been used to detect angiogenic activity 
in plaque vasa vasorum and tumor vasculature, as presented in chapter 
4 and 6, respectively. In addition, several endoscope-compatible optical 
techniques are discussed that would allow intravascular observation of 
cardiovascular disease in the clinical setting. 
In chapter 4, a feasibility study is presented in which TPLSM 
was used to visualize vasa vasorum microvessels in intact 
atherosclerotic murine arteries. Moreover, it is shown that these 
microvessels display (inhomogeneous) angiogenic activity.
Tumor microvessel density may serve as an indicator of 
malignant potential of several tumors and of their propensity to 
metastasize.30 Image processing was applied to three-dimensional 
TPLSM datasets to quantify microvessel radius, density, and length 
of microvasculature. In chapter 5 this quantification method was 
applied to evaluate in vivo magnetic resonance vessel size imaging 
(MR-VSI) in determining the fractional blood volume and an index 
of microvessel radius of murine tumors and muscle tissue. 
Whereas in chapter 5 morphological characteristics of tumor 
microvasculature were quantified with MR-VSI and TPLSM, in 
chapter 6 tumor angiogenic activity was visualized with in vivo 
MRI and ex vivo TPLSM. To enable bimodal imaging, a targeted 
contrast agent was developed with combined paramagnetic and 
luminescent properties.
The general discussion in chapter 7 provides a critical evaluation 
of the results presented in the data chapters. In addition, future 
perspectives of TPLSM are discussed.
General introduction
13
References
1. Barger AC, Beeuwkes R, 3rd, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and 
neovascularization of human coronary arteries. A possible role in the pathophysiology 
of atherosclerosis. N Engl J Med 1984;310:175-7.
2. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for 
anti-angiogenesis and normalization. Microvasc Res 2007;74:72-84.
3. Neimatallah MA, Ho VB, Dong Q, et al. Gadolinium-enhanced 3D magnetic resonance 
angiography of the thoracic vessels. J Magn Reson Imaging 1999;10:758-70.
4. Leunig M, Yuan F, Menger MD, et al. Angiogenesis, microvascular architecture, 
microhemodynamics, and interstitial fluid pressure during early growth of human 
adenocarcinoma LS174T in SCID mice. Cancer Res 1992;52:6553-60.
5. Oostendorp M, Douma K, Hackeng TM, et al. Quantitative molecular magnetic 
resonance imaging of tumor angiogenesis using cNGR-labeled paramagnetic quantum 
dots. Cancer Res 2008;68:7676-83.
6. Gong N, Chatterjee S. Platelet endothelial cell adhesion molecule in cell signaling and 
thrombosis. Mol Cell Biochem 2003;253:151-8.
7. Mina-Osorio P, Winnicka B, O’Conor C, et al. CD13 is a novel mediator of monocytic/
endothelial cell adhesion. J Leukoc Biol 2008;84:448-59.
8. Muller WA. Leukocyte-endothelial-cell interactions in leukocyte transmigration and 
the inflammatory response. Trends Immunol 2003;24:327-34.
9. Mulder WJ, Strijkers GJ, Habets JW, et al. MR molecular imaging and fluorescence 
microscopy for identification of activated tumor endothelium using a bimodal lipidic 
nanoparticle. Faseb J 2005;19:2008-10.
10. Prinzen L, Miserus RJ, Dirksen A, et al. Optical and magnetic resonance imaging of 
cell death and platelet activation using annexin a5-functionalized quantum dots. Nano 
Lett 2007;7:93-100.
11. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 
2002;105:1135-43.
12. Stary HC, Blankenhorn DH, Chandler AB, et al. A definition of the intima of human 
arteries and of its atherosclerosis-prone regions. A report from the committee on vascular 
lesions of the council on arteriosclerosis, American Heart Association. Circulation 
1992;85:391-405.
13. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of 
atherosclerotic lesions and a histological classification of atherosclerosis. A report from 
the committee on vascular lesions of the council on arteriosclerosis, American Heart 
Association. Circulation 1995;92:1355-74.
14. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and 
intermediate lesions of atherosclerosis. A report from the committee on vascular lesions of 
the council on arteriosclerosis, American Heart Association. Circulation 1994;89:2462-78.
15. Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and 
vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler 
Thromb Vasc Biol 2005;25:2054-61.
16. Gössl M, Versari D, Mannheim D, Ritman EL, Lerman LO, Lerman A. Increased 
spatial vasa vasorum density in the proximal LAD in hypercholesterolemia--implications 
for vulnerable plaque-development. Atherosclerosis 2007;192:246-52.
17. Corti R, Hutter R, Badimon JJ, Fuster V. Evolving concepts in the triad of 
atherosclerosis, inflammation and thrombosis. J Thromb Thrombolysis 2004;17:35-44.
18. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
19. Canoglu A, Gogus C, Beduk Y, Orhan D, Tulunay O, Baltaci S. Microvessel density 
as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and 
prognosis. Int Urol Nephrol 2004;36:401-5.
20. Zheng H, Tsuneyama K, Cheng C, et al. Expression of KAI1 and tenascin, and 
microvessel density are closely correlated with liver metastasis of gastrointestinal 
adenocarcinoma. J Clin Pathol 2007;60:50-6.
21. Trivella M, Pezzella F, Pastorino U, Harris AL, Altman DG. Microvessel density as a 
prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient 
data. Lancet Oncol 2007;8:488-99.
22. Jockovich ME, Pina Y, Alegret A, Cebulla C, Feuer W, Murray TG. Heterogeneous 
tumor vasculature in retinoblastoma: implications for vessel targeting therapy. Retina 
2008;28:S81-6.
23. Diaspro A, Robello M. Two-photon excitation of fluorescence for three-dimensional 
optical imaging of biological structures. J Photochem Photobiol B 2000;55:1-8.
24. Dorph-Petersen KA, Nyengaard JR, Gundersen HJ. Tissue shrinkage and unbiased 
stereological estimation of particle number and size. J Microsc 2001;204:232-46.
25. Megens RT, Reitsma S, Schiffers PH, et al. Two-photon microscopy of vital murine 
elastic and muscular arteries. Combined structural and functional imaging with 
subcellular resolution. J Vasc Res 2007;44:87-98.
26. Padera TP, Stoll BR, So PT, Jain RK. Conventional and high-speed intravital 
multiphoton laser scanning microscopy of microvasculature, lymphatics, and leukocyte-
endothelial interactions. Mol Imaging 2002;1:9-15.
27. Mulder WJ, Strijkers GJ, Griffioen AW, et al. A liposomal system for contrast-enhanced 
magnetic resonance imaging of molecular targets. Bioconjug Chem 2004;15:799-806.
28. Barrett T, Brechbiel M, Bernardo M, Choyke PL. MRI of tumor angiogenesis. J Magn 
Reson Imaging 2007;26:235-49.
29. Troprès I, Lamalle L, Peoc’h M, et al. In vivo assessment of tumoral angiogenesis. 
Magn Reson Med 2004;51:533-41.
30. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: 
microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst 2002;94:883-93.

Chapter 2
Neo-vasculature in atherosclerosis and cancer: 
two-photon laser scanning microscopy 

Neo-vasculature in atherosclerosis and cancer: TPLSM
17
Neo-vasculature contributes to the growth of atherosclerotic plaques 
and tumors by providing oxygen and nutrients to the metabolically 
highly active inflammatory cells and tumor cells. In addition, 
neo-vasculature provides an additional conduit for inflammatory 
cells to enter the plaque core. In plaques, these inflammatory cells 
excrete matrix degrading enzymes, thereby causing mechanical 
destabilization of the plaque. Visualization and quantification of 
structural and functional vascular features, including vascular 
morphology and permeability, and of angiogenic activity of 
vascular endothelial cells (VECs) might therefore allow assessment 
of vulnerable plaque development. In tumors, the neo-vessels not 
only sustain growth but may at the same time facilitate cytostatic 
delivery to the tumor. Visualization of tumor angiogenesis may 
therefore guide anti-tumor therapy. In addition, the efficacy of anti-
angiogenic therapy may be monitored.
  
Neo-vascularization: focus on angiogenesis
  
Vascular growth can occur via vasculogenesis (de novo formation of 
vasculature), angiogenesis (sprouting from pre-existing vasculature), 
and arteriogenesis (collateral growth).1 This thesis concentrates 
on angiogenesis, since it is the most common way by which neo-
vascularization occurs in pathological tissues. Angiogenesis is 
involved in physiological processes including embryogenesis and 
wound healing as well as in pathological conditions such as ischemic 
heart disease, cancer, diabetic retinopathy, and chronic inflammation 
including atherosclerosis.2 The angiogenic cascade roughly involves 
four distinct processes: formation, maturation, remodeling, and 
specialization.1 In the formation stage, the angiogenic cascade may 
be initiated by hypoxia,3 metabolic4 and mechanical stress,5 immune-
inflammatory reactions,6,7 and genetic mutations,8 which disrupt the 
finely tuned balance between expression and activity of pro- and 
anti-angiogenic factors. Upon initiation, vascular endothelial growth 
factor (VEGF) and nitric oxide (NO) cause dilation and increased 
permeability of the existing vasculature, after which proteolytic 
enzymes, e.g., matrix metalloproteinases (MMPs), ensure migration 
of VECs that eventually align into immature tubes under control 
of pro-angiogenic growth factors.9-11 During maturation, attraction 
of pericytes12 and the generation of a basal membrane stabilize the 
hyperpermeable endothelial sprouts. Subsequent remodeling of the 
matured vascular network is governed by survival and apoptosis 
of VECs and pericytes, thereby regulating vascular expansion and 
regression. The functionality of the neo-vasculature depends on the 
specialization stage, involving arterio-venous differentiation.13 
The hypoxia inducible factor (HIF) is considered the main 
initiator of the angiogenic cascade and has been correlated to 
neo-vasculature in both atherosclerotic plaques7 and various 
tumor types.14,15 HIF is composed of subunits HIF-1α/2α and HIF-
1β, which are oxygen-dependent and constitutively expressed, 
respectively. The activity and stability of HIF-1α/2α is controlled by 
numerous factors, including factor inhibiting HIF-1α/2α (FIH),16 the 
macrophage-derived peptide PR39,17 and the p53 tumor suppressor 
gene.18 Under normoxic conditions HIF-1α/2α is targeted for 
proteosomal degradation,19,20 causing a half-life of less than 5 
minutes. Under hypoxic conditions, however, HIF-1α/2α dimerizes 
with HIF-1β to form HIF that functions as a transcription factor 
for hypoxia responsive genes that are involved in angiogenesis, 
cell proliferation and survival, and glucose and iron metabolism.21 
These include VEGF and its receptor flt-1, platelet-derived growth 
factor-A/B (PDGF-A/B) and its receptor PDGFR-α/β, interleukin-1 
(IL-1), tissue necrotic factor-α (TNF-α), tissue growth factor-β 
(TGF-β), Ang-1 and -2 and its vascular endothelial receptor Tie-2, 
glucose transporters 1 and 3 (GLUT1/3), and endothelial nitric oxide 
synthase (eNOS).22-24 In addition, HIF-1α expression may be induced 
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by non-hypoxic stimuli, including inflammation.25,26 The exact role 
of reactive oxygen species (ROS) in neo-vascularization is currently 
unknown since they were shown to induce both angiogenic27 and 
anti-angiogenic effects in vivo.28
  
Atherosclerosis and angiogenesis
  
Atherogenesis
Atherosclerosis is well-accepted as a chronic inflammatory 
disease of large arteries that is characterized by accumulation of 
inflammatory cells and lipids in the vascular tree.29 Development of 
atherosclerotic lesions occurs at predisposed sites in the vasculature 
that are characterized by low and oscillatory endothelial shear 
stress.30,31 Early human atherosclerotic lesions (AHA type I) are 
characterized by endothelial activation, i.e., endothelial expression 
of intercellular (ICAM), vascular (VCAM), and platelet endothelial 
(PECAM) cell adhesion molecules, and the lectin-like oxidized 
low-density lipoprotein (oxLDL) receptor LOX-1. Supposedly, 
disruption of the endothelial glycocalyx increases the extravasation 
of macromolecular structures, e.g., LDL and proteins, to the 
subendothelial space.32 Upon accumulation of inflammatory cells 
and intracellular lipids, an inflammatory response is initiated, 
thereby increasing the expression of adhesion molecules to attract 
increased amounts of inflammatory cells and lipids (AHA type 
II). AHA type III lesions are characterized by small extracellular 
lipid pools, apoptotic cells, and MMP activity. Due to continued 
apoptosis of lipid-laden macrophages, a necrotic core develops in 
AHA type IV lesions. Moreover, these lesions are characterized 
by intraplaque microvasculature that predominantly originates 
from the vasa vasorum (VV), a plexus of adventitial microvessels 
that continues to expand with plaque growth. AHA type V lesions 
are termed fibroatheroma’s since these lesions are characterized 
by a subendothelial fibrotic cap formed by deposition of collagen 
by SMCs. Complicated AHA type VI lesions develop when 
surface defects arise due to ongoing inflammation and apoptosis 
and thinning of the fibrous cap by MMPs. These defects initiate 
haematoma’s, plaque instability, and potentially plaque rupture, 
leading to thrombus formation and embolization.
Plaque growth and rupture: contribution of vasa vasorum 
(VV) and intraplaque microvasculature
The contribution of hypoxia and/or inflammation, which both 
may initiate the angiogenic cascade, to plaque neo-vascularization 
appears to vary between species. In mouse, rabbit, and human 
atherosclerotic lesions, hypoxia has been observed and correlated 
with the presence of inflammatory cells in the plaque.7,33,34 However, 
in mouse and rabbit a causative relation between hypoxia and neo-
vascularization has not been established. In contrast, in human 
atherosclerotic plaques, the expression of HIF and VEGF colocalized 
with the presence of hypoxia7 and neo-vasculature.35 These findings 
indicate that both inflammation and hypoxia may be involved in 
human plaque neo-vascularization.
Both the VV and intraplaque neo-vasculature are believed 
to contribute to the development of (vulnerable) atherosclerotic 
lesions by providing additional conduits for nutrients, oxygen, 
and inflammatory cells to enter the plaque.36,37 The vast majority 
of intraplaque neo-vasculature originates from the vasa vasorum, 
whereas the remainder is derived from the lumen of the affected blood 
vessel.38 In pigs, which show great similarity to humans considering 
vasculature, a great variation in VV density is present among 
various vascular beds.39 This observation may explain the variable 
propensity of atherogenesis in vascular beds, i.e., the local VV 
density determines the predilection sites for atherosclerotic plaque 
development. It has been established that VV density correlates with 
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plaque progression and several studies suggest a role for VV neo-
vascularization in the initial stage of atherogenesis in the coronary 
vascular bed of pigs.40,41 However, in carotid arteries of rodents, 
Khurana et al. identified that the initiation of plaque formation 
is independent of VV neo-vascularization.42 These seemingly 
contradicting observations between pig and mouse arteries suggest 
that vessel wall dimensions influence the contribution of VV neo-
vascularization to the initiation of atherogenesis. This hypothesis 
requires experimental validation.
Intraplaque neo-vasculature is characterized by a paucity of tight 
junctions, a discontinuous basal membrane, and a lack in smooth 
muscle cells, indicating that these microvessels have not passed 
the maturation phase of the angiogenic cascade.43,44 Considering 
the fragility and permeability of these neo-vessels and the effect 
of intramural pressure on neo-vascular perfusion, intraplaque 
hemorrhage and/or ischemia-induced infarction may easily be 
initiated. In addition, the process of neo-vascularization itself, 
which involves proteolytic activity,45 may affect the mechanical 
stability of the plaque. Moreover, plaque neo-vasculature provides 
a vascular network for infiltration of inflammatory cells,46,47 which 
have been associated with the presence of proteolytic enzymes in 
atheromatous plaques.48 These observations favor the destabilizing 
effect of neo-vasculature in atherosclerotic plaques.49,50
Animal models of atherosclerosis and plaque rupture
Due to the limited availability of non-invasive detection methods for 
(longitudinal) characterization of human lesions, mechanistic studies 
on the initiation, progression, and rupture of atherosclerotic lesions 
have been predominantly performed in (hypercholesterolemic) 
animals, including mice, rats, and rabbits.51-55 In atherosclerosis 
research, predominantly mouse models are being used. This is based 
on the great diversity in available inbred strains and the ability of 
genetic modifications to over- or under-express specific genes 
involved in atherogenesis. 
In the majority of genetically modified mice, lipid metabolism 
has been altered to induce hypercholesterolemia, one of the main 
initiators of atherosclerotic plaque formation. Both apolipoprotein-E 
(ApoE-/-) and LDL receptor (LDLR-/-) knockout mice exhibit 
accelerated lesion formation.56-58 Of these, ApoE-/- mice have 
higher total plasma cholesterol levels and develop more extensive 
atherosclerotic lesions.59 High fat diets exacerbate lesion formation 
in both mice types. In addition, mice deficient in both ApoE and 
LDLR (ApoE-/-/LDLR-/- double knockout mice) display similar 
cholesterol levels as ApoE-/- mice.60 However, the progression 
of atherosclerotic lesions is usually more marked.61 In addition, 
ApoE-/- mice deficient in high density lipoprotein (HDL) receptor 
scavenger receptor class B, type I (SRBI) or endothelial nitric oxide 
synthase (eNOS) develop occlusive coronary artery disease62 and 
peripheral coronary atherosclerosis,63 respectively. The cellular 
composition and development of atherosclerotic lesions in these 
mice resemble those found in humans. Whereas highly developed 
human atherosclerotic lesions are associated with plaque rupture, 
spontaneous rupture of murine lesions is limited. However, 
intraplaque hemorrhage64,65 and plaque rupture66-69 have been 
frequently observed in the brachiocephalic artery of ApoE-/- mice. 
Therefore, this artery is proposed as the preferred site for future 
systemic intervention studies.70 Nevertheless, the physiological and 
clinical relevance of the presented animal models is under debate 
due to the lack in typical human features such hemorrhagic lesions 
and thromboembolic complications.71
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Cancer and angiogenesis
  
Carcinogenesis
Cancer is considered a complex, dynamic disease with high genetic 
heterogeneity: more than 100 distinct types of human cancer have 
been distinguished and various tumor subtypes can be found within 
specific organs.72,73 Carcinogenesis is initiated by oncogenesis, i.e., 
the process by which a normal cell is rendered malignant due to the 
accumulation of genetic mutations, as well as epigenetic changes 
that activate pro-oncogenes or downregulate tumor-suppressor genes 
and lead to uncontrolled cellular division. Mutations of about 300 
human genes have been causally associated with oncogenesis. This 
accounts for more than 1% of the human genome.74 In addition to 
heritable changes in the phenotype, carcinogenesis may be initiated 
by food contaminants and oxidative stress.75,76 
Despite the high genetic heterogeneity, most tumors share the 
following characteristics.72 Self-sufficiency in growth factors and 
receptors creates a positive feedback in proliferation thereby causing 
partial independency on host tissue. Disruption of the tumor suppressor 
proteins retinoblastoma (Rb) and p53 renders cells insensitive to 
anti-growth factors and apoptosis, respectively. Maintenance of 
telomere-length in malignant cells above critical threshold allows 
limitless replication. Growth of tumors beyond diffusion limits (100 
μm) initiates local hypoxia and subsequent sustained angiogenesis. 
Tissue invasion and metastasis are correlated with the expression 
of cellular adhesion molecules, which allow intercellular or cell-
environment interactions, and of MMPs, which proteolytically 
degrade the basal membrane. However, due to extensive control of 
DNA replication at multiple levels, several cooperating oncogenes 
need to be expressed in order for human cells to become malignant.77 
Taken together, these characteristics allow extensive expansion of 
the tumor mass, provided that tumor cells are supplied with oxygen 
and nutrients to cope with their increased metabolic demands.
  
Tumor growth: contribution of microvasculature 
Small tumors (less than 1 mm in diameter) are generally avascular and 
are characterized by extensive hypoxia. Several studies have shown 
the presence of hypoxic areas78,79 and HIF-180 in tumors, dedicating 
hypoxia as a primary physiological initiator of angiogenesis by which 
tumors become vascularized and grow beyond the diffusion limits of 
oxygen. The hypoxic stress in tumors of more than 2 mm in diameter 
is significant to initiate production of pro-angiogenic growth factors 
and trigger neo-vascularization.81,82 Persistent hypoxia in perinecrotic 
regions and intrinsic expression of growth factors by tumor cells in larger 
tumors (more than 5 mm in diameter) ensure permanent angiogenic 
activity and expansion of the microvascular network. Angiogenesis 
has been shown to strongly contribute to tumor growth and metastasis 
in a wide array of tumors, including lung cancer, gastric cancer, 
prostate cancer, neuroblastoma, breast cancer, and colon cancer.83-88 
Several anti-angiogenic therapies have therefore been developed 
to inhibit angiogenesis or to impair existent microvasculature in 
experimental tumors and to attenuate tumor growth and metastasis.89-91 
Normalization of angiogenic tumor microvasculature reduces 
angiogenesis, thereby inhibiting tumor growth and potentially 
therapeutic efficacy.92,93 In addition, microvessel density (MVD) has 
been recognized as a prognostic indicator for various tumor types94 
and correlates with the extent of hematological dissemination of tumor 
cells leading to metastasis, e.g., in melanoma.95 However, tumor MVD 
cannot be directly used as indicator for the efficacy of anti-angiogenic 
therapy due to the interdependence of tumor cell proliferation and 
microvascular expansion.94
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Murine models of solid tumor growth
Rodents with genetically induced immune deficiencies, including 
Swissnu/nu and severe combined immunodeficient (SCID) mice, have 
been used extensively for their reduced ability to reject transplanted 
human tumor cells.96,97 Tumor growth in rodents may be induced by 
intravenous,98 left ventricular,99 intraplenic,100 and intraperitoneal82 
injection of human tumor cells to yield tumors in the lung, bone, liver, 
and peritoneum, respectively. However, with respect to visualization 
of tumor microvasculature, subcutaneously induced tumors offer 
several advantages: (1) because tissue-invasion is limited, neo-
vasculature in implanted tumors can be clearly discriminated from 
pre-existing vasculature of surrounding tissue; (2) in vivo imaging of 
subcutaneous tumors in the flank of the mouse is not obstructed by 
cardiac, respiratory, and/or peristaltic movements; (3) subcutaneous 
tumors are close to the surface and, hence, can be visualized with 
imaging modalities with limited penetration depth; and (4) a minimally 
invasive procedure is required for implantation of tumor cells.
  
Animal experiments in this thesis
  
In this thesis, ApoE-/- mice, fed a Western type diet, and Swissnu/nu mice, 
subcutaneously injected with human colorectal adenocarcinoma 
cells, were used as animal models for atherosclerosis and cancer, 
respectively. Using ApoE-/- mice and two-photon laser scanning 
microscopy (TPLSM), we developed a method to visualize 
(angiogenic activity of) the vasa vasorum in intact aortic segments 
in order to determine the feasibility of this method for future 
(in vivo) experiments. In the tumor-bearing mice, we performed 
in vivo MRI to visualize and quantify angiogenic activity and 
vascular morphology, i.e., measures for vessel size radius and 
fractional blood volume. Subsequent ex vivo TPLSM was used to 
evaluate the angiogenic activity as assessed by MRI. Dedicated 
image processing was performed on the obtained TPLSM data, in 
order to yield quantitative measures for the microvessel radius, 
fractional vessel volume, microvessel length, and the number of 
branching points to determine the degree of branching.
  
Techniques for visualizing neo-vasculature
  
Morphology, permeability, and angiogenic activity
Neo-vasculature has distinct features that differentiate it from pre- 
existing microvessels. Intraplaque and tumor neo-vasculature consists 
of tortuous microvessels with a high heterogeneity in diameter. The 
morphology deviates from the strongly organized microvasculature 
in, for example, muscle tissue. Clinical imaging modalities, including 
X-ray radiography and micro-computed tomography (μCT), have been 
applied to directly visualize and quantify microvascular morphology in 
animals.101,102 Currently, these methods require excision and processing 
of the tissue of interest and lack the ability to visualize vessels of 
less than 20 μm in diameter. Similarly, the resolution of MRI does 
not allow direct visualization of individual microvessels. However, 
an in vivo MRI-based method, i.e., magnetic resonance vessel size 
imaging (MR-VSI),103,104 has been developed that yields values 
related to microvessel density and radius. Studies have shown that 
MR-VSI displays a systematic overestimation of these morphological 
measures with a large variation between the different studies (see 
table 3 of Chapter 5 and references within). The large variation may 
be attributed to differences in experimental setup and data analysis. 
The resulting non-physiological values can therefore not be used for 
absolute quantification. Nevertheless, with MR-VSI the angiogenic 
rim of tumors may be discriminated from the less vascularized core. 
Therefore, MR-VSI may allow assessment of the spatial distribution 
of the microvessel density and radius on a voxel-by-voxel basis. 
This method is insensitive to vessel orientation and displays the 
Figure 1 Molecular imaging of angiogenic endothelial cells lining the 
vessel wall. The angiogenesis marker CD13, expressed by vascular 
endothelial cells (VECs), is targeted via the blood flow by a contrast agent 
bound to the CD13 ligand cyclic NGR (cNGR).
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average microvessel density and radius per voxel (voxel volume of 
approximately 0.1 μm3). Using optical techniques, morphologic 
parameters such as fractional blood volume, microvessel radius, and 
microvessel orientation, may be quantified with a sub-micrometer 
resolution, although these techniques are confined to superficial 
observations due to the limited tissue penetration depth of light.105-107
The increased endothelial permeability of neo-vasculature offers 
an additional opportunity for visualization. In that case, intravascular 
contrast agents are able to move out of the vessel compartment into 
the interstitial space surrounding the neo-vasculature. Quantification 
of the extravasation rate provides a measure for the endothelial 
permeability and, hence, angiogenic activity and may be assessed 
with MRI,108 ultrasound,109 and optical techniques.110
The endothelium of neo-vasculature displays angiogenic 
activity, i.e., (over-) expresses biologically functional epitopes. The 
most widely used epitopes for molecular imaging of angiogenesis 
are the α
ν
β
3
 integrin and the aminopeptidase CD13 (Figure 1). The 
α
ν
β
3
 integrin has been successfully targeted with RGD-conjugated 
contrast agents for MRI of angiogenic activity in atherosclerosis 
and cancer.111-113 Mulder et al. developed bi-modal liposomes 
to visualize angiogenic endothelial cells with in vivo MRI and 
subsequent ex vivo fluorescence microscopy.111 In addition, Cai et al. 
employed whole-body in vivo optical imaging to assess angiogenic 
in subcutaneous tumors.114 The ligand for CD13, NGR, was initially 
used for targeted therapy of anti-cancer drugs115 and later for optical 
molecular imaging of angiogenic activity in tumors116 and after 
myocardial infarction.117 The tripeptide NGR has not been used for 
molecular imaging of angiogenesis in atherosclerosis.
  
Two-photon laser scanning microscopy (TPLSM) of 
neo-vasculature and angiogenesis
  
Basic principles of two-photon laser scanning microscopy
In 1990, Denk et al. described TPLSM,118 an optical technique with 
three-dimensional resolution. The main physical principle of TPLSM 
was predicted by Maria Göppert-Mayer in 1929 and involves the 
near-simultaneous (within 10-18 s) absorption of two near-infrared 
(NIR) photons (wavelength about 800 nm) by a fluorophore to reach 
the excited state (Figure 2).119  In contrast, in single-photon excited 
fluorescence microscopy the excited state is reached by absorption 
of a single photon (wavelength: 350 - 650 nm). 
In general, the efficiency of two-photon excitation is low. There-
fore, high intensity lasers and high numerical aperture (NA) objective 
lenses are required to ensure spatiotemporal overlap of ample NIR 
Figure 2 A) Jablonksi diagram. For simplicity, the vibrational transitions 
have been omitted. Electron (O) transitions during single- and two-photon 
excitation (left and right panel, respectively) and subsequent fluorescence 
emission. B) In single-photon excitation fluorescence occurs within the 
whole cone of illumination and contributes to the image (left panel); in 
two-photon excitation fluorescence is restricted to the focal zone and 
detected light originates from the focal plane only (right panel).
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photons and cause excitation. Continuous wave lasers are not suitable 
since continuous laser illumination with the required high intensity 
causes photodamage and -bleaching due to concentration of the 
excitation light in the focal point. In mode-locked, pulsed lasers the 
high peak power of the pulses suffices for two-photon excitation, but 
the average output power is lower, thereby decreasing photodamage 
and -bleaching. Mode-locked lasers refer to laser systems that operate 
at a limited range of output wavelengths, usually 700 - 1000 nm.120 The 
phase between these frequencies is fixed such that inference between 
them causes a standing wave between the mirrors in the laser cavity, 
resulting in a train of light pulses of which the repetition rate depends 
on the distance between the laser cavity end mirrors and the speed of 
light.121 During TPLSM experiments described in chapters 4, 5, and 6, 
the laser was tuned around a center wavelength of 800 nm and had a 
pulse repetition rate of 82.5 MHz and a pulse width of 140 fs.
The probability of two-photon excitation is confined to a volume 
of 0.1 - 1 μm3 centered about the focal point122 and decreases with 
the fourth power of distance from that focal point.123 Thus in TPLSM, 
fluorescence emission originates exclusively from the focal zone, 
which, combined with reduced scattering and out-of-focus absorption 
of NIR photons, enables optical sectioning deep in biological tissue 
without affecting its integrity.124,125 The use of NIR excitation limits 
photodamage as long as a critical threshold, which depends on potential 
fluorophore phototoxicity, tissue, and laser power, is not exceeded.126,127 
Fluorescence intensity in TPLSM depends on the square of the 
excitation power; however, two-photon photobleaching is associated 
with higher-order photon interactions, implying that photobleaching 
increases highly non-linear with increasing laser power.128 Whereas in 
confocal fluorescence microscopy pinholes are used to reject out-of-
focus contributions, pinholes are not required in TPLSM. However, 
pinholes do increase spatial resolution in TPLSM, albeit at the cost of 
a severe reduction in signal-to-noise ratio (SNR).129 
In theory, the spatial resolution of TPLSM is approximately 70% 
of that of CLSM due to the longer-wavelength photons.130 However, 
the effective (practical) resolution depends on the SNR and contrast 
of the sample. Therefore, the spatial resolution of TPLSM deteriorates 
far less than that of CLSM when tissue penetration depth is increased 
(Figure 3).131 Thus, in superficial layers, CLSM is to be preferred, 
whereas TPLSM is ideal for imaging deeper in intact tissue.
Figure 3  Effect of penetration depth on the effective spatial resolution 
obtained with TPLSM (A, C, F) and CLSM (B, D, E, G). TPLSM and 
CLSM were applied to a mouse carotid artery, which was embedded in 
agarose gel. Cell nuclei of the artery were labeled with SYTO13 (green). 
Images are obtained from the tunica adventitia (A-B, 15 μm depth), the 
tunica media (C-E, 40 μm depth), and the tunica intima (F-G, 80 μm 
depth). Due to out-of-focus fluorescence in CLSM, the effective resolution 
deteriorates far more with increasing depths as compared with TPLSM. 
Confocal images obtained with optimal pinhole settings,131 except for E in 
which the pinholes were fully open. Bar indicates 20 μm. Figure is adapted 
from131 and used with permission from S. Karger AG, Basel Germany.
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Two-photon laser scanning microscopy for visualization and 
quantification of (micro-) vascular characteristics
TPLSM offers a high spatial resolution with limited effect on 
tissue integrity. However, inherent fluorescence from tissue, i.e., 
autofluorescence, is generally not sufficient to provide adequate 
contrast. With fluorophore-conjugated antibodies and other specific 
fluorophores, molecular expression patterns, cells, and vascular 
structures can be discriminated, including inflammation and apoptosis 
related adhesion molecules,132-134 the endothelial glycocalyx, and 
elastin and collagen fibers.131,135,136 In addition, fluorescent labeling 
of blood-borne macromolecules, e.g., serum albumin, allows in vivo 
quantification of perfusion and diffusion in tumors62,137,138 and vascular 
dynamics in the brain cortex and tumors139-142 at depths of over 200 
μm.105  Moreover, TPLSM may be used for in vivo quantification of 
vascular morphology, e.g., volume density of angiogenic vessels.143 
Optical systems are characterized by a point spread function (PSF) 
that describes the response to a point source and, hence, is a measure 
of the resolving power of the optical system. However, the PSF 
causes anisotropic deformation of components in the acquired (three-
dimensional) datasets (Figure 4). Quantification of vessel diameters 
and volumes requires restoration of the acquired anisotropic dataset. 
Therefore, blind and non-blind deconvolution methods have been 
developed. Blind deconvolution is an iterative procedure during which 
the initial PSF is estimated based on configurations of the optical 
system (Figure 5), e.g., magnification, emission wavelength, refractive 
index, and signal-to-noise ratio, whereas non-blind deconvolution 
refers to deconvolution using an experimentally obtained PSF. 
Recently, deconvolution methods were developed with a static and 
adaptive depth-dependent PSF to correct for decreased intensity and 
axial resolution with increasing depths, respectively.144,145 In this 
thesis commercially available deconvolution software was utilized to 
perform straightforward blind deconvolution.
Figure 4 Transformation in optical imaging (optical axis parallel to 
z-axis). Due to the point spread function (see text) of the TPLSM setup, 
which has different lateral (x, y) and axial (z) dimensions, spheres are 
visualized as spheroids.
Object Image
Figure 5 Schematic representation of blind deconvolution. The initial PSF 
estimate is based on parameters of the optical system, e.g., magnification, 
emission wavelength, refractive index, and signal-to-noise ratio. Image 
estimates are obtained by convolution of the object estimate with the PSF 
estimate. Deconvolution is performed n times.
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Two-photon laser scanning microscopy as complementary 
high-resolution method
The routinely used in vivo (molecular) imaging modalities, e.g., 
MRI, positron emission tomography (PET), and computed tomo-
graphy (CT), offer a limited spatial resolution. Hence, these methods 
may fail to discriminate between contrast agents that specifically 
bind to (angiogenic) endothelial cells and contrast agents that 
have extravasated from the blood into the perivascular interstitial 
space. TPLSM offers a sub-micrometer spatial resolution and thus 
allows visualization and quantification of contrast agent binding 
and extravasation. Furthermore, immunohistological slices are 
often associated with cutting artifacts. In contrast, TPLSM allows 
imaging in intact, unprocessed tissue. However, TPLSM offers 
a penetration depth limited to several hundreds of micrometers, 
which inhibits whole-body imaging. The limited sampling volume 
requires adequate sampling of the tissue of interest to obtain reliable 
information.
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Abstract
Molecular imaging contributes to future personalized medicine 
dedicated to treat cardiovascular disease, the leading cause of 
mortality in industrialized countries. Endoscope-compatible optical 
imaging techniques would offer a stand-alone alternative and high 
spatial resolution validation technique to the clinically accepted 
imaging techniques in the (intravascular) assessment of vulnerable 
atherosclerotic lesions, which are predisposed to initiate acute 
clinical events. Efficient optical visualization of molecular epitopes 
specific for vulnerable atherosclerotic lesions requires targeting of 
high quality optical contrast-enhancing particles. In this review, 
we provide an overview of both current optical nanoparticles and 
targeting ligands for optical molecular imaging of atherosclerotic 
lesions and speculate on their applicability in the clinical setting.
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Introduction
    
Cardiovascular disease is the leading cause of death in industrialized 
countries and places a social and financial burden on Western society 
by contributing strongly to acute clinical events, such as myocardial 
infarction. Myocardial infarction typically results from exposure of 
the plaque’s thrombogenic content to hte blood upon rupture. It would 
be of great clinical relevance to non-invasively assess atherosclerotic 
plaques in the pre-symptomatic phase, including detection of 
vulnerable plaques and intraplaque hemorrhage, and to classify the 
plaque’s stage of development, thus allowing stratification of patients-
at-risk. Assessment of atherogenesis in the early stage of development 
would direct early treatment to impede this process. The majority of 
current clinical imaging platforms, including X-ray angiography and 
computed tomography (CT), focus on post-symptomatic detection of 
morphological alterations of the arterial wall that affect the lumen 
diameter. However, the assessment of plaque extent is obscured by 
outward remodeling and does not provide direct information on 
plaque vulnerability. Therefore, molecular imaging strategies are 
being developed for non-invasive diagnosis of coronary artery disease 
at various stages. Most of these strategies are based on recognizing 
the stage-specific expression of molecules that allow binding of 
ligand-conjugated nanoparticles (NPs),1 which can be detected with 
non-invasive clinical imaging platforms such as magnetic resonance 
imaging (MRI), radionuclide-based imaging (positron emission 
tomography, PET), single photon emission computed tomography 
(SPECT), CT and ultrasound (US). The routine application of NPs 
is still far ahead, but it is an actively evolving field of research with 
encouraging results that hold promise for future clinical use. 
Feasibility of molecular imaging studies is based on progress 
made in three scientific fields: (1) non-invasive imaging platforms, 
(2) molecular epitope recognition and ligand identification, and (3) 
design of high quality contrast agents. As far as the latter is concerned, 
significant progress is being made in the design of contrast-enhancing 
NPs for molecular imaging,2-5 enabling detection of these NPs with 
clinical imaging platforms, including MRI and PET/SPECT. However, 
these imaging platforms have either limited sensitivity or low spatial 
resolution and therefore lack the ability to detect sparsely expressed 
molecular epitopes. Moreover, discrimination between specific and 
non-specific binding or even between bound and circulating NPs is 
often difficult. In contrast, optical techniques combine high sensitivity 
with high spatial resolution6 and therefore have gained considerable 
attention as techniques that allow (sub-) cellular localization of 
targeted hybrid NPs with additional luminescent properties.
In this review, we explore the feasibility of optical imaging 
techniques in combination with NPs to visualize and identify 
vulnerable plaques and discuss the potential clinical applications. 
Common for all optical imaging techniques is the limited penetration 
depth, which ranges from sub-millimeter to several centimeters. 
Penetration depth depends on tissue type, as each type has different 
absorbance and scattering properties, which depend on composition 
and density. In order to reduce tissue absorbance, excitation and 
emission light should match the optical window, which is usually 
in the 700 - 1200 nm range.7 Below 650 nm, absorbance of light by 
hemoglobin increases, while water absorbs light above 1200 nm. 
Scattering of light may cause an additional reduction in penetration 
depth. In plaque tissue, cholesterol esters and calcifications are 
known to scatter light more than other tissue components. Scattering 
is also wavelength determined and may partially be resolved using 
long wavelength excitation light and near infrared (NIR) NPs.
Several optical imaging techniques are discussed. Two-photon 
laser scanning microscopy (TPLSM) allows fluorescence imaging 
at larger penetration depths than single-photon techniques, such as 
confocal microscopy. Optical coherence tomography (OCT) is the 
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optical equivalent of ultrasound, in which the backscatter of emitted 
light is captured into an image. Raman micro-spectroscopy (RMS) uses 
the vibration of chemical bonds to identify molecular composition. 
In photoacoustic tomography (PAT) light is converted into acoustic 
signals. These techniques will be discussed more extensively in the 
next paragraph. This review further provides an overview of the 
physicochemical properties of five optical NPs that have been utilized 
in in vitro and in vivo studies. Additionally, various possible targeting 
strategies are provided that ensure homing of the presented NPs to 
(vulnerable) atherosclerotic lesions. Subsequently, multi-modal NPs 
are presented that enable (sequential) visualization of pathological 
processes with complementary imaging platforms in. Finally, we 
consider the clinical perspectives of the presented optical NPs.
  
Optical imaging platforms for cardiovascular research
   
Optical imaging techniques offer a spatial resolution superior to 
conventional clinical imaging platforms and enable simultaneous 
visualization of multiple molecular epitopes. With optical imaging 
techniques, contrast can be generated by detecting (differences 
in) fluorophore emission spectra (fluorescence microscopy and 
derivatives), fluorescence lifetime (fluorescence lifetime imaging, 
FLIM), polarization (polarization microscopy), molecular resonances 
(RMS), backscattering (OCT) or photoacoustic waves (PAT). Due to 
the limited penetration depth of light, non-invasive whole-body animal 
luminescence imaging is confined to superficial or subcutaneous 
events, whereas exposure of tissue is mandatory in other situations, 
for example atherosclerosis. However, with progress made in (near) 
real-time endoscope-compatible microscopic systems, including 
multi-photon laser scanning microscopy (MPLSM),8,9 RMS,10 
OCT,11,12 and PAT,13 state-of-the-art intravascular and real-time optical 
examination of the morphology of atherosclerotic plaques is within 
reach. Additionally, targeted optical NPs would allow assessment of 
the molecular expression patterns of these lesions (see Table 1 for the 
specifications of the optical imaging platforms).
TPLSM is the most frequently encountered version of MPLSM 
and is based on the non-linear absorption of two NIR photons,14 i.e., 
photons with wavelengths ranging 700 - 1000 nm. The probability of 
excitation depends on the spatial and temporal overlap of two NIR 
photons at the excitable molecule. Even then absorption cross sections 
are extremely small and consequently excitation only occurs effectively 
at the objective’s focal zone, the probability rapidly decreasing away 
from focus. Absence of out-of-focus absorption and emission allows 
optical slicing and additionally limits photobleaching and -damage, 
allowing vital imaging of intact tissue. Furthermore, NIR photons have 
a wavelength approximately double that of traditional fluorescence 
microscopy and are thus less scattered, resulting in increased 
penetration depths up to 250 μm, the exact value strongly depending 
on tissue absorbance and scattering properties. In cardiovascular 
research, TPLSM has primarily been applied ex vivo,15-17 but in vivo 
applications are within reach due to recent developments in imaging 
speed and optical detection efficiency.
RMS is based on detecting vibrational alterations of chemical 
bonds in molecules upon interaction with monochromatic light and 
hence provides detailed information on the molecular composition of 
tissue. For example, ex vivo RMS allows quantification of cholesterol 
content in arterial walls18 and recognition of atherosclerotic 
vasculature.19,20 Furthermore, in vivo studies have shown that RMS 
is suitable for characterizing arterial wall composition10 and is 
applicable in molecular imaging of tumors.21
OCT utilizes the echo time delay and intensity of backscattered 
light to create cross-sectional images of sub-surface tissue structures. 
The penetration depth 10-fold larger than that of TPLSM, whereas the 
spatial resolution is 10-fold lower. OCT allows ex vivo intravascular 
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imaging and characterization of plaque morphology22-24 and in vivo 
visualization of vulnerable atherosclerotic plaques in mice25 and 
morphology in human coronary atherosclerotic plaques.26,27
In PAT, ultrasonic sources are generated by absorption of pulsed 
light. Though the application of PAT to cardiovascular disease is in its 
infancy, PAT allows vascular imaging in vivo with28,29 and without30,31 
exogenous contrast agents. More interestingly, with intravascular 
PAT atherosclerotic plaques can be identified and characterized ex 
vivo,32,33 which holds great promise for in vivo applications.
Taken together, RMS and OCT allow in vivo assessment of 
the molecular and structural changes of the atherosclerotic arterial 
wall. Examples of the in vivo application of TPLSM and PAT in 
visualizing atherosclerosis are currently unavailable in scientific 
literature. However, various ex vivo applications have shown 
their feasibility in atherosclerosis research. Optical NPs, targeted 
towards molecular epitopes specifically expressed in each stage of 
plaque development, will increase the sensitivity in the microscopic 
evaluation of the plaque’s stage of development.
   
Optical nanoparticles for cardiovascular research
   
For in vivo molecular imaging, optical NPs require good 
physicochemical properties for efficient optical detection and 
functionalization by targeting ligands. In addition to NP size and shape, 
modifications in surface structure, e.g., by altering surface charge 
and attachment of bio-molecules, affect the pharmacokinetics.34 
Numerous covalent, amphiphilic and electrostatic strategies have 
been developed to coat optical NPs and adapt circulation half-
life, organ accumulation and excretion pathways. However, these 
coatings may affect luminescence properties, either by increasing35 
or decreasing36 the NP’s brightness. We refer to Niemeyer37 
for additional information on these surface modifications.
   
The optical NPs described here are relatively new (see Figure 
1 for graphical representations and Table 2 for physicochemical 
properties), but some have already been tested in vivo in preclinical 
disease models. Note that the physicochemical properties in Table 
2 apply to water-soluble optical NPs without targeting ligands. 
Quantum dots (QDs) and gold NPs (AuNPs) have proven extremely 
useful in molecular imaging with optical methods, including TPLSM, 
OCT and PAT, but presumably have limitations with respect to long 
term biocompatibility. Three recently synthesized NPs, diamond 
(DNP), carbon (CNP) and silica (SNP), theoretically have a better 
biocompatibility and have been tested in vitro for imaging purposes 
and were shown to have characteristics highly suitable for in vivo 
optical imaging. The physical principles behind luminescence from 
QDs, AuNPs and CNPs are beyond the scope of this paper. Therefore 
light emitted by these NPs is simply referred to as luminescence.
Table 1 Optical imaging platforms suitable for intravascular applications.
Optical 
platform
Contrast Penetration 
depth [a]
Spatial 
resolution [μm]
Temporal 
resolution [fps] [b]
TPLSM Spectral ~ 250 [μm] Axial < 1 up to 50
Lateral < 1
OCT Echo delay & 
backscatter
1 - 2 [mm] Axial ~ 20 30
Lateral 2 - 4
RMS Molecular 
resonance
450 [μm] Axial - 1
Lateral 25
PAT Laser-induced 
ultrasound
several [cm] Axial 25 1
Lateral 100
[a] Penetration depth: maximal depth from which an adequate signal may be 
acquired.
[b] Temporal resolution: maximal frame-rate (in frames per second, fps) that may 
be attained.
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Quantum dots
Quantum dots (QDs) are nanometer-sized, semiconductor crystals 
(Figure 1A) that offer superior photophysical properties over organic 
dyes,38,39 including high quantum yields,40 broad excitation spectra 
and narrow emission spectra and high photostability (Table 2).41,42 
Importantly, they allow efficient two-photon excitation, which 
together with the aforementioned advantageous properties makes 
them suitable for TPLSM imaging deep in scattering tissue. Moreover, 
the size-dependent emission wavelength allows simultaneous 
visualization of differently sized QDs with a single-wavelength 
excitation source.43 The photophysical properties of QDs are strongly 
dependent on regularity in core structure and size-distribution and 
their synthesis therefore requires stringent conditions.44,45 The QD 
quantum yield can reach 70% by encapsulating the QD core with 
an inorganic shell to obtain core/shell QDs.46,47 The organic shell 
furthermore reduces desorption and subsequent oxidation of the 
toxic core components.48 Moreover, additional organic coating of 
core/shell QDs provides both water-solubility and increased core/
shell stability,35 which are required for in vivo applications. 
In mice, QDs are generally cleared from the blood by accumulation 
in organs of the reticuloendothelial system and in some cases also the 
kidneys,49,50 although this varies depending on the surface chemistry 
and ligands attached. However, QDs are usually not excreted through 
urine or feces,50,51 even for months after intravascular administration, 
and are therefore assumed to reside in these organs. Hence, 
accumulated QDs may eventually degrade chemically and release 
cytotoxic components and are therefore considered to be clinically 
unsafe. Therefore, several methods were recently developed to 
produce QDs that are composed of non-toxic components,52,53 are 
encapsulated in a silica-shell to increase biocompatibility,54 and are 
cleared by the kidneys.49 These new developments will potentiate the 
use of QD in future clinical applications.55
Targeted QDs are obtained by covalently binding ligands to 
the shell-surface56 or via non-covalent strategies,57 including the 
streptavidin-biotin bond.58 The latter is frequently used in biomedical 
research. Thus far, QDs have been applied to cancer research in animals, 
including sentinel node mapping59,60 and in vivo molecular imaging of 
tumors.57,61 The application of (targeted) QDs to cardiovascular research 
is advancing. QDs have been used to visualize ex vivo the expression 
of the oxLDL receptor CD36,62 vascular adhesion molecule-1 
(VCAM-1) and intracellular adhesion molecule-1 (ICAM-1),63 the 
angiogenic marker CD13,15 and phosphatedylserine (PS) exposing 
cells.64 Recently, ICAM-, VCAM-, as well as platelet endothelial cell 
adhesion molecule (PECAM-) conjugated QDs have been used for 
simultaneous targeting and imaging of the endothelial phenotype in 
retinal vasculature.65 In addition, the proteolytic activity of matrix 
metalloproteinases (MMPs) in atherosclerotic plaques, contributing 
to a mechanically unstable phenotype, may be visualized using QD-
based biosensors,66 which were successfully applied in vivo in tumors.67 
However, the approaches mentioned above require external excitation, 
often implying exposure of the tissue of interest. By chemical excitation 
of infrared emitting QDs via bio-luminescence resonance energy 
transfer (BRET),68 true non-invasive optical imaging may be realized.
The examples above show that QDs are highly suitable for 
optical imaging in cardiovascular research. However, besides 
optical properties, local contrast-enhancing effects of targeted NPs 
depend on ligand-receptor interactions. Various studies have shown 
that QDs allow quantification of ligand-receptor binding kinetics69 
and monitoring of receptor-mediated endocytosis.41,58 Therefore, 
QDs may be applicable to in vivo probing of binding affinity and 
subsequent processing of ligands specific for atherosclerosis-related 
molecular epitopes.
   
   
Figure 1 Schematic overview of the composition of A) quantum dot, B) 
gold nanoparticle, C) diamond nanoparticle, D1) carbon nanotube, D2) 
carbon dot (C-Dot), E1) silica nanoparticle with encapsulated organic 
fluorophores, E2) silica nanoparticle with fluorescent core. Several 
chemical methods for surface binding of bio-active compounds are 
mentioned in the text. See Table 2 for spatial dimensions.
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narrow excitation and broad emission spectra with quantum yields 
up to 40%.71 Similar to QDs, the emission spectra of AuNPs are size-
dependent.73 Moreover, AuNPs are strongly luminescent upon two-
photon absorption74 and may display specific surface scattering,75 
indicating that AuNPs can be visualized by both TPLSM and OCT. 
Furthermore, excitation with NIR photons induces ultrasonic waves, 
which allow detection with PAT (see Table 2).
In vitro, organically stabilized AuNPs are internalized via 
endocytosis76,77 without affecting cell viability.77,78 In vivo, AuNPs 
predominantly accumulate in the liver and spleen of mice,79 do 
not initiate (hepatic) toxicity,80 and are slowly excreted via the 
feces.81 AuNPs are clinically approved for treatment of rheumatoid 
arthritis82,83 and are considered safe84 although several studies 
showed a correlation between AuNP therapy and lung disease.85,86
Covalent attachment of amine87 and thiol88 groups to the AuNP 
surface allow functionalization with amino acids89 and proteins90 for 
targeted delivery, e.g., to atherosclerosis-related markers. Moreover, 
direct capping of the AuNP surface with certain amino acids yields 
stable, water-dispersible and functionalized particles.89,91 
Agglutination of AuNPs enhances their detection with reflectance 
microscopy, including OCT,92 allowing in vitro visualization of cancer 
cells.75,76 This phenomenon can be exploited in molecular imaging since 
surface-expressed markers spatially coincide, thereby bringing targeted 
AuNPs in close contact with each other. Additionally, TPLSM allows 
visualization of non-targeted AuNPs in vivo93 and identification of 
AuNP-labeled cancer cells in tissue phantoms targeted by AuNPs.94
Diamond nanoparticles
Diamond nanoparticles (DNPs) represent a potentially ideal optical 
label, combining efficient scattering properties (i.e., they can be used 
for OCT),95 bright and photostable fluorescence,96 low cytotoxicity,97 
and chemical stability (Table 2). Fluorescence arises from so-called 
   
Gold nanoparticles
Gold particles are used extensively in electron microscopy.70 However, 
recent progress in synthesis of gold nanoparticles (AuNPs, Figure 
1B) has yielded highly luminescent NPs with emissions ranging 
from 400 - 1200 nm.71,72 This NIR emission makes them suitable for 
optical imaging of biological tissues, since tissue absorption at these 
wavelengths is limited. AuNPs require an adequate protecting and 
stabilizing organic shell for their luminescence and display relatively 
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CNPs are internalized via endocytosis in vitro,105,112 but both 
CNTs and C-Dots display no acute toxicity.104,113 However, long-
term effects of CNPs on cell viability strongly depend on surface-
bound (bio-) molecules and dose112,114 and traces of metal catalysts 
used during synthesis.113 In addition, CNTs may penetrate the 
nuclear membrane physically115 and elicit DNA damage through 
ROS generation.116 After intravenous administration of CNTs, no 
pathological abnormalities were found in the liver, kidneys and other 
organs.117 In rodents, CNTs are cleared by the kidneys,118 whereas 
excretion routes of C-Dots are currently unknown. CNPs may be 
functionalized for molecular imaging by coating with ligand-bound 
phospholipids119 and amino-terminated dendrimers.110
Until now, few studies have utilized CNPs for in vivo optical 
imaging. Nevertheless, the NIR and Raman signals from CNTs 
were detected in the blood pool of Drosphilia melanogaster106 and 
in subcutaneously implanted tumors in mice,21 respectively. These 
preliminary results indicate the potential of TPLSM in visualizing 
CNPs in biological tissue.
   
Silica nanoparticles
Fluorescent silica nanoparticles (SNPs) are synthesized by trapping 
fluorophores in a mesoporous silica matrix (Figure 1E1 and 1E2). 
The spectral properties thus depend on the entrapped fluorophores 
and can therefore not be specified. The quantum yield has an optimum 
since both a low concentration and too high concentration (inducing 
self-quenching120) will affect SNP brightness.121 The brightness of 
dye-doped SNPs (Figure 1E1) additionally suffers from dye-leakage 
from the silica pores, hampering accurate assessment of the spatial 
distribution of SNPs by optical imaging modalities. Leakage can 
be reduced by covalent42 or electrostatic interactions120 between the 
fluorophore and the silica precursors, by increasing the size of the 
dye molecule,120 or by stabilizing the fluorophore-doped silica core 
point defects (Figure 1C),98 initiated by high-energy irradiation.99 
Each of the point defects has a fluorescence brightness comparable to 
a single organic fluorophore, enabling detection of individual DNPs 
by fluorescence microscopy,97 including TPLSM.100 However, current 
DNPs have broad emission spectra,96 which significantly hampers 
multi-color imaging. For functionalization, DNPs are chemically 
modified to yield carboxylated DNPs for the covalent attachment of 
bioactive ligands.96,101 Recent progress in the dispersion of DNPs in 
aqueous media has facilitated their use in physiological solutions.102 
Preliminary results yield DNPs non-toxic in vitro97 as well as 
in vivo.103 Long term follow-up studies on DNP toxicity, however, 
are currently lacking. The favorable photophysical and potential 
pharmacodynamic characteristics of DNPs show great promise for 
biological applications, yet preclinical research on DNPs is still in 
its infancy. In vitro, DNPs were shown to enable single-particle 
tracking96 and detection of growth hormone receptor expression.101
   
Carbon nanoparticles
Carbon nanoparticles (CNPs), which include carbon nanotubes 
(CNTs, Figure 1D1) and carbon dots (or C-Dots,104 Figure 1D2), 
may offer a less cytotoxic alternative to the aforementioned quantum 
dots. CNTs and C-Dots are photostable,104,105 but display relatively 
broad - excitation wavelength dependent - emission spectra (Table 
2).105,106 Therefore, in contrast to QDs, multi-color TPLSM imaging 
of CNPs in tissue is limited. Non-aggregated CNTs display an 
inherent NIR luminescence with a tube-length dependent quantum 
yield,107 reaching values up to 10%.108 C-Dots, however, require a 
large surface-to-volume ratio and surface stabilization with organic 
polymers, such as PEG
1500
, to become luminescent.105 Several 
strategies were developed to obtain individualized and hydrophilic 
CNTs, including non-covalent functionalization with proteins,109 
dendrimers110 and phospholipids.111 
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with a dye-free silica shell (Figure 1E2).42,120 Core/shell SNPs exhibit 
a relatively high brightness, but still display an approximately 3-fold 
lower luminescence intensity than QDs.42 
Reactive silica precursors enable chemical modifications of 
the SNP surface. For example, maleimide and iodoacetyl groups 
can be introduced122 and amino groups123 can be ionized to enable 
(covalent) attachment of bioactive ligands. 
In vitro experiments show cytotoxic responses to SNPs. Upon 
internalization by endocytosis,124 SNPs impair proliferative activity, 
stimulate the release of the inflammation marker interleukin-8, and 
reduce cell viability in vitro in a dose- and time-dependent manner.125-127 
In mice, however, intravenous administration of colloidal core/shell 
SNPs at biologically relevant concentrations do not induce acute or 
chronic responses, even 60 days post-injection.128 
Several in vitro fluorescence microscopy studies have shown 
that SNPs allow peripheral labeling of cancer cells by targeting 
folate receptors.42,129 In addition, antibody-conjugated SNPs allow 
multi-target monitoring of bacteria species.130
Table 2 Physicochemical properties of water-soluble non-targeted nanoparticles for optical molecular imaging.
Quantum Dot Gold Diamond
Carbon
Silica
Dot Tube
Quantum yield < 70%46,47,131 < 40%71 ~ 50%96 ~ 10%105 < 10%108,132 Fluorophore & 
concentration 
dependent
Fluorescence
excitation spectrum 
[nm]
> 200 [a] 300 ~ 45071 [a] 450 ~ 55097,133,134 [a] 450 ~ 650105 [a] Unknown Fluorophore 
dependent
Fluorescence emission 
spectrum [nm]
~ 30 [b] ~ 60 [b] ~ 10096,133 [b] ~ 100105 [b] ~ 500106,114,117 [a] Fluorophore 
dependent
Hydrodynamic 
diameter [nm]
< 20 1 - 50 35 - 100 < 5 ~ 1 nm (Ø)
< 500 (length)
 ~ 15
Blood clearance Predominantly
spleen and liver
Predominantly
spleen and liver
Unknown Unknown Kidneys Spleen, liver, and 
lung128
Excretion None Slowly via feces81 Unknown Unknown Urine118 Urine and feces135
Optical platform TPLSM TPLSM
OCT
PAT
TPLSM
OCT
TPLSM TPLSM TPLSM
[a] Total bandwidth
[b] Full-width-at-half-maximum
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Detection of optical nanoparticles
   
For efficient detection, optical NPs should have favorable 
luminescence properties, i.e., high quantum yield, broad excitation 
spectrum and narrow emission spectrum that matches the optical 
window of tissue. The presented optical NPs share the ability to be 
detected with TPLSM (Table 1). However, the 250 µm penetration 
depth of TPLSM in biological tissue restricts its clinical application 
to early atherosclerotic lesions. The penetration depth of OCT and 
PAT are 1 and 2 orders larger, respectively, and may therefore be 
preferred over TPLSM when greater depths should be attained, i.e., 
intraplaque visualization of developed lesions.
   
Targeting nanoparticles to atherosclerotic lesions
   
The application of molecular imaging in assessing vulnerable 
atherosclerotic plaques is a challenging task, since these plaques are 
highly complex and constantly evolving structures. Consequently, 
these lesions display numerous molecular targets, expressed either at 
the endothelial surface or subendothelially by cells and extracellular 
matrix in the vascular wall. 
The American Heart Association (AHA) has recognized six states 
of plaque development in humans (Figure 2), divided in precursor and 
advanced types. Precursor lesions (types I, II, III) are asymptomatic 
and do not narrow the lumen;136 whereas advanced lesions (types 
IV, V, VI) are hemodynamically and clinically more relevant since 
they may lead to ischemic complications.137 Type I plaques are 
characterized by endothelial activation, which is accompanied by 
luminal expression of various adhesion molecules;138 these include 
intercellular (ICAM), vascular (VCAM), and platelet endothelial 
(PECAM) cell adhesion molecules, and the lectin-like oxLDL 
receptor LOX-1. These adhesion molecules initiate the accumulation 
of macrophages and lipids in the vascular wall, causing gradual 
progression to type II lesions. Type III lesions contain extracellular 
lipid and apoptotic cells and typically show extracellular matrix-
degrading enzymes, such as matrix metalloproteinases (MMPs) and 
cathepsins.138 In type IV lesions the necrotic core develops, as large 
amounts of extracellular lipid accumulate in the intima. Capillaries 
surround the lipid core, mostly in the shoulder of the plaque, and 
calcifications may also be present. Macrophages, foam cells, and 
lymphocytes are mainly present in the periphery of the lesion, most 
notably in the shoulders of the plaque. Type V lesions develop 
when the subendothelial layer grows into more collagen-rich tissue, 
forming the fibrous cap. More and larger capillaries are present 
in these lesions. Type VI lesions closely resemble type IV and V 
lesions, but have had disruptions of the lesion surface, hematoma or 
hemorrhages, with subsequent thrombus formation. It is important 
to stress that vulnerable plaques do not necessarily coincide with 
rupture-prone plaques. More accurately, vulnerable plaques are at 
risk for thrombotic complications and consequent rapid progression 
of plaque instability, as was proposed by Naghavi et al.139
Each stage of plaque development displays specific features, 
such as inflammation, activated endothelium, accumulated lipid 
and macrophages, collagen-rich fibrous cap, angiogenic activity, 
apoptosis and thrombi. Each of these features is associated with 
specific molecular targets that may be used for molecular imaging. 
Available targets and corresponding ligands, which have been 
used in clinical and pre-clinical studies, are mentioned in Table 
3. The NPs in Table 3 include both optical and non-optical NPs. 
The ligands mentioned in Table 3 can be combined with the optical 
NPs mentioned earlier, to generate particles for specific and high-
resolution visualization of vulnerable plaques using (endoscope-
based) optical imaging techniques. Optical techniques described in 
Table 3 either require exposure of the tissue of interest or served as 
Figure 2 Schematic representation of human plaque progression. The different types of plaque morphology are not necessarily successive and not all plaques 
progress to ruptured plaques (AHA type VI).
AHA
stage
I II III IV V VI
Endothelial cell
Macrophage
Foam cell
Necrotic core
Neo-vasculature
Colagen fiber
Fibrin
Adhesion molecules
Lipid
Apoptotic
Matrix-degrading enzyme
Calcification
Activated platelet
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an ex vivo validation tool. Optical imaging techniques are currently 
being developed that would allow in vivo endoscopy-based imaging.
A distinction should be made between luminal (e.g.,  CD13)15,140 
and sub-endothelial targets (e.g., apoptotic cells in atherosclerotic 
plaques141). For sub-endothelial targets the hydrodynamic size 
of the NP should be considered, as the particle has to translocate 
   
through the endothelial layer. Furthermore, the permeability of the 
endothelium should be taken into account, as plaque endothelium is 
more permeable than healthy endothelium, allowing translocation 
of larger NPs. In advanced plaques, NPs may also reach the 
intraplaque targets through the vasa vasorum, an adventitial vascular 
network that often expands into the lesion during plaque growth.
Chapter 3
42
Table 3 Molecular targets utilized in in vivo studies for stage-specific visualization of plaque progression.
AHA
stage
Characteristic Molecular target 
(location)
Ligand NP Imaging modality Reference
I Activated endothe-
lium
VCAM-1 
(luminal)
Peptide sequence (not 
specified)
123I or 99mTc Nuclear 142
VCAM-1 
(luminal)
Antibodies Magneto-optical nano-
particles
Microbubbles
Iron oxide particles
Optical
Ultrasound
MRI
143
144
145
VCAM-1 
(luminal)
Peptide sequence 
VHSPNKK
Magnetofluorescent NPs Optical and MRI 146
VCAM-1 
(luminal)
Peptide sequence 
VHPKQHR
Magnetofluorescent NPs Optical and MRI 147
P-selectin 
(luminal)
Antibodies Iron oxide NPs
Microbubbles
MRI
Ultrasound
148
149
II/III Macrophages/
Inflammation
MMPs
(sub-endothelial)
Peptide sequence 
GGPRQITAG
Near infrared probe Optical 150
Cathepsin K 
(sub-endothelial)
Peptide sequence 
GHPGGPQKC
Near infrared probe Optical 151
Macrophage Scaven-
ger Receptor (CD204) 
(sub-endothelial)
Antibodies Immunomicelles Optical and MRI 152
P2 receptors or 
adenosine nucleotide 
receptors
(sub-endothelial)
Adenosine nucleotides 18F Nuclear 153
Glucose transporters
(sub-endothelial)
FDG 18F Nuclear 154,155
III Apoptosis Cell surface expressed 
phosphatedylserine
(sub-endothelial)
Annexin A5 99mTc
Iron oxide NPs
Paramagnetic QDs
Nuclear
MRI
Optical and MRI
141,156,157
158
64
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IV Angiogenesis α
v
β
3
 
(luminal)
Peptide sequence RGD Paramagnetic NPs MRI 159
CD13 
(luminal)
Peptide sequence 
cNGR
Paramagnetic QDs Optical and MRI 140
Vascular endothelial 
growth factor recep-
tor 2
(luminal)
VEGF
DEE
 (VEGF
121
 
mutant)
64Cu Nuclear 160
Vascular endothelial 
growth factor receptor 
(luminal)
Single chain VEGF Near infrared probe
99mTc
64Cu
Optical
Nuclear
Nuclear
161
161
161
IV/V Fibrous cap/ extra-
cellular matrix
Collagen types I, 
III, IV 
(sub-endothelial)
CNA35 Fluorescent probe Optical 16
Elastin BMS753951 MRI contrast agent MRI 162
VI Thrombus Fibrin 
(luminal)
EP-1873 Gadolinium MRI 163
Fibrin 
(luminal)
EP-2104R Gadolinium MRI 164-167
Fibrin 
(luminal)
Peptide sequence 
GPRPP
99mTc Nuclear 168
Activated factor XIII 
(luminal)
α2-antiplasmin-based 
contrast agent
Fluorescent probe and 
gadolinium
Optical and MRI 169
Activated platelets 
(luminal)
Antibody fragment Microbubbles Ultrasound 170
Activated platelets 
(luminal)
Peptide sequence (not 
specified)
Microbubbles Ultrasound 171
Cell surface expressed 
phosphatedylserine
(luminal)
Annexin A5 99mTc Nuclear 172
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Hybrid nanoparticles for multimodal imaging
   
Clinically approved imaging techniques allow non-invasive 
evaluation of the localization of targeted contrast enhancing NPs, 
yet lack the sensitivity and resolution to prove target specificity. 
Therefore, high spatial resolution validation of non-invasive 
molecular imaging is mandatory and requires NPs suitable for multi-
modal imaging. Hybrid NPs can be detected by optical imaging 
methods as well as by non-invasive clinical imaging methods. These 
hybrid NPs may also be linked to the ligands in Table 3, for imaging 
of atherosclerosis-related molecular markers. In such a set up, a 
combination of non-invasive imaging for macroscopic detection, 
followed by invasive optical imaging, allows determination of 
distribution and exact location. Hybrid NPs developed so far mostly 
include MRI and fluorescent labels. Of the hybrid NPs currently 
available, few have been applied in vivo.
Hybrid lipidic structures, such as liposomes and micelles, are 
composed of natural amphiphilic lipids and are therefore highly 
biocompatible. They can be easily formulated and adjusted for various 
purposes. The maximum payload of added moieties, e.g., ligand or 
contrast agent, depends on the liposome’s size, but may be thousands 
per liposome. The size of liposomes often exceeds 100 nm, which 
is large compared to the optical NPs presented in Table 2. In recent 
decades, though, liposomes have been investigated extensively as 
drug carriers173,174 and two liposomal cytostatic formulations have 
been approved for clinical use so far.175 Incorporation of contrast 
agents allows their application in imaging purposes, e.g., for in 
vivo MRI detection of intimal thickening.176 When contrast agents 
with different functionalities are incorporated in the lipid bilayer, 
dual detection with for instance MRI and fluorescence microscopy 
is enabled. Hybrid liposomes have been developed to specifically 
target and visualize the expression of E-selectin177 and apoptotic 
cells.178 α
v
β
3
 targeted liposomes with surface-conjugated RGD 
have been used to detect angiogenic activity in tumors179 and in 
atherosclerotic plaques159 by in vivo MRI and subsequent ex vivo 
validation with fluorescence microscopy.179 Bimodal micelles 
targeting the macrophage scavenger receptor (MSR) by surface-
bound anti-MSR antibodies allow visualization of macrophage-
uptake in atherosclerotic plaques of mice with in vivo MRI, and by 
ex vivo fluorescence microscopy.180
QDs may serve as a highly luminescent scaffold for MR probes, 
PET/SPECT tracers and CT contrast agents to produce multi-modal 
imaging probes. The payload of additional contrast agents or ligands 
is estimated to be 10 - 30 per QD. QDs provided with a paramagnetic 
lipid-coating were applied to MR and optical visualization of α
v
β
3
-
expression on the membranes of activated HUVECs181 or for PS 
exposure of apoptotic cells.182 A different approach was chosen through 
silica-coated QDs with a hydrophobic phase between the QD surface 
and the silica-shell183 in order to incorporate hydrophobic contrast 
agents. The drawback of this approach is the rather tedious and stringent 
synthesis protocol to produce monodisperse NPs containing a single 
QD. The time-consuming synthesis makes these particles less suitable 
for PET/SPECT applications, due to decay of radioactive tracers. 
A more flexible scaffold is provided by streptavidin-coated QDs, 
since the QD-surface can easily be functionalized by biotinylated 
moieties, including ligands and non-optical imaging probes. To 
further increase detectability, dendritic wedges with 8 DTPA or DOTA 
compounds were developed to incorporate paramagnetic gadolinium 
or radioactive PET/SPECT tracers, respectively.184 Utilizing these 
dendritic structures, paramagnetic QDs were successfully applied 
for MR and optical imaging of apoptosis ex vivo using Annexin A5.64 
Moreover, cyclic Cys-Asn-Gly-Arg-Cys (cNGR-) coupled QDs 
were successfully utilized for in vivo optical detection of angiogenic 
activity after myocardial infarction.15 Recently, a bimodal cNGR-
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coupled QD with a dendritic gadolinium wedge was shown to enable 
the detection of angiogenic activity in tumor-bearing mice by in vivo 
MRI and ex vivo TPLSM.140 A different type of hybrid NP is a QD 
containing a shell doped with paramagnetic manganese.185 This NP 
was shown to be taken up by macrophages in vitro as shown by MRI 
and optical methods. 
The mesoporous matrix of silica NPs and coatings allows the 
incorporation of probes with different functionality. By coating a 
luminescent ruthenium core with a silylated Gd complex, bimodal 
NPs were obtained for efficient luminescent and paramagnetic 
labeling of monocytes in vitro,186 with the potential to extrapolate this 
to in vivo visualization of leukocyte accumulation in atherosclerotic 
plaques. Also, gadolinium oxide cores may be covered by a 
fluorophore-containing silica layer.187 In contrast to the previously 
discussed NPs, these PEGylated NPs were excreted mainly via the 
kidney when intravenously injected in mice, as visualized in vivo 
with both fluorescence imaging and MRI. In addition, magnetite 
(Fe
3
O
4
) can be coated with a silica shell, containing luminescent 
iridium, in order to visualize their passive ingestion in vitro.188 
In contrast to gadolinium, superparamagnetic compounds, such 
as iron oxide generate negative contrast with MRI. Several different 
iron oxide-based multi-modal nanoparticles have been developed, 
but only few have been applied in vivo so far. Magnetite particles 
to which NIR fluorophores were conjugated,189 were used to load 
macrophages for in vivo imaging applications. In addition, iron 
oxide particles covered with a phospholipidic layer containing 
fluorophores were developed to specifically visualize apoptotic cells 
in vitro.178 Also so-called nanosponges were developed in which the 
magnetic and luminescent characteristics of their components are 
maintained.190 The in vivo experience with iron oxide based hybrids 
is still limited. Small (3 nm) iron oxide NPs coated with fluorescent 
cyanine 5.5, allowed visualization of atherosclerotic lesions in mice 
with in vivo MRI and ex vivo fluorescence microscopy,191 apparently 
by virtue of their macrophages uptake. These results have promising 
implications for non-invasive assessment of inflammation, and 
vulnerability to rupture, of an atherosclerotic plaque.
Also, conjugtation of CNT to iron oxide nanoparticles resulted 
in a bimodal NP allowing visualization of the in vitro uptake by 
macrophages with MRI and optical techniques.192 To increase 
biocompatibility, this NP was encapsulated in DNA.
   
Summary and outlook
   
In this paper, optical and hybrid contrast enhancing NPs were 
described that have been applied to in vitro and in vivo animal studies. 
As such, these particles may play a role in confirming (sub-) cellular 
localization following non-invasive imaging in animal models. In 
the future, NPs may be applied clinically in conjunction with optical 
imaging techniques, due to fast developments in this field. Ideal NPs 
for optical molecular imaging in clinical use should bear the following 
characteristics: (1) highly luminescent upon irradiation, (2) high 
binding affinity and specificity for the target, (3) resistant to chemical 
degradation and (4) cleared via kidney or liver upon intravenous 
injection to prevent organ accumulation. It should be kept in mind 
that the in vivo targeting behavior, as well as the level of toxicity, of 
the NPs highly depend on geometrical (i.e., NP size), biophysical (i.e., 
the availability of the target and hemodynamic forces), chemical (i.e., 
NP stability), and biological (i.e., ligand-target affinity and excretion 
pathway) parameters. As such, a thorough quantitative analysis of 
the in vivo bio-distribution and pharmacokinetics of each individual 
construct (i.e., NP and applied surface modifications) should be 
performed and should result in a well defined and uniform safety and 
efficacy profile prior to clinical use.
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The relatively narrow emission spectra of QDs and AuNPs offer 
a valuable contribution to the research of complex and multi-factorial 
diseases, including atherosclerosis, since multiple molecular targets 
may be visualized simultaneously. However, the current commercially 
available QDs consist of heavy metals such as cadmium, and are 
therefore not likely to be suitable for clinical use, despite encapsulation 
of the core. CNPs offer a potentially non-toxic alternative to QDs, 
but display a low quantum yield and broad emission spectrum, both 
hampering multi-color imaging in vivo. AuNPs, DNPs and SNPs 
combine high luminescence with a non-toxic potential in vivo, 
although it is not yet known whether DNPs are excretable. Therefore, 
based on current knowledge on toxicity and optical properties of the 
presented NPs, AuNPs and SNPs are the most promising NPs for 
clinical use in optical molecular imaging of atherosclerosis. The use of 
AuNPs is clinically approved in treatment of rheumatoid arthritis;82,83 
however, both AuNPs and SNPs have been poorly characterized for 
in vivo imaging applications at this moment.
Many of the presented optical NPs hold a dual-purpose character, 
i.e., they may be used as contrast agent in optical imaging as well 
as therapeutic agent to specifically disrupt processes that contribute 
to plaque formation and destabilization. These processes include 
MMP expression by macrophages and angiogenic expansion of the 
vasa vasorum that penetrate the plaque. The use of optical NPs as 
therapeutic agent is still in initial phase of development, but several 
approaches can be recognized. First, surface binding or encapsulation 
of photosensitizers may employ QDs and SNPs, respectively, for 
targeted photodynamic therapy (PDT) of atherosclerotic lesions.193-199 
In PDT, (indirect) illumination of the photosensitizers induces local 
formation of reactive oxygen species, which stimulates apoptosis of 
the surrounding cells. Second, AuNPs200 and CNTs119 convert absorbed 
radiation into heat200 and hence may allow directed photothermal 
destruction of cells76 to which these NPs were targeted. This technique 
is referred to as photothermal therapy (PTT). Third, AuNPs,201,202 
CNTs,119 and SNPs123 may serve as scaffold for targeted gene therapy 
or, in the case of SNPs, may be filled with chemotherapeutic drugs203 
to attenuate the progression of atherosclerotic lesions.
Research committed to finding the most suitable target, as 
well as the accompanying ligand for the assessment of vulnerable 
atherosclerotic plaques, has increased tremendously in recent years. 
Molecular targets used in molecular imaging and therapy of tumors 
show great resemblance to the targets expressed in atherosclerotic 
plaques, including inflammation,204 proteolytic activity,205,206 neo-
vascularization,207,208 and apoptosis.209,210 Although both pathologies 
have different origins and progressions, the shared molecular 
markers may aid in the development and testing of ligands for 
specific targeting of NPs towards vulnerable plaques, as research 
committed to targeted tumor treatment is more advanced than 
targeted atherosclerotic plaque therapy.
In conclusion, current optical techniques and associated 
nanoparticles are promising for their application in high-resolution 
and high-sensitivity stand-alone imaging platforms as well as 
complementary techniques to clinically accepted imaging modalities.
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Abstract
   
Atherosclerotic plaques are associated with an increased density in 
vasa vasorum (VV), an adventitial plexus of microvessels. The VV 
potentially contribute to vulnerable plaque formation by providing 
conduits for inflammatory cells. Therefore, sensitive and high-
resolution visualization of the VV may aid in further understanding 
(vulnerable) plaque development. Vascular endothelial cells (VECs) 
in atherosclerotic ApoE-/- mice were labeled in vivo by intravenous 
injection of fluorescent CD31 antibody. To assess angiogenic activity, 
quantum dots (QDs) were targeted in vivo to CD13, expressed by 
angiogenic VECs, by binding cyclic Ans-Gly-Arg (cNGR) to the 
QD surface (cNGR-QDs). The aortic arch and abdominal aorta were 
embedded in agarose gel and observed with two-photon laser scanning 
microscopy (TPLSM). C57BL/6J mice served as control. VV were 
found in aortic abdominal bifurcations of 4 out of 5 ApoE-/- mice, but 
not in other aortic segments. A single adventitial microvessel was 
observed in 2 control mice (n = 6). In the ApoE-/- mice, two groups of 
axial VV microvessels with different median diameter were recognized: 
6.0 μm (2.1 - 16.5 μm) and 22.7 μm (16.6 - 43.8 μm). Microvessels, 
penetrating the media up to 60 μm, could be distinguished from axial 
VV and had a median diameter of 4.4 μm (2.6 - 6.4 μm). cNGR-QDs 
colocalized with VV VECs in 30% of the axial VV of ApoE-/- mice, 
indicating angiogenic activity. We demonstrated visualization and 
3D representation of in vivo fluorescently labeled VV associated 
with plaques and of angiogenic activity in excised, but intact aortic 
adventitia of ApoE-/- mice. TPLSM may be employed to evaluate the 
mechanisms underlying destabilization of atherosclerotic lesions in 
longitudinal studies.
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Introduction
   
In 1876, Köster suggested that (advanced) atherosclerotic lesions are 
associated with an increased density in vasa vasorum (VV), i.e., the 
adventitial plexus of microvessels providing the arterial wall with 
oxygen and nutrients and removing “waste” products.1 Ever since, a 
growing number of studies imply that both intraplaque vasculature 
and VV expansion enhance atherosclerotic plaque development.2,3 
Experimental evidence that coronary VV expansion precedes 
plaque formation and endothelial dysfunction4,5 favors a regulating 
function of VV in plaque progression. Thus, VV contribute to plaque 
development and the observed expansion can be considered not 
merely a reaction to plaque progression. Intraplaque microvessels 
predominantly originate from VV,6 providing additional conduits 
for inflammatory cells to invade the plaque.7-9 These cells may 
affect the stability of the fibrous cap by releasing metalloproteinases 
(MMPs).10,11 Moreover, microvessels have been observed in the 
plaque shoulder,12 a location considered prone to rupture.3 Upon 
rupture, the plaque’s thrombogenic contents is exposed to the 
blood,12 leading to acute cardiovascular events, including infarction, 
stroke, and critical limb ischemia. 
Several studies have shown a correlation of VV density with 
plaque size13,14 and inflammatory content.15 However, evidence for a 
causative relation between VV and plaque vulnerability stems from 
studies with angiogenesis inhibitors in atherosclerotic mice with 
low VV density.16 The effect of anti-angiogenic therapy in these 
animals is stage-dependent and was shown to reduce macrophage 
accumulation, intimal vasculature, and plaque growth.15-17 These 
features likely contribute to plaque stabilization or regression.17 
However, in an intervention study, statin treatment failed to affect 
VV density in hypercholesterolemic pigs, although the expression 
of key players in the angiogenic cascade and neo-vascularization 
such as hypoxia inducible factor-1α (HIF-1α), vascular endothelial 
growth factor (VEGF), and MMPs was reduced.18 Conversely, VEGF 
promotes plaque progression and accumulation of inflammatory 
cells without increasing plaque vasculature in ApoE-/- mice.19 Hence, 
the causal relation between plaque neo-vascularization and stability 
remains to be elucidated.20
To gain better insight into the role of VV in plaque destabilization, 
assessment is required of morphological and functional alterations 
of the arterial wall, and microvessels therein, during lesion 
development and therapeutic interventions. Several approaches 
have been employed to visualize plaque microvasculature in animal 
models of atherosclerosis, including immunohistochemistry (IHC),3 
micro-computed tomography (μCT),14 magnetic resonance imaging 
(MRI),21,22 and intravascular ultrasound (IVUS).23 However, these 
methods require tissue processing and affect tissue integrity 
(IHC and μCT) or lack the spatial resolution necessary to detect 
functional and structural properties of individual microvessels 
and to discriminate between angiogenic activity of the endothelial 
lining of the large vessel and VV endothelium (MRI and IVUS). 
We have demonstrated previously that two-photon laser scanning 
microscopy (TPLSM) allows detailed imaging of vessel wall 
structures with subcellular resolution in intact tissue.24-26 Therefore, 
in this study, TPLSM was applied to excised, but intact segments of 
the aortic arch and abdominal aorta from ApoE-/- mice to visualize 
plaque-associated microvasculature, which was labeled in vivo 
by intravenous injection of FITC-conjugated anti-CD31 antibody 
(αCD31-FITC). Moreover, highly luminescent quantum dots (QDs) 
were targeted in vivo to aminopeptidase N/CD13, which is over-
expressed by angiogenic endothelium.27
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Materials and methods
Fluorescent probes and preparation of CD13-targeted 
quantum dots
For in vivo fluorescent labeling of vascular endothelial cells (VECs), 
FITC-conjugated monoclonal rat anti-mouse αCD31 (3.03 μmol/L 
stock solution; BD Biosciences Pharmingen, Alphen aan de Rijn, The 
Netherlands) was injected without modification. Unless otherwise 
indicated, prior to examination with TPLSM the excised vasculature 
was incubated ex vivo for 15 minutes with SYTO41 (5 mmol/L stock 
solution; Invitrogen, Breda, The Netherlands), diluted to 1 μmol/L in 
Hanks Balanced Saline Solution (HBSS, pH 7.4, Invitrogen). SYTO41 
is a vital DNA/RNA fluorescent probe that enables visualization of 
the nuclei of VECs, smooth muscle cells (SMCs), and fibroblasts.25
CD13-targeted quantum dots (QDs) were prepared as follows. 
Biotinylated cNGR was synthesized as described previously, 
lyophilized and stored at -20 ºC.24,28 QDs (1 μmol/L stock solution, 
Invitrogen) are composed of a CdSe core with a ZnS shell to yield highly 
luminescent particles and covered with polyethyleneglycol-2000 for 
increased circulation half-life. Each QD holds 5 - 8 surface-conjugated 
streptavidin moieties to allow approximately 20 biotinylated cNGR 
moieties to bind. For each experiment, cNGR-QDs were prepared 
freshly by mixing 100 μL of QD stock solution with freshly dissolved 
biotinylated cNGR in a molar ratio of 1:20 to a maximal volume of 
140 μL.
Animal model and vessel excision
Animal experiments were carried out in accordance with 
institutional guidelines and were approved by the local animal 
welfare committee. Male ApoE-/- mice (n = 5, Charles River, 
Maasticht, The Netherlands) were fed a Western type diet ad libitum 
for 18 - 19 weeks to yield atherosclerotic lesions at predisposed 
sites of the vasculature.29 At the age of 22 - 23 weeks, the mice were 
anesthetized by a subcutaneous injection of 100 mg ketamine and 20 
mg xylazine per kg of mouse (Nimatek and Sedamun, respectively, 
Eurovet Animal Health, Bladel, The Netherlands). The tip from a 
30G needle was removed from its plastic holder and placed in a 28 
mm (inner diameter) polyethylene tube. The other end of the tubing 
was fitted to a 1 mL syringe by a 30G needle. Next, the left jugular 
vein was exposed and canulated and 80 μL αCD31-FITC (n = 1) or 
80 μL αCD31-FITC and 140 μL of cNGR-QDs (n = 4) was gently 
administered. After 15 minutes of circulation, the diaphragm was 
cut and mice were bled to death. Subsequently, to expose the tunica 
adventitia, connective tissue was removed and the aortic arch and 
the thoracic and abdominal aorta were excised such that the tunica 
adventitia remained intact. The lumen of these aortic segments was 
flushed with HBSS after which the excised vasculature was placed 
in HBSS prior to examination with TPLSM. In the ApoE-/- mice two 
areas of interest were examined under a bright field microscope for 
the presence of atherosclerotic plaques: the aortic arch, including 
the base of the carotid arteries and the left subclavian artery, and 
the abdominal aorta bifurcation, including the base of the femoral 
arteries (Figure 2A). If plaques were present, the abluminal media 
and adventitia were screened systematically with TPLSM 5 mm 
distally and proximally from the plaque centre.
Male C57BL/6J wild type mice (n = 6, aged 29 - 32 weeks) 
served as negative control. These mice are free of atherosclerotic 
lesions when fed normal chow. These mice received similar 
treatment as the ApoE-/- mice and were intravenously injected 
with αCD31-FITC (n = 3) or αCD31-FITC and cNGR-QDs (n = 
3). In ApoE-/- mice, vasa vasorum (VV) were found abluminal to 
plaques in the abdominal aorta bifurcation and not the aortic arch of 
ApoE-/- mice (see Results), therefore the abdominal aorta bifurcation 
of C57BL/6J mice served as control tissue for the presence of VV.
High resolution vasa vasorum imaging in intact murine atherosclerotic arteries 
59
Upon intravenous injection, QDs and αCD31-FITC are cleared 
from the blood and accumulate in spleen and kidney. In order to 
determine whether the intravenous injection was successful, these 
organs were excised from each mouse and checked with TPLSM for 
the presence of cNGR-QDs and/or αCD31-FITC.
 
Two-photon laser scanning microscopy of the abdominal aorta
After ex vivo labeling, the vascular segments were embedded in 2% 
(w/v) agarose gel (Invitrogen). TPLSM imaging was performed by 
using a Nikon Eclipse E600FN upright microscope (Tokyo, Japan), 
equipped with a Bio-Rad Radiance 2100MP imaging system and 
operated by Lasersharp2000 V6.0 software (Bio-Rad, Hemel 
Hempstead, UK). Fluorescent probes in tissues were excited by a 
Tsunami Ti:sapphire laser (Spectra-Physics, Mountain View, CA, 
USA), which was pumped by a Millennia Vs 5 W pump laser 
(Spectra-Physics) and mode-locked at 800 nm, with a 82.5 MHz 
repetition rate and 140 fs pulse width. Tissues were observed through 
a water-dipping 60× fluor objective with a 1.00 numerical aperture 
(Nikon). Photomultiplier tubes (PMTs, Electron Tubes, Ruislip, 
UK) were used to collect fluorescence emission in three spectral 
regions: 420 - 470 nm (SYTO41 and autofluorescence), 520 - 560 
nm (αCD31-FITC) and 570 - 600 nm (cNGR-QDs). These spectral 
regions were tuned such that bleed-through of the fluorescent 
markers to adjacent PMTs was minimized. The as-obtained images, 
color-coded blue, green, and red, were subsequently merged into 
a single image. The in-plane pixel dwell-time was 11.8 μs, which 
together with Kalman averaging (K = 2) for reduced noise, resulted 
in an image acquisition speed of 0.16 Hz. Field of view was 179 × 
179 μm2 to which a 512 × 512 matrix was applied, resulting in 0.35 
× 0.35 μm2 sized pixels. In-depth scans were obtained by acquisition 
of consecutive images with a 1.05 μm interplanar distance.
   
Data analysis
Data were analyzed with Image-Pro V6.2 (MediaCybernetics, Silver 
Spring, MD, USA) and ImageJ V1.37 software (NIH, Bethesda, MD, 
USA). Intraluminal diameters of the VV microvessels were measured in 
between bifurcations and presented as median (minimum - maximum).
   
Results
   
In all mice, the in vivo injection of αCD31-FITC and/or cNGR-
QDs was successful as can be concluded from the presence of the 
respective fluorescence in kidney and splenic tissue (Figure 1). 
αCD31-FITC allowed clear discrimination of vessels within these 
organs. Moreover, cNGR-QDs were typically observed inside the 
lumen of spleen (Figure 1B) and kidney vasculature (not shown).
Luminal endothelium and adventitial microvessels in 
C57BL/6J mice
The in vivo injection of αCD31-FITC and subsequent ex vivo TPLSM 
observation of the embedded aortic segment allowed visualization 
of vascular endothelial cells (VECs) in the lumen of healthy aortic 
segments of control C57BL/6J mice (Figure 2B). Additional labeling 
of the nuclei of VECs, smooth muscle cells (SMCs), and fibroblasts 
with SYTO41 allowed orientation, i.e., discrimination between 
intima, media, and adventitia within the vascular wall (Figure 2B). 
In two of the six control C57BL/6J mice a single adventitial 
CD31-positive (CD31+) microvessel was found in the bifurcation of 
the abdominal aorta (not shown). Both microvessels (diameters 10.2 
μm and 12.7 μm) were oriented axially without visible branches 
over their observed length (~ 300 μm).
Figure 1 TPLSM images from C57BL/6J mice obtained from A) kidney 
and B) spleen. The mice were injected solely with αCD31-FITC (A-B, 
green) or co-injected with cNGR-QDs (B, red). The results indicate that 
the intravenous injection of αCD31-FITC and cNGR-QDs was successful. 
In both tissues, αCD31-FITC allowed detection of vasculature (A-B, white 
arrows). In the kidneys, CD31+ vasculature and glomeruli (A, red ellipse), 
including afferent and efferent arterioles (A, red arrowheads), could be 
discerned. Blue: autofluorescence of kidney tubuli. Bars indicate 50 μm.
A B
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Plaque-associated adventitial neo-vasculature in ApoE-/- mice
Atherosclerotic lesions were present in the aortic arch, innominate 
artery, carotid and subclavian arteries, and bifurcation of the 
abdominal aorta of all ApoE-/- mice. In atherosclerotic arteries, 
VECs of the main artery could not be observed due to insufficient 
penetration depth of TPLSM in atherosclerotic lesions.30 CD31+ vasa 
vasorum (VV) were observed in the adventitia of the abdominal aorta 
abluminal to the atherosclerotic lesions in 4 out of 5 ApoE-/- mice 
(Figure 2C-E). However, VV were not observed in the adventitia 
abluminal to plaques in the aortic arch, innominate artery, base of 
the carotid arteries and subclavian arteries of ApoE-/- mice. In the 
aortic abdominal bifurcation, two groups of axially oriented VV 
microvessels could be clearly discriminated: one with a median 
diameter of 6.0 μm (2.1 - 16.5 μm), which accounted for ~ 80% 
of the axial microvessels, whereas the other group had a median 
diameter of 22.7 μm (16.6 - 43.8 μm). In the latter population, 
individual endothelial cells could be discriminated by combined 
CD31 and SYTO41 labeling (Figure 2D). Furthermore, nuclear 
staining allowed visualization of cells closely associated to the VV 
(Figure 2E). These cells presumably represent pericytes.
In the adventitia of the abdominal bifurcation of 2 
ApoE-/- mice, VV microvessels (n = 3) with a median diameter of 
4.4 μm (2.6 - 6.4 μm) were found to originate from the small axial 
VV microvessels and could be followed penetrating the medial 
layer to a maximal depth of ~ 60 μm, which excluded visualization 
of microvasculature inside atherosclerotic plaques, whereas the 
large axial VV microvessels did not display branching over their 
observed length (~ 500 μm).
Angiogenic activity of adventitial neo-vasculature
cNGR-QDs colocalized with αCD31-FITC on endothelial cells of 
the small axial VV microvessels abluminal to the atherosclerotic 
plaque in the abdominal bifurcation of ApoE-/- mice only (n = 2, 
Figure 3A-B). This accounted for ~ 30% of the observed axial 
microvessels. This indicates the presence of angiogenic activity 
and the potential for angiogenic expansion. Figure 3B displays 
a three-dimensional reconstruction of 68 consecutive in-depth 
scans acquired from the adventitia of the abdominal bifurcation. 
Angiogenic sprouts, originating from CD31+ microvasculature, can 
clearly be observed (Figure 3B, arrows). 
Atherosclerotic lesions are characterized by an increase in 
permeability of the endothelium covering the lesion.31 However, 
little is known about the permeability of VV that is associated with 
these lesions.32 In the present study, cNGR-QDs were found both 
colocalized with αCD31-FITC and present outside the endothelial 
Figure 2 A) Schematic overview of the mouse aorta, ranging from the aortic root to the femoral arteries, including its main side-branches, i.e., left and right 
carotid arteries, left subclavian artery and renal and femoral arteries. Areas of interest are highlighted by grey ellipses. B-E) TPLSM images from control 
C57BL/6J mice (B) and ApoE-/- mice (C-E) obtained at the abdominal bifurcation. In blue nuclei of cells: VECs (B, D and E, white arrows), SMCs (B, yellow 
arrow), fibroblasts (D, red arrows), and presumably pericytes (D-E, green arrows). The green staining (αCD31-FITC) surrounding the endothelial nuclei 
confirms the presence of endothelial cells. B) Intimal layer at abdominal bifurcation. C) Vasa vasorum microvessel (diameter 6.6 μm) with media-penetrating 
side branches (white arrowheads). D) Large vasa vasorum microvessel (diameter 34.8 μm) in the adventitial layer abluminal to the aortic plaque. Endothelial 
membranes can be distinguished (red arrowheads). E) Vasa vasorum microvessel (diameter 4.7 μm), abluminal to the aortic plaque, with closely associated 
cells that presumably represent pericytes. Bars indicate 25 μm.
A
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Figure 3 A-B) TPLSM images obtained from the adventitia of the 
abdominal bifurcation of ApoE-/- mice. A) Colocalization of cNGR-QDs 
(red) with αCD31-FITC (green) in adventitial microvasculature (diameter 
6.3 μm) indicates the presence of angiogenic endothelial cells (ellipse). B) 
Three-dimensional reconstruction of a 200 × 200 × 70 μm3 dataset shows 
the presence of angiogenic sprouts (arrows), branching off from non-
angiogenic microvasculature (arrowheads), and extravasation beyond the 
luminal boundaries. Bar indicates 25 μm. 
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boundaries of the adventitial VV in one of the ApoE-/- mice (Figure 
3B), which indeed indicates leaky endothelium. However, in all 
other ApoE-/- mice, cNGR-QDs were only found on the luminal 
side of VV endothelium, suggesting maturation of the observed 
microvessels and normal endothelial permeability.
   
Discussion
   
This study shows the feasibility to visualize plaque-associated vasa 
vasorum (VV) and angiogenic activity thereof in the adventitia of 
excised, but intact abdominal aortic bifurcations of ApoE-/- mice after 
fluorescent labeling in vivo. Two-photon laser scanning microscopy 
(TPLSM) offered the ability to (1) image intact tissue without affecting 
its integrity,33 (2) determine size and distribution of VV microvessels, 
(3) follow microvessels penetrating the adventitia towards the medial 
layer (4) detect structural characteristics of the microvessels, e.g., 
presence of closely associated pericytes, and (5) detect angiogenic 
activity in adventitial microvasculature with cNGR as targeting 
ligand. The present results provide direct evidence on the presence of 
adventitial microvasculature abluminal from atherosclerotic plaques 
in the abdominal bifurcation and their angiogenic expansion.
The prevalence of VV in the abdominal bifurcation differed between 
control C57BL/6J and ApoE-/- mice. In two of the control mice a single 
adventitial microvessel was observed in the wall of the abdominal aortic 
bifuraction, whereas in 4 out of 5 ApoE-/- mice small microvascular 
networks, i.e., vasa vasorum, were observed in the plaque-associated 
adventitia of the abdominal aortic bifurcation only. These observations 
comply with Moulton et al., who obtained similar results in ApoE-/- mice 
fed a high-cholesterol diet for 24 weeks.15 In the aortic arch, VV was 
not observed abluminal to plaques, which may be related to the extent 
of plaque size. In a more severe mouse model of atherosclerosis, i.e., 
ApoE-/-/LDL-/- mice with AHA type IV or higher atherosclerotic plaques, 
VV were observed in the aortic arch.13,14 Therefore, in future TPLSM 
experiments ApoE-/- mice should be fed a Western type diet for a longer 
period to yield highly developed lesions. Due to practical incompatibility 
of histology with TPLSM, the observed atherosclerotic plaques could not 
be classified according to AHA standards. However, based on literature, 
the atherosclerotic lesions were estimated AHA type III.
A B
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In contrast to standard immunohistochemical methods, the in vivo 
injection of contrast agent restricted the visualization of adventitial 
microvasculature to perfused (micro-) vessels. The minimal cylindrical 
diameter of mouse erythrocytes is reported to be about 2.65 μm,34 which 
indicates that the diameter of the media-penetrating microvessels is 
large enough to be designated as functional. Although it is suggested 
that intraplaque vasculature and the expanding VV are hyperpermeable 
like tumor vasculature,22,32 cNGR-QDs were only once found 
beyond the endothelial microvascular boundaries, which accounts to 
approximately 7% of the total VV vasculature found in ApoE-/- mice 
and may be related to the relatively short blood circulation time. 
Therefore, further research is required to investigate hyperpermeability 
of the VV in a qualitative and quantitative manner. These results 
indicate that the in vivo injection of fluorophore-conjugated anti-CD31 
antibody allows visualization of perfused adventitial microvasculature. 
However, if CD31-negative (CD31-) microvasculature was present 
and/or the CD31-expression pattern of the observed microvessels 
was discontinuous, as is the case for human arteries,35 we may have 
underestimated the number of microvessels. Beside the moderately 
developed lesions mentioned above, the presence of CD31- VECs may 
also explain the controversial observation that VV were not detected in 
the aortic arch adventitia of ApoE-/- mice, whereas Langheinrich et al. 
did.13 However, in that study the aorta was perfused with a radiopaque 
polymer, detecting both CD31- and CD31+ VV with μCT.
Winter et al. showed that targeting of the α
ν
β
3
-integrin, specific of 
angiogenic endothelium, allows visualization of angiogenic activity22 
and is suitable for anti-angiogenic therapy,17 as assessed by in vivo 
magnetic resonance imaging (MRI) in a rabbit model of atherosclerosis. 
The current and previous studies24,26,36 suggest that targeting of CD13 by 
cNGR offers an alternative route in visualizing angiogenic activity. In 
addition, cNGR may be employed therapeutically, as was underscored 
by the reduction in tumor growth by cNGR-conjugated tissue necrotic 
factor-α (TNF-α),37 to reduce plaque angiogenesis, decelerate plaque 
progression, and potentially prevent spontaneous plaque rupture.
A major point of discussion in current literature is the actual 
contribution of intraplaque vasculature to plaque destabilization. 
Current concepts are based on guilt-by-association evidence 
obtained from human endarterectomy specimen.12 Physiologically 
relevant animal models of spontaneous vulnerable plaque formation 
and rupture are currently limited or strongly debated and lack the 
correlation with the presence of intraplaque microvasculature.38-40 
Further research is therefore required to assess a causative relation 
between intraplaque vasculature and plaque rupture. In this respect, 
TPLSM offers the ability to evaluate this putative causal relation. 
In a first attempt, we show here that TPLSM allows visualization of 
VV and, hence, may contribute to research that involves assessment 
of mechanisms underlying destabilization of atherosclerotic lesions. 
Penetration depth of TPLSM in atherosclerotic lesions, which in 
this study was limited to approximately 60 μm, may be increased by 
utilizing stable near-infrared fluorophores, adaptive optics, and pulse-
narrowing protocols41 in order to enable visualization of intraplaque 
microvasculature. In addition, methods to quantify microvessel 
characteristics, e.g., microvessel functionality, permeability, and 
morphology would contribute to functional and longitudinal studies 
investigating the role of VV expansion and intraplaque vasculature 
in (vulnerable) atherosclerotic lesion formation. 
In conclusion, this study indicates a higher plaque-
associated VV prevalence in the abdominal aorta bifurcation of 
ApoE-/- mice than of control C57BL/6J mice. In other arterial segments, 
VV were absent in both ApoE-/- and control mice. Moreover, the VV of 
ApoE-/- mice displayed angiogenic activity, as was assessed by CD13-
targeted cNGR-labeled quantum dots. TPLSM proved a feasible tool 
in visualizing the VV of intact arterial segments.
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Abstract
Magnetic resonance vessel size imaging (MR-VSI) is increasingly 
applied to non-invasively assess microvascular properties of tumors 
and to evaluate tumor response to anti-angiogenic treatment. MR-
VSI provides measures for the microvessel radius and fractional 
blood volume of tumor tissue, which has not yet been evaluated 
with 3D microscopy techniques. Therefore, 3D two-photon 
laser scanning microscopy (TPLSM) was performed to assess 
microvascular radius and fractional vessel volume in tumor and 
muscle tissue. TPLSM data displayed a maze-like architecture of 
the tumor microvasculature and mainly parallel oriented muscle 
microvessels. For both MR-VSI and TPLSM, a larger vessel radius 
and fractional blood volume were found in the tumor rim than in the 
core. On average, the microvessel radius was approximately 6 times 
larger in tumor and muscle for MR-VSI than for TPLSM. The tumor 
blood volume was 4-fold lower with MR-VSI than with TPLSM, 
whereas muscle blood volume was comparable for both techniques. 
Differences between the tumor rim, core and muscle tissue showed 
similar trends for both MR-VSI and TPLSM parameters. These 
results indicate that MR-VSI does not provide absolute measures 
of microvascular morphology, however, reflects heterogeneity in 
microvascular morphology. Hence, MR-VSI may be used to assess 
differences in microvascular morphology.
Evaluation of magnetic resonance vessel size imaging by two-photon laser scanning microscopy
69
Introduction
   
Tumor growth and metastasis formation are accompanied by the 
angiogenic expansion of the supporting microvascular network.1 
Clinical studies have shown that the immunohistochemical 
microvessel density (MVD) is a valuable prognostic indicator for 
various tumor types.2 In addition, changes in MVD may provide 
a rough indication of therapeutic efficacy.2 However, tumor MVD 
as assessed on biopsy samples significantly hampers longitudinal 
evaluation, is prone to sampling errors in heterogeneous tumors, 
and is discomforting for patients. Magnetic resonance vessel size 
imaging (MR-VSI) has been proposed as a non-invasive alternative 
to the histologically determined MVD, as it allows in vivo estimation 
of a vessel radius index and fractional blood volume in whole tissue 
on a voxel-by-voxel basis.3
MR-VSI is based on the different nature of changes in the 
transverse relaxation rates R
2
 and R
2
* of blood and surrounding tissue 
as a function of microvascular dimensions. These changes can be 
induced either by endogenous contrast mechanisms, i.e., a change in 
blood deoxyhemoglobin concentration4 or by exogenous intravascular 
contrast agents such as ultra-small superparamagnetic iron oxide 
(USPIO) particles.5 In regions adjacent to large vessels, a strong 
increase in R
2
* and only a small increase in R
2
 are expected, whereas 
changes in R
2
* and R
2
 will be about the same near small capillaries.4 
Therefore, the ratio of relaxation rate changes (ΔR
2
*/ΔR
2
) was shown 
to be related to the average dimensions of the microvessels.4,5 This 
principle was extended by Troprès et al., who suggested that MR-
VSI allows estimation of a tumor vessel radius index and fractional 
blood volume.3
MR-VSI has been applied to assess vascular development 
in various pre-clinical tumors, including brain tumors3,6,7 and 
subcutaneously induced solid tumors.8,9 It allowed monitoring of 
therapeutic intervention8-10 and the effects of stimulated pericyte 
recruitment11 and hypoxia.12 However, evaluation of MR-VSI 
with standard histology showed a systematic overestimation of the 
MR-derived vessel radius index with a considerable inter-study 
variability.6,7,10 Pathak et al. developed a histological method based 
on tissue sectioning, three-dimensional (3D) reconstruction and 
stereological principles, to yield a fractional blood volume that 
correlated well with MR-VSI.13 However, the main drawback of 
histological methods for MVD and vessel size quantification is (non-)
isotropic tissue shrinkage, thereby disturbing the morphological 
characteristics of the microvasculature.14,15 In addition, histologic 
preparation results in loss of the endothelial glycocalyx, which 
constitutes a significant part of the total vascular volume,16 and hence, 
may result in an overestimation of vessel radius and volume.
The goal of the present study was to compare MR-VSI 
measurements with 3D two-photon laser scanning microscopy 
(TPLSM). TPLSM enables optical sectioning of intact tissue with 
high spatial resolution (<1 μm) and penetration depths of more 
than 200 μm,17 which allows visualization and quantification of 
individual microvessels.
In addition, MR-VSI has been applied predominantly to assess 
vascular morphology in brain tumors, in which the microvasculature 
is disorganized and the blood-brain-barrier may affect the observed 
contrast between healthy and cancer tissue. Therefore, an additional 
goal of this study was to apply 3D TPLSM and MR-VSI to both 
the disorganized and the highly organized microvasculature of 
subcutaneous tumors and skeletal muscle tissue, respectively.
   
   
   
   
   
Chapter 5
70
Materials and methods
   
Contrast agents
The USPIO contrast agent Sinerem® (ferumoxtran-10) was kindly 
provided by Guerbet (Aulnay-sous-Bois, France). The administered dose 
was 200 μmol Fe/kg body weight, as described previously.3 USPIOs 
were diluted in saline to obtain a total administered volume of 100 μL.
For TPLSM, the vasculature was demarcated from surrounding 
tissue by fluorescent labeling of vascular endothelial cells. Therefore, 
excised tissues were incubated for 30 minutes in FITC-conjugated 
anti-mouse anti-CD31 (αCD31-FITC, 0.5 mg/mL, BD Biosciences 
Pharmingen, Alphen a/d Rijn, The Netherlands), diluted 20× in 
Hanks Balanced Saline Solution (HBSS, pH 7.4).
   
Spectrophotometry
The inherent fluorescence of the USPIOs was measured using a 
NanoDrop ND3300 fluorospectrometer (Thermo Fisher Scientific, 
Waltham, MA). The potential influence of USPIOs on the fluorescence 
intensity of αCD31-FITC was analyzed in triplicate using an UVIKON 
923 spectrophotometer (Bio-Tek, Kontron Instruments, Milan, Italy). 
The intensity of diluted αCD31-FITC (1 μM in HBSS) was measured 
at wavelengths of 500 - 700 nm (step size 4 nm) with increasing 
USPIO concentration (0, 2.2, 8.8, and 22 mM Fe). Fluorescence 
resonance energy transfer from αCD31-FITC to USPIO was analyzed 
by comparing the fluorescence lifetime (SPC-830, Becker&Hickl 
GmbH, Berlin, Germany) of αCD31-FITC (1 μM in HBSS) in the 
absence and presence of USPIOs (22 mM Fe).
   
Animal model
All animal experiments were approved by the institutional ethical 
review committee on animal experiments. Ten male Swissnu/nu mice 
(Charles River, Maastricht, The Netherlands) received a subcutaneous 
unilateral injection of approximately 3 × 106 human colorectal 
adenocarcinoma cells (LS174T, American Type Culture Collection CL-
188, Rockville, MD) in the flank. MRI examinations were performed 
when tumors reached a volume of about 1 cm3 (approximately 14 
days after tumor induction). For TPLSM imaging, a separate group 
of eleven LS174T tumor-bearing mice was used because USPIOs 
reduced the vascular fluorescence intensity (vide infra).
Mice were anesthetized using 1-2% isoflurane (Abbott 
Laboratories Ltd, Queensborough, UK) in medical air. An infusion 
line of PE-10 tubing (Smiths Medical International Ltd, Hythe, 
UK) was placed in the jugular vein for contrast agent injection. 
Subsequently, mice were placed prone in an animal holder with 
built-in anesthesia mask. Body temperature and respiration 
rate were continuously monitored via an MR compatible small 
animal monitoring system (SA Instruments, Stony Brook, NY). 
Physiological body temperature was maintained using a warm water 
heating pad placed over the mouse.
   
MRI protocol
MRI was performed on a 7 Tesla Bruker Biospec 70/30 USR scanner 
(Bruker Biospin GmbH, Ettlingen, Germany), using the BGA12-S 
mini-imaging gradient (maximum gradient strength 720 mT·m-1, slew 
rate 6000 Tm-1s-1), interfaced to an AVANCE II console. All images were 
recorded with a 3.5 cm inner diameter quadrature volume resonator.
Tumors were localized using coronal and axial T
2
-weighted spin 
echo images with a repetition time (TR) of 3000 ms and an echo time 
(TE) of 36 ms. Pre- and post-contrast R
2
 values were determined 
using a multi-slice multi-echo (MSME) spin echo sequence with 
increasing echo times (TR 4000 ms, TE 10, 20… 80 ms). A 4.0 × 
4.0 cm2 field-of-view was used with a 128 × 128 matrix, resulting in 
an in-plane resolution of 0.31 × 0.31 mm2. Slices were recorded in 
axial direction with a thickness of 1.2 mm. Depending on tumor size 
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and orientation, 12 slices (range 5 - 17) were recorded. Acquisition 
time of the MSME sequence was 6.5 minutes.
Pre- and post-contrast R
2
* values were measured using 
sequentially recorded multi-slice gradient echo (FLASH) images 
with increasing echo times (TR 1000 ms, TE 2, 4, 6, 8, 10, 15, 20 
ms, flip angle 35°). Spatial parameters were identical to those of the 
MSME measurements and the total acquisition time of the FLASH 
series was 15 minutes. Post-contrast image acquisition was started 
at least 5 minutes after USPIO injection to allow circulation and 
obtain adequate distribution.
The apparent diffusion coefficient (ADC) was determined 
using a diffusion-weighted spin echo sequence with 6 orthogonal 
directions (TR 2000 ms, TE 30 ms, b = 0 and 572 s·mm-2, diffusion 
gradient duration 8 ms, diffusion gradient separation 13 ms, 4 axial 
slices positioned around the tumor centre, 1.2 mm thickness with 1.2 
mm gap, 128 × 64 matrix, field-of-view 4.0 × 4.0 cm2, 2 averages, 
acquisition time 30 minutes). Diffusion-weighted imaging was only 
performed before contrast administration.
After MRI, mice were sacrificed by cervical dislocation. Tumors 
were excised and embedded in optimal cutting temperature compound 
(Sakura Finetek Europe, Zoeterwoude, The Netherlands), snap-
frozen in cold 2-methylbutane (Acros Organics, Geel, Belgium) 
and subsequently transferred to liquid nitrogen. The contralateral 
quadriceps femoris muscle was excised up to ~1 cm proximal to 
the knee joint and frozen likewise. Tumor and muscle tissues were 
stored at -80 °C until TPLSM measurements.
   
MRI data analysis
All data processing was performed using customized software 
programmed in Matlab (The MathWorks, Natick, MA), unless 
indicated otherwise. Image coregistration was performed in 
SPM2 (Statistical Parametric Mapping, Wellcome Trust Centre 
for Neuroimaging, London, UK) to correct for any animal motion 
between the MSME and FLASH series. Images were smoothed 
using an in-plane Gaussian smoothing kernel with a full-width-at-
half-maximum of 0.7 × 0.7 mm2 in SPM2. Regions of interest were 
defined manually for tumor and muscle tissue using MRIcro.18
Pre- and post-contrast R
2
 and R
2
* values were determined on 
a voxel-by-voxel basis by non-linear curve fitting of the signal 
intensity versus TE function, obtained from spin echo and gradient 
echo acquisitions, respectively:
  S(TE) = S
0
 exp(-TE·R
2
(*))      [1]
using the Levenberg-Marquardt optimization algorithm. Here, S
0
 
is a scaling factor depending on TR, proton density, and general 
scanner settings including preamplifier and receiver gain, and 
pulse profiles. Subsequently, ΔR
2
(*) values were calculated as 
ΔR
2
(*) = R
2,post
(*) - R
2,pre
(*). The thresholds for significantly positive 
ΔR
2
(*) values were determined using Monte-Carlo simulations, as 
described previously.19
Mean tumor and muscle ADC values of 1334 and 1718 µm2s-1, 
respectively, were calculated using Paravision 4.0 (Bruker Biospin). 
Voxel-based ADC mapping was not performed due to the differences 
in spatial resolution between the ADC and ΔR
2
(*) measurements.
Next, the vessel radius index RI 
MRI
 and fractional blood volume 
fBV
MRI
 were calculated on a voxel-by-voxel basis according to 
Troprès et al.:3
         [2]
          [3]
RI
MRI
 (μm) = 0.424
ADC
γΔχB
0
DR
2
*
DR
2
3/2
fBV
MRI
 (%) = 
3
4p
DR
2
*
γΔχB
0
×
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Here, γ is the gyromagnetic ratio, Δχ is the USPIO-induced 
susceptibility difference between blood and surrounding tissue, and 
B
0
 is the main magnetic field strength. Δχ was set to 0.571 ppm.3 
Only voxels with a significantly positive ΔR
2
(*) were included in 
the calculation. For tumor rim, core and muscle tissue the resulting 
percentage of significant voxels was 59.0 ± 6.1%, 57.8 ± 5.7% and 
86.1 ± 4.2%, respectively (mean ± standard error). An upper boundary 
of 100 µm was set for RI
MRI
 to exclude unrealistically high values.6
To investigate differences in RI 
MRI
 and fBV
MRI
 between the tumor 
rim and core, the rim was defined manually as an approximately 1 
mm thick peripheral zone, as described previously.19 The tumor core 
was defined as the difference between whole tumor and tumor rim.
   
TPLSM protocol
Prior to TPLSM measurements, tumor and muscle tissue were thawed 
and washed with HBSS. Tumors were cut in half to resemble the central 
MR slices; muscle tissue was not processed. Tissues were incubated in 
αCD31-FITC, embedded in 2% (w/v) agarose gel (Invitrogen, Breda, 
The Netherlands) and imaged with TPLSM. Note that due to the ex vivo 
labeling of the vascular endothelial cells, TPLSM detects all vessels 
resulting in the fractional vessel volume. In contrast, MR-VSI only 
detects the perfused vessels, resulting in the fractional blood volume.
TPLSM was performed as described previously at randomly 
selected locations within the tissue.19 In brief, in-depth images 
were recorded with an Eclipse E600FN upright microscope (Nikon, 
Tokyo, Japan) equipped with a Radiance 2100MP optical imaging 
system (Bio-Rad, Hemel Hempstead, UK). Fluorophores were 
excited by a mode-locked Tsunami Ti:Sapphire laser (Spectra-
Physics, Mountain View, CA, USA) with a central wavelength 
of 800 nm and a 140 fs pulse width. 3D datasets were acquired 
using a 60× water-dipping objective lens (Nikon) with a numerical 
aperture of 1.00. Fluorescence (520 - 560 nm) was detected by a 
photo-multiplier tube (Electron Tubes, Ruislip, UK) and color-
coded in green. A 512 × 512 matrix was applied to the 196 × 196 
μm2 field-of-view, resulting in in-plane pixels of 0.38 × 0.38 μm2. 
The pixel dwell time was 11.8 μs, which together with a two-fold 
Kalman averaging for noise reduction resulted in an acquisition rate 
of 0.16 Hz for each of the subsequent images in the 3D dataset. The 
interplanar distance was 1.05 μm or 0.6 μm.
   
TPLSM data analysis
The acquired 3D datasets were deconvolved using AutoQuant X2 – 
AutoDeblur (MediaCybernetics, Bethesda, MD, USA) in 3D blind 
deconvolution mode, which required objective lens specifications, 
refractive index of the medium (n = 1.33), spatial parameters, and the 
emission wavelength maximum of FITC (λ = 518 nm) to estimate 
the initial point spread function. Deconvolution was optimized using 
4.43 ± 0.31 μm diameter fluorescent microspheres (Polysciences 
Inc., Warrington, PA, USA), which were diluted 20× in 2% (w/v) 
hot agarose gel, homogenized, solidified at room temperature, and 
imaged with TPLSM. Using 10 iterations, 3D blind deconvolution 
reduced the microsphere volume from 100.11 ± 3.46 μm3 to 42.41 
± 4.02 μm3 (mean ± SD, n = 5), which is not different from the 
theoretical volume (45.52 μm3, P = 0.1).
After 3D blind deconvolution of the vasculature datasets, in-plane 
radiuses (R 
TPLSM
) of the tumor and muscle microvasculature were 
determined using Image Pro Plus V6.2 (MediaCybernetics). R 
TPLSM
 
values were determined manually between vessel bifurcations at 8 
random locations in each 3D dataset to yield the median vessel radius. 
The fractional vessel volume (fVV
TPLSM
) and total microvessel 
length (MVL
TPLSM
) were determined using 3D Constructor 5.1 
(MediaCybernetics), as outlined in Figure 1. In short, (1) the deconvolved 
3D datasets (Figure 1 A/E) were smoothed using a 3 × 3 × 3 voxel 
Gaussian kernel, (2) a 3D closing filter was applied to create massive 
Figure 1 Schematic representation of the TPLSM data processing steps 
(left) with corresponding images for representative tumor (panels A-D, 
box size 179 × 179 × 77 μm3) and muscle (panels E-H, box size 179 × 
179 × 52 μm3) datasets. The different post-processing steps are indicated 
in different colors. Grey: data after 3D blind deconvolution (A/E). The 
median vessel radius R 
TPLSM
 was measured during this step. Green: Data 
after application of a 3 × 3 × 3 Gauss filter, a closing filter, and a second 
Gauss filter (B/F). Red: Data after isosurface rendering, which was used to 
determine the fractional vessel volume fVV
TPLSM
 (C/G). Blue: Skeletonized 
data (D/H) used to extract the total microvessel length MVL
TPLSM
 and 
degree of branching B
TPLSM
.
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cylinder-shaped structures and (3) the dataset was convolved with an 
isotropic 3D Gaussian filter with dimensions of the dataset’s median 
microvessel diameter (Figure 1 B/F), (4) an isosurface (Figure 1 C/G) 
was applied by means of intensity thresholding such that the applied 
isosurface closely matched the raw dataset (visual inspection), (5) the 
volume of all voxels within the isosurface was integrated and divided 
by the total dataset volume to yield the fVV
TPLSM
, (6) a skeletonization 
procedure was applied to yield the central lines of the microvasculature, 
and (7) a pruning filter was set to twice the median microvessel diameter 
as a restriction for the side branches. Next, the MVL
TPLSM
 was calculated 
and expressed per unit of volume (Figure 1 D/H). In addition, the total 
number of branching points in the skeletonized dataset was expressed 
per unit of volume to obtain the branching index B
TPLSM
.
   
Statistical analysis
Statistical analysis was performed using SPSS 15.0 (SPSS, Chicago, 
Ill). MRI data were tested using a paired non-parametric Wilcoxon 
signed-rank test. For TPLSM, the datasets from the tumor rim and 
core originated from different mice. Therefore, these data were 
analyzed using a non-paired non-parametric Mann-Whitney U-test.
   
Figure 2 Negative effect of USPIOs on the fluorescence intensity of αCD31-
FITC. A clearly decreasing signal intensity is observed in the emission 
spectrum of αCD31-FITC with increasing USPIO concentration. The 
concentrations of αCD31-FITC and USPIO in the tissue were estimated 
to be approximately 0.7 μM and 5 mM, respectively. Values are presented 
as mean ± standard deviation.
In
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.)
Emission wavelength (nm)
FITC 1 μM
FITC 1 μM + Sinerem 2.2 mM
FITC 1 μM + Sinerem 8.8 mM
FITC 1 μM + Sinerem 22.2 mM
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Results
   
Spectrophotometry
Spectrophotometry revealed no inherent fluorescent signal of the 
USPIOs. However, the fluorescence intensity of αCD31-FITC 
decreased with increasing USPIO concentrations (Figure 2). 
Fluorescence lifetime imaging displayed no alterations in αCD31-FITC 
lifetime (not shown), indicating that fluorescence resonance energy 
transfer was absent. The low intensity of αCD31-FITC was probably 
caused by scattering/absorption of αCD31-FITC fluorescence and/or 
absorption of excitation light by the USPIOs.
   
Animal inclusion
Eight out of ten mice successfully developed a subcutaneous tumor. 
Therefore, tumor MR-VSI was performed in 8 mice, whereas 
muscle imaging was performed in 10. For TPLSM, a separate group 
of 11 tumor-bearing mice was used since a low and discontinuous 
fluorescent signal of the vasculature was observed in tissue of mice 
injected with USPIOs (data not shown). The total number of 3D 
TPLSM datasets for the tumor rim, tumor core, and muscle tissue 
was 10 (5 mice), 13 (6 mice), and 32 (9 mice), respectively.
   
MR-VSI vascular morphology
The mean pre- and post-contrast R
2
 and R
2
* values and the differences 
ΔR
2
 and ΔR
2
* that were used for the MR-VSI calculations are 
summarized in Table 1. Figure 3 shows T
2
-weighted anatomical images 
of a tumor with color-coded overlay of the calculated vessel radius 
index RI 
MRI
 and fractional blood volume fBV
MRI
. A heterogeneous 
distribution of RI 
MRI
 and fBV
MRI
 was found throughout the tumor, with 
both parameters showing higher values in the tumor rim than in the 
tumor core (Figure 3A/C). In healthy muscle tissue, the distribution 
was more homogeneous and significantly lower values of RI 
MRI
 and 
fBV
MRI
 values were found compared with tumor tissue (Figure 3B/D).
   
R 
2,pre
 (s-1) R 
2,post
 (s-1) ΔR 
2
 (s-1) R 
2,pre
* (s-1) R 
2,pre
* (s-1) ΔR 
2
* (s-1)
Tumor 
rim
24.4 ± 1.0 25.8 ± 1.1 1.6 ± 0.2 173.5 ± 28.9 254.6 ± 34.8 81.2 ± 19.7
Tumor 
core
22.3 ± 0.9 23.4 ± 0.9 1.3 ± 0.1 133.0 ± 23.9 193.8 ± 26.3 60.7 ± 13.3
Muscle 47.9 ± 2.2 55.8 ± 2.0 8.2 ± 0.7 132.0 ± 140 200.2 ± 20.4 68.4 ± 12.3
Table 1 Overview of the mean pre- and post-contrast R
2
 and R
2
* values for tumor rim, 
tumor core and muscle. Values are presented as mean ± standard error.
Figure 3 Sections of T
2
-weighted images (TE = 30 ms) of tumor (A/C) and 
muscle (B/D) with color-coded overlay of RI
MRI
 (A/B) and fBV
MRI
 (C/D). 
Note the different scales for RI
MRI
 for tumor and muscle tissue.
20 100 5 20
0.8 2.0 0.8 2.0
RI 
MRI
 (μm) RI MRI (μm)
fBV
MRI
 (%)fBVMRI (%)
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The differences in RI 
MRI
 and fBV
MRI
 between tumor rim, tumor core, 
and muscle tissue were further investigated by histogram analysis (Figure 
4), which confirmed a wide distribution for the tumor and a narrow 
distribution centered at relatively low values for muscle (Table 2). RI 
MRI
 
values in tumor rim and tumor core were approximately 3-fold higher 
compared with muscle tissue. Although RI 
MRI
 was slightly higher in the 
tumor rim than in the tumor core, this difference was not significant. In 
contrast, fBV
MRI
 was significantly higher in tumor rim compared with 
core, and in tumor rim compared with muscle (Table 2).
Tumor rim Tumor core Muscle
RI 
MRI
 (µm) 38.0 (33.6 - 49.9) * 34.3 (22.8 - 47.8) * 11.9 (7.0 - 16.7)
R 
TPLSM
 (µm) 6.0 (4.5 - 6.6) * 4.3 (3.1 - 4.8) * 2.2 (1.7 - 2.7)
fBV
MRI
 (%) 1.8 (1.2 - 2.2) *† 1.2 (0.9 - 1.7) 1.2 (0.9 - 1.5)
fVV
TPLSM
 (%) 8.9 (6.1 - 11.8) *† 4.6 (4.0 - 6.5) * 1.5 (1.0 - 1.9)
MVL 
TPLSM
 (×10-4 μm-2) 8.1 (5.2 - 11.4) * 7.3 ( 6.3 - 9.4) * 3.5 (2.7 - 5.3)
B 
TPLSM
 (×10-6 μm-3) 7.9 (3.5 - 13.8) * 11.0 (9.8 - 14.9) * 3.3 (1.6 - 5.1)
Table 2 Overview of microvascular morphology parameters for blood vessels in the 
tumor rim, tumor core and muscle tissue, as determined by MR-VSI and TPLSM. All 
values are presented as median with their quartile ranges indicated in parentheses. Note 
that no MRI equivalent is available for the total microvessel length MVL 
TPLSM
 and the 
degree of vessel branching B 
TPLSM
.
TPLSM vascular morphology
Qualitative comparison of the tumor and muscle tissue datasets showed 
clear differences in vessel radius and orientation (Figure 1). In muscle 
tissue, vessels were generally oriented parallel with the muscle fibers 
with occasional interconnecting side branches, whereas the tumor 
microvasculature lacked a distinct orientation and displayed a more 
arbitrary, maze-like architecture. In correspondence with MR-VSI data, 
tumor tissue displayed a wide distribution in vessel radius (Figure 5).
R 
TPLSM
 was significantly larger in the tumor rim and core compared 
to muscle tissue (Table 2). Similar to MR-VSI, no significant difference 
was observed in R 
TPLSM
 between tumor rim and core. However, the 
histogram of microvessel radius displayed a slight left-shift in R 
TPLSM
 
in the tumor core compared to the rim, suggesting that the tumor core 
holds smaller sized microvessels (Figure 5). In accordance, the tumor 
rim displayed a significantly larger fVV
TPLSM
 compared with the 
tumor core and muscle tissue (Table 2). Moreover, the fVV
TPLSM
 in the 
tumor core was significantly larger than in muscle tissue. In addition, 
significantly higher MVL 
TPLSM
 and B
TPLSM
 values were found in the 
tumor rim and core compared with muscle tissue.
   
* P < 0.05 compared with muscle tissue. † P < 0.05 compared with tumor core.
Figure 4 Histograms of the vessel radius index (A) and fractional blood 
volume (B) for the tumor rim (black), tumor core (grey) and muscle tissue 
(white), as determined using MR-VSI. Values were normalized to tissue 
volume and are represented as median ± standard error.
Figure 5 Histogram of the vessel radius as determined with TPLSM for the 
tumor rim (black), tumor core (grey) and muscle tissue (white). Values are 
presented as mean ± standard error. Due to the limited number of available 
data points for fVV
TPLSM
, MVL
TPLSM
, and B
TPLSM
 (1 per animal versus 8 for 
R
TPLSM
), histogram analysis was impractical for these parameters.
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Discussion
   
Current findings
In the present study, the vessel radius index and fractional blood 
volume, as determined by MR-VSI in subcutaneous tumors, were 
evaluated using 3D TPLSM. In addition, the performance of MR-VSI 
was investigated in healthy muscle tissue, which, in contrast to tumors, 
has a fully matured and highly organized microvasculature. Image 
processing of the TPLSM datasets resulted in values for the vessel 
radius and the fractional vessel volume that comply with literature (cf. 
Table 2 and 3).20,21 MR-VSI displayed non-physiological vessel radius 
values for both the tumor and muscle tissue, thereby indicating that 
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Table 3 Overview of available literature values for the average tumor vessel radius (index) R and fractional blood volume fBV, measured by MR-VSI, histology, or intravital 
microscopy. The applied tumor model, tumor location, animal kind, and contrast agent are also presented. The contrast agent dose was 200 µmol Fe/kg body weight, unless indicated 
otherwise. Values are given as mean ± standard deviation.
[a] MION: Monocrystalline iron oxide nanoparticle; VSOP: Very small superparamagnetic iron oxide particle. 
[b] NA: Not available. 
[c] S.c.: subcutaneous. 
[d] Calculated from reported vessel diameters.
Tumor model Location Animal Contrast agent [a] R (µm) fBV (%) Technique Reference
C6 glioma Brain Rat MION 12.5 ± 6.8 NA [b] MR-VSI 5
Sinerem® 20.0 ± 6.3
5.8 ± 4.1
NA
2.0 ± 0.7
MR-VSI
Histology
6
Sinerem® 19.5 ± 4.8
9.9 ± 2.1
4.0 ± 1.4
2.9 ± 0.6
MR-VSI
Histology
7
RG2 glioma Brain Rat Sinerem® 11.0 ± 2.0
7.4 ± 1.3
5.2 ± 1.6
NA
MR-VSI
Histology
7
GH3 prolactinoma S.c. [c] Rat Sinerem® 13 ± 4 2.9 ± 0.8 MR-VSI 8
Shionogi prostate 
carcinoma
S.c. Mouse Sinerem® 35.2 ± 25.5 NA MR-VSI 9
B16 melanoma S.c. Mouse Clariscan 
45 µmol Fe/kg
13.5 ± 1 4.1 ± 0.5 MR-VSI 11
LS174T colorectal 
adenocarcinoma
Skin-fold chamber Mouse Texas-Red labeled 
bovine serum 
albumin and FITC-
dextran
6.1 ± 0.5 9.2 ± 2.9 Intra-vital 
microscopy
20,21
HaCaT-ras-
A-5RT3 skin 
squamous cell 
carcinoma
S.c. Mouse VSOP C200 
(Ferropharm)
62 ± 18
10 ± 7 [d]
NA
1.4 ± 0.2
MR-VSI
Histology
10
A431 skin 
squamous cell 
carcinoma
S.c. Mouse VSOP C200 
(Ferropharm)
42 ± 7
10 ± 3 [d]
NA
1.1 ± 0.3
MR-VSI
Histology
10
Various Brain Human Magnevist®
0.2 mmol/kg
79 ± 68 NA MR-VSI 24
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MR-VSI provides an index, and not an absolute measure, of the vessel 
radius. However, TPLSM and MR-VSI showed similar trends for the 
vessel radius (index) and the fractional blood volume in the observed 
tissues, i.e., generally higher values in the strongly vascularized tumor 
rim compared with the tumor core and muscle tissue. 
The MR-derived vessel radius index was significantly higher 
in the tumor compared with muscle tissue, with no significant 
difference between tumor rim and core. The latter may be due to 
the heterogeneous distribution of vessel radius index found over 
the tumor. The fractional blood volume obtained with MR-VSI 
indicated that the tumor rim was more vascularized than the tumor 
core and muscle tissue. This corresponds with the reported higher 
level of angiogenic activity in the tumor rim19,22,23 and with more 
necrosis and higher interstitial pressures in the core. 
With TPLSM, a heterogeneous distribution of vessel radius was 
observed over the tumor, showing higher values in the tumor rim 
than in the core. However, these differences were not statistically 
significant. Muscle tissue displayed a significantly smaller radius, 
which was approximately 2-3 fold smaller compared with the 
tumor (Table 2). The TPLSM-derived fractional vessel volume was 
significantly higher in the tumor rim compared with tumor core and 
muscle tissue, and in the tumor core compared with muscle tissue. 
The total microvessel length and the degree of vessel branching, 
which can be uniquely assessed by TPLSM, were also significantly 
higher in the tumor than in muscle tissue. Although the individual 
tumor vessels may appear shorter than the muscle vessels (Figure 1), 
note that TPLSM measures the total, and not the average, microvessel 
length. Taken together, these results indicate that the tumors were 
more strongly vascularized than skeletal muscle tissue.
In comparison with TPLSM, MR-VSI showed a 6-8 fold 
overestimation of the vessel radius index for all tissue types. This 
may be explained by partial volume effects due to the limited 
spatial resolution of MR-VSI, relative to the dimensions of the 
microvessels in tumor and muscle tissue. In addition, Kiselev et al. 
suggested that an overestimation of vessel caliber can be explained 
by a deviation from the static dephasing regime of relaxation around 
capillaries, and by the native paramagnetism of venous blood, which 
are both neglected in the simplified MR-VSI theory.24 Interestingly, 
lower intratumoral blood volumes were found for MR-VSI than 
for TPLSM, whereas these values for the skeletal muscle were 
similar. These observations may be related to the heterogeneous 
perfusion effects observed in tumors.25 Hence, tumor regions with 
no or relatively low USPIO concentration will result in a lower 
detected blood volume. This heterogeneous perfusion may also have 
contributed to the exclusion of approximately 40% of the tumor 
voxels in the VSI calculations (see Materials and methods). The 
good correspondence of the present TPLSM results with literature 
values20,21 suggests that the differences in vascular labeling between 
MR-VSI and TPLSM, i.e., in vivo versus ex vivo, did not contribute 
to the observed discrepancies between the two methods.
Although the MR vessel radius index and fractional blood 
volumes did not correspond with their TPLSM equivalents, the 
observed differences between tumor rim, tumor core and muscle 
showed the same trends for both methods. MR-VSI is therefore not 
suited for absolute quantification of vascular morphology, but does 
allow detection of differences within tumors and between tissues. 
This suggest that MR-VSI may be applied for longitudinal in vivo 
evaluation of relative changes in vessel architecture, induced for 
instance by tumor growth or by anti-angiogenic therapy. 
Quantitative vascular morphology in current literature
Table 3 provides an overview of available literature values for 
tumor vessel radius (index) and blood volume, measured either 
by MR-VSI, histology, or microscopy techniques, and the applied 
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experimental setup. Direct comparison with the present results 
is hampered due to large differences in tumor models. Different 
tumor locations, stages of tumor growth, and animal species have 
been studied and a distinction between the tumor rim and core is 
usually not made. Moreover, tumor vasculature typically harbors 
unpredictable flow, adding non-systematic variability to MR-VSI 
measurements as these were shown to depend on the intravascular 
USPIO concentration.26 Also, ΔR
2
 and ΔR
2
* measurements depend 
on technical parameters such as field strength, pulse sequence, field 
homogeneity and shimming, echo times, etc.
Extensive data processing is required to convert contrast 
agent induced changes in signal intensity into quantitative vessel 
parameters, and different approaches have been described in 
literature. For instance, different maximum RI
MRI
 values were 
applied, above which vessel radius was considered unrealistic: an 
upper limit of 100 µm was set by Troprès et al.,3 whereas Valable 
et al. used a 50 µm threshold.7 In addition, diffusion-weighted 
experiments are not always conducted, although the measurement 
of individual ADC values was shown to be important for accurate 
MR-VSI.24
Taken together, reported literature values are highly variable, 
indicating that MR-VSI is strongly dependent on experimental 
setup (Table 3). Also, vessel radius and diameter appear to be used 
interchangeably, thereby adding a factor 2 to the observed variability.
Limitations
Direct comparison of the MR-VSI results with 3D TPLSM in the 
same tumors was unfeasible in the present study due to a reduction 
in αCD31-FITC intensity by USPIO. This necessitated the use of two 
separate animal groups for MR-VSI and TPLSM. Moreover, tissue 
freezing and thawing may have caused deformation and hence affect 
TPLSM quantification of microvascular morphology. These problems 
may be circumvented by applying long-circulating bimodal, i.e., 
fluorescent and superparamagnetic, nanoparticles.27 Combined with in 
vivo TPLSM,17 this would theoretically provide the optimal validation 
method for MR-VSI. Nevertheless, the current ex vivo TPLSM results 
are in good agreement with previous in vivo studies.20,21
During TPLSM post-processing, blind 3D deconvolution was 
performed iteratively using an initial point spread function based 
on the configuration of the optical system. Although the validity of 
this approach was confirmed using fluorescent microspheres, von 
Tiedemann et al. showed that significant improvements may be 
obtained when using an a depth-dependent point spread function 
that is automatically estimated from the dataset.28 However, this 
method is still under development.
Conclusions
MR-VSI allows in vivo estimation of the microvascular radius index 
and blood volume in both tumor and healthy muscle tissue. TPLSM 
offers high-resolution 3D visualization of the microvasculature 
and provides a useful tool in pre-clinical research. Compared with 
3D TPLSM, MR-VSI resulted in a large overestimation of the 
average vessel radius index, whereas the fractional blood volume 
was slightly lower. However, for both techniques, morphologic 
measures were higher for tumor than for muscle tissue, and higher 
for tumor rim relative to core. Thus, although MR-VSI is not suitable 
for absolute quantification of vessel radius and blood volume, the 
image contrast of MR-VSI reflects microvascular morphology and 
spatial heterogeneity thereof. MR-VSI may therefore be suitable to 
investigate relative microvascular differences between tissues and 
the effects of anti-angiogenic therapy in longitudinal studies.
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Abstract
The objective of this study was to develop and apply cyclic Asn-Gly-
Arg-labeled paramagnetic quantum dots (cNGR-pQDs) for the non-
invasive assessment of tumor angiogenic activity using quantitative 
in vivo molecular magnetic resonance imaging (MRI). cNGR was 
previously shown to colocalize with CD13, an aminopeptidase that 
is highly over-expressed on angiogenic tumor endothelium. Since 
angiogenesis is important for tumor growth and metastatization, its 
in vivo detection and quantification may allow objective diagnosis 
of tumor status and evaluation of treatment response.
Intravenous injection of cNGR-pQDs in tumor-bearing mice 
resulted in increased quantitative contrast, comprising increased 
longitudinal relaxation rate and decreased proton visibility, in the 
tumor rim but not in tumor core or muscle tissue. This demonstrated 
that cNGR-pQDs allow in vivo quantification and accurate 
localization of angiogenic activity. MRI results were validated using 
ex vivo two-photon laser scanning microscopy (TPLSM), which 
showed that cNGR-pQDs were primarily located on the surface of 
tumor endothelial cells and to a lesser extent in the vessel lumen. In 
contrast, unlabeled pQDs were not or only sparsely detected with 
both MRI and TPLSM, supporting a high specificity of cNGR-pQDs 
for angiogenic tumor vasculature. 
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Introduction
   
Angiogenesis, the formation of new capillaries from existing blood 
vessels, is key to tumor growth and metastatization by providing 
proliferating tumor cells with oxygen and nutrients.1,2 Moreover, 
angiogenic activity is related to tumor malignancy.3,4 Non-invasive 
detection of angiogenic activity is therefore highly relevant for 
adequate tumor diagnosis. Quantification of angiogenesis may 
furthermore allow objective monitoring of tumor progression, for 
instance in response to treatment.
Currently, molecular imaging techniques are being developed that 
allow direct visualization and characterization of cellular or molecular 
activation of angiogenesis-related pathways.5 More specifically, 
molecular imaging uses contrast agents that home to upregulated 
biomolecules (e.g., receptors and enzymes) via interaction with high-
affinity ligands coupled to the contrast agent. Ideally, this results in 
an altered signal intensity at the location of these molecules. Of the 
different imaging modalities, magnetic resonance imaging (MRI) may 
be the most desirable for molecular imaging due to its excellent spatial 
resolution and soft tissue contrast. Moreover, molecular MRI potentially 
allows direct covisualization of tumor angiogenic activity with 
anatomy. However, the inherently low sensitivity of MRI is a problem 
due to the typically low abundance of upregulated biomolecules. This 
can be overcome by large molecular weight constructs carrying a 
high payload of gadolinium or iron, and multiple targeting ligands to 
enhance the particle’s relaxivity and targeting efficacy, respectively.6
One of the best-defined ligands for molecular imaging of angio-
genesis is the cyclic Arg-Gly-Asp (cRGD) peptide, which binds 
specifically to the α
v
β
3
-integrin.7,8 However, for the cyclic Asn-Gly-
Arg (cNGR) motif, the tumor-homing capability was shown to be 
3-fold higher compared with cRGD.9 The clinical applicability of 
cNGR as a tumor-homing ligand was previously demonstrated by 
conjugating cNGR to tumor necrosis factor α (TNFα). Compared 
with unlabeled TNFα, cNGR-TNFα displayed a significantly 
increased anti-tumor activity with similar systemic toxicity.10-12
The vascular address of cNGR is a specific isoform of CD13 
(aminopeptidase N), a transmembrane glycoprotein involved in 
cancer angiogenesis, tumor invasion and metastasis, which is 
overexpressed by activated vascular endothelial cells (VECs) of 
tumor vasculature.9,13,14 CD13 is not required for vessel growth during 
embryonic development and normal adult function, as shown in 
CD13-/- mice.15 In a model of retinal neo-vascularization, these mice 
had significantly decreased vessel growth, suggesting that CD13 is 
important in pathological neovascularization. In addition, fluorophore-
conjugated cNGR allowed detection of the in vivo expression of 
CD13 in tumors and infarcted myocardium.16,17 Competition with 
unconjugated cNGR significantly decreased the fluorescence signal, 
indicating high specificity of cNGR for CD13.16,17
Despite the aforementioned high tumor-homing capability of 
cNGR, its potency as a targeting ligand for molecular imaging of 
tumor angiogenesis is currently unknown. Therefore, the objective of 
this study was to explore cNGR-labeled paramagnetic quantum dots 
(cNGR-pQDs) for the non-invasive and selective in vivo detection 
of tumor neovascularization using quantitative molecular MRI. QDs 
were chosen as contrast agent scaffolds because of their excellent 
photophysical properties, i.e., broad excitation, small emission 
spectra and limited photo-bleaching.18,19 Furthermore, QDs enabled 
binding of multiple targeting ligands and gadolinium chelates. The 
particle’s bimodal nature (i.e., paramagnetic and fluorescent) allowed 
validation of the results with ex vivo two-photon laser scanning 
microscopy (TPLSM). With TPLSM, three-dimensional contrast 
agent localization can be obtained at subcellular resolution with a 
penetration depth reaching 250 μm in tumors.
MRI data were analyzed via absolute quantification of contrast 
agent induced changes in the tissue’s longitudinal relaxation rate R
1
 
(1/T
1
), which is proportional to contrast agent concentration, and 
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proton visibility. The latter expectedly decreases at high densities 
of paramagnetic contrast material. Quantitative analysis requires 
acquisition of a series of images and may provide improved sensitivity 
of molecular MRI. Theoretically, the employed inversion recovery (IR) 
technique has an inherent two-fold higher sensitivity than spin echo 
pulse sequences and by measuring a series of images it potentially 
allows detection of smaller changes in R
1
 than a single image.
Both MRI and TPLSM showed specific binding of cNGR-pQDs 
to VECs in the angiogenic tumor rim, but not in tumor core or muscle 
tissue. Furthermore, a significantly lower quantitative contrast 
was found with unlabeled pQDs, indicating a high specificity of 
the cNGR-labeled contrast agent for angiogenic VECs. To our 
knowledge, this is the first non-invasive in vivo application of cNGR 
as a targeting ligand for molecular MRI of tumor angiogenesis.
   
Materials and methods
   
Preparation of cNGR-labeled paramagnetic quantum dots
NAc-Cys(4MeBzl)-Asn(Xanthyl)-Gly-Arg(Tosyl)-Cys(4MeBzl)-
Gly-Gly-Lys(Fmoc)-peptide was synthesized by tBoc solid phase 
peptide synthesis, as described previously.16,20 On the resin, the 
lysine side chain was selectively deprotected by treatment with 
20% piperidine/dimethylformamide (4 × 3 minutes). After covalent 
coupling of biotin-succinimidyl ester (Molecular Probes, Eugene, OR) 
to the lysine ε-amino group to obtain biotinylated peptide-resin, the 
peptide was deprotected and cleaved from the resin using anhydrous 
hydrogen fluoride for 1 h at 0 °C with 4% p-cresol as scavenger and 
lyophilized. Electrospray ionization mass spectrometry (ESI-MS) 
revealed a mass of 1287.4, corresponding well to the theoretical 
average mass (1288.7) of the reduced biotinylated Nac-Cys-Asn-Gly-
Arg-Cys-Gly-Gly-Lys(biotin)-NH
2
 peptide. Oxidative folding of the 
crude product in 0.1 M Tris, pH 8, 1 M guanidin at 4 °C for 16 hours 
yielded the internal disulfide bridged biotin-cyclic NGR, which was 
HPLC-purified (C18 RP-HPLC) and lyophilized. ESI-MS confirmed 
a mass decrease of 2, representing the loss of 2 protons from the 
cystein side chains due to the generation of 1 disulfide bond (S-S). 
Biotinylated poly(lysine) dendritic wedge, a construct comprising 8 
Gd-DTPA moieties, was synthesized and purified similarly.21,22
Curnis et al. previously showed that cNGR spontaneously converts 
into isoDGR by asparagine deamidation at slightly basic pH, generating 
an α
v
β
3
-integrin ligand.23 Using a combination of HPLC and mass 
spectrometry up to 24 hours after dissolving cNGR in water (pH 6.0) 
and 1 μM borate buffer (pH 8.3, supplemented with 0.05% NaN
3
), 
respectively, it was found that this process did not occur in the time-
period of the experiments (data not shown).
Bi-modal, multivalent contrast agent was prepared as follows. 
Streptavidin-conjugated QDs (1 μM in borate buffer pH 8.3, emission 
at 585 nm) were purchased from Invitrogen (Breda, The Netherlands). 
QDs were composed of a CdSe core with a ZnS shell and covered 
with polyethyleneglycol-2000. Each QD holds approximately 10 
surface-bound streptavidins, allowing 30 biotinylated compounds 
to bind on average (personal communication with Invitrogen). 
For each experiment, cNGR-pQDs were prepared freshly at room 
temperature by sequential mixing of 100 μL QD solution with biotin-
cNGR and biotin-poly(lysine) dendritic wedge, both dissolved in 
Hanks Balanced Salt Solution (HBSS, pH 7.4, Invitrogen), in a 
molar ratio of 1:6:24 to a total volume of approximately 120 μL. 
Samples were mildly vortexed during each preparation step to ensure 
a homogeneous distribution of biotin-cNGR and biotin-poly(lysine) 
dendritic wedge over the QD surface. Overall, each QD carried a 
maximum of 192 Gd ions and 6 cNGR peptides. Unlabeled pQDs 
carried the same number of Gd constructs but no cNGR. A schematic 
representation of the cNGR-pQD particle is shown in Figure 1.
   
Figure 1 Schematic representation of a cNGR-labeled paramagnetic quantum 
dot. Each particle carries approximately 10 streptavidin moieties to which 6 
cNGR groups and 24 dendritic gadolinium constructs were bound. The total 
number of gadolinium ions per particle was maximally 192.
Biotin Gd-DTPA wedge
Streptavidin
Biotin cNGR peptide
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Animal model
All animal studies were approved by the institutional animal welfare 
committee. 1.5 - 3 × 106 human colorectal adenocarcinoma cells 
(LS174T, American Type Culture Collection CL-188, Rockville, 
MD) were subcutaneously and unilaterally injected on the flank 
of ~ 15 week old male Swissnu/nu mice (Charles River, Maastricht, 
The Netherlands). Mice were subjected to the MRI examination 
when the tumor diameter was greater than 1.0 cm, which was 
approximately 16 days after LS174T injection.
For in vivo MRI, mice were anesthetized using 1.5 - 2.0% 
isoflurane (Abbott Laboratories Ltd, Queensborough, UK) in 
medical air and were placed prone in a dedicated animal holder with 
built-in mask for anesthesia gas supply. An infusion line was placed 
in the jugular vein for contrast agent administration during the MRI 
experiment. A heating pad was placed over the mice to maintain 
normothermic conditions. Respiration rate and body temperature were 
continuously monitored via a balloon sensor and rectal temperature 
probe, respectively, interfaced to an MR compatible small animal 
monitoring system (SA Instruments Inc, Stony Brook, NY).
Mice were randomly selected for injection with either cNGR- or 
unlabeled pQDs. Seven mice were included for each contrast agent 
group. Mice were kept inside the magnet during the entire MRI 
experiment to preserve their position.
   
MRI protocol
All MRI experiments were performed on a 7 T Bruker Biospec 70/30 
USR MRI system, interfaced to an AVANCE II console (Bruker Biospin 
GmbH, Ettlingen, Germany). The BGA12-S mini imaging gradient 
(maximum gradient strength 720 mTm-1, slew rate 6000 Tm-1s-1) and a 
3.5 cm inner diameter quadrature volume resonator were used.
   
Molecular MRI 
Tumors were localized using T
2
-weighted anatomical images (TR 
4200, TE 37.4 ms). Next, pre-contrast R
1
 values were determined 
using a series of IR measurements with increasing inversion times 
(TR 4000, TE 8.4, TI 500, 1000, 1500, 2000, 2500 and 3500 ms; 
total scan time 18 minutes). Subsequently, mice were injected with 
120 μL of cNGR- or unlabeled pQDs, followed by a 50 μL saline 
flush. IR experiments were repeated approximately 30 minutes post-
contrast to ensure adequate contrast agent circulation and a reduced 
level of intravascular contrast agent. Images were recorded using 
a field-of-view (FOV) of 4.0 × 4.0 cm2, a 192 × 192 acquisition 
matrix interpolated to 256 × 256 by means of zero-filling, and a slice 
thickness of 1.2 mm, resulting in 0.16 × 0.16 × 1.2 mm3 sized voxels. 
On average, 15 contiguous slices were recorded in multi-slice mode 
(range 11 - 22 slices, depending on tumor size and orientation). 
After MRI, mice were euthanized by cervical dislocation.
   
Competition experiment 
Four tumor-bearing mice were randomly selected for a competition 
experiment of cNGR-pQDs with unconjugated cNGR, i.e., non-
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biotinylated, non-paramagnetic, and non-fluorescent. Imaging 
was performed as described above, except that 525 μg/mouse of 
unconjugated cNGR, i.e., a 1000-fold excess as compared to 
QD-bound cNGR, was injected intravenously 10 minutes after 
administration of cNGR-pQDs.
   
Biodistribution 
Healthy Swiss mice (Charles River) were injected with either cNGR-
pQDs, unlabeled pQDs or no contrast agent. After approximately 
1 hour circulation time, mice were sacrificed and whole body T
1
-
weighted spin echo images were recorded (TR 1100, TE 8.5 ms, 
FOV 4.0 × 6.0 cm2, matrix 256 × 512, resolution 0.16 × 0.12 × 1.2 
mm3). Two mice were included per group. 
   
Tissue harvesting 
After MRI, tumor, spleen, liver, kidney, hind limb muscle, heart and 
lung were excised and embedded in optimal cutting temperature 
(OCT) compound (Sakura Finetek Europe, Zoeterwoude, The 
Netherlands). Next, tissues were snap-frozen in cold 2-methylbutane 
(Acros Organics, Geel, Belgium) for approximately 2 minutes and 
subsequently transferred to liquid nitrogen. Tissues were stored at 
-80 °C until TPLSM measurements.
   
Contrast agent relaxivity 
T
1
 relaxivity (r
1
) was determined by diluting cNGR-pQDs in 
HBSS in 9 steps to concentrations of 0 - 0.001 mM (corresponding 
gadolinium concentrations: 0 - 0.192 mM). The R
1
 of each sample 
was determined using the IR series as described above. Absolute 
gadolinium concentrations were measured using inductively coupled 
plasma mass spectrometry. Longitudinal relaxivity was determined 
by the slope of a linear fit of R
1
 versus gadolinium concentration.
MRI data analysis
All data processing was performed in Matlab (The Mathworks, Natick, 
MA), unless stated otherwise. IR images were first spatially coregistered 
using the mutual information algorithm in the MIRIT software package24 
to correct for possible animal motion in the images with different T
1
 
contrast, and smoothed with a three dimensional Gaussian kernel with 
a full-width-at-half-maximum of 0.4 × 0.4 × 3.0 mm3. Regions of 
interest (ROIs) were drawn manually in MRIcro25 to define tumor and 
muscle tissue. Both T
1
- and T
2
-weighted images were used to accurately 
delineate tumors from surrounding tissue and edema.
Pre- and post-contrast R
1
 values were determined on a voxel-
by-voxel basis by non-linear curve fitting of the IR signal intensity 
function:26
  S = S
0
 (1 - 2exp(-TI·R
1
) + exp(-TR·R
1
))   [1]
   
using the Levenberg-Marquardt optimization algorithm. S
0
 is a 
scaling factor including proton density, excitation pulse profile, 
echo time and pre-amplifier gain.
The detection limit for changes in R
1
 (DR
1
 = R
1,post  
- R
1,pre
) was 
determined with a Monte Carlo simulation using equation 1, in vivo 
relaxation rates and representative noise levels as derived from the 
in vivo experiments. A voxel was considered significantly enhanced 
when DR
1
 was more than 1.96 (i.e., 95% confidence interval) 
times higher than the detection limit of 0.005 s-1. We defined the 
quantitative contrast derived from the DR
1
 measurements (QC
R1
) 
as the product of the mean DR
1
 and the percentage of significantly 
enhanced voxels for each tissue type, i.e., tumor rim and core, and 
muscle tissue. QC
R1
 indicates both the level and spatial extent of 
contrast agent binding. Changes in S
0
 (DS
0
 = S
0,post
 - S
0,pre
) were 
also evaluated and the quantitative contrast from S
0
 (QC
S0
) was 
defined analogously to QC
R1
 to yield a quantity that reflects proton 
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visibility.27
Tumor rim/core analysis
To investigate the differences between tumor rim, i.e., the region with 
the highest expected angiogenic activity, and core, the tumor rim was 
first defined as an approximately 1 mm thick peripheral zone with the 
strongest enhancement in R
1
, in accordance with the approach taken 
by others.28,29 Using this thickness, the difference between cNGR- 
and unlabeled pQDs was maximal (Figure 3C). The rim comprised 
29.0 ± 5.8% and 31.6 ± 3.5% of all tumor voxels for mice injected 
with cNGR- and unlabeled pQDs, respectively. The tumor core was 
defined as the difference between whole tumor and tumor rim ROIs. 
Secondly, a contour was drawn to calculate the number of voxels with 
a significantly increased DR
1
 as a function of the distance to the tumor 
rim. As an empiric measure of spatial heterogeneity in angiogenic 
tumor activity, the half-value-depth was defined as the distance from 
the rim at which the percentage of enhanced voxels has decreased 
by 50% compared to its value at zero distance, i.e., the rim. The 
half-value-depth was calculated by fitting the group-averaged data 
presented in Figure 3C with a mono-exponential decay function.
   
Biodistribution
ROIs defining the spleen, liver, kidney, heart, lung and aorta were 
drawn manually in MRIcro. Signal intensities were averaged over 
the entire tissue and normalized to hind limb muscle.
   
Statistical analysis
Analysis of paired samples was performed using a non-parametric 
Wilcoxon signed ranks test in SPSS 14.0 (SPSS, Chicago, Ill).
As both QC
R1
 and QC
S0
 represent contrast agent presence, QC
R1
 
and QC
S0
 were combined to a summary value according to O’Brien 
and Läuter,30,31 which is more sensitive to contrast effects than the 
individual measures. Therefore, QC
R1
 and QC
S0
 were first standardized 
by z = (QC - mean(QC)/sd(QC)). Subsequently, the absolute values 
of z
QCR1
 and z
QCS0
 were averaged per animal. The resulting summary 
measure was tested using a non-parametric Mann-Whitney U-test. 
P < 0.05 was considered statistically significant.
TPLSM data acquisition
Tissue samples were thawed and washed with HBSS to remove OCT 
compound. Except for the spleen and liver, tissues were incubated 
with 25-fold diluted αCD31-FITC (0.5 mg/mL, BD Biosciences 
Pharmingen, Alphen aan de Rijn, The Netherlands) to fluorescently 
label VECs. Next, tissues were embedded in 2%  (w/v) agarose gel 
(Invitrogen), with their rim upwards. For measurements in the tumor 
core, tumors were cut transversally to resemble the slice orientation 
of the MRI measurements.
TPLSM imaging was performed using a Nikon Eclipse E600FN 
upright microscope (Tokyo, Japan), incorporated in the Bio-Rad 
Radiance 2100MP imaging system and operated by Lasersharp2000 
V6.0 (Bio-Rad, Hemel Hempstead, UK). Tissue samples were excited 
by the Tsunami Ti:sapphire laser (Spectra-Physics, Mountain View, 
CA), which was pumped by a Millennia Vs 5 W pump laser (Spectra-
Physics) and mode-locked at 800 nm, with a 82.5 MHz repetition 
rate and 140 fs pulse width. Tissues were observed through a water 
dipping 60×  fluor objective with a 1.00 numerical aperture (Nikon). 
Photomultiplier tubes (PMTs 9108B02 and 9136B05, Electron Tubes 
Limited, Ruislip, UK) were used to acquire fluorescence photons in 
three spectral regions: 420 - 470 nm (autofluorescence), 520 - 560 nm 
(FITC) and 570 - 600 nm (QDs). Each PMT was tuned for minimal 
bleed-through of the fluorescent markers to adjacent PMTs. Images, 
color-coded blue, green and red, respectively, were subsequently 
merged into a single image. The in-plane pixel dwell time was 11.8 
μs, which, together with a 2-fold Kalman averaging, resulted in an 
imaging speed of 0.16 Hz. The FOV was 179 × 179 μm2 with a matrix 
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size of 512 × 512, resulting in 0.35 × 0.35 μm2 sized pixels.
TPLSM data analysis
Data were analyzed with Image-Pro Plus 6.0 (MediaCybernetics, 
Silver Spring, MD) and ImageJ 1.35 (NIH, Bethesda, MD). Image 
quality was improved by convolution with a 1.05 × 1.05 μm2 
Gaussian filter. Spatial distribution of pQDs was classified into 
four groups: intravascular, intracellular, colocalized with the EC 
membrane or extravasated to the interstitium.
   
Results
   
In vivo targeting of activated tumor endothelium
The ability of cNGR to target angiogenic tumor VECs was evaluated in 
tumor-bearing nude mice by injecting them with cNGR- or unlabeled 
pQDs. Tumor volumes of cNGR and control groups did not differ on MR 
images (mean ± SD 1.0 ± 0.7 cm3 and 1.0 ± 0.6 cm3, respectively).
For both cNGR- and unlabeled pQDs, changes in R
1
 (DR
1
) 
were spatially heterogeneous throughout the tumor and were most 
pronounced at the tumor rim (Figure 2A). Averaged over all mice, 
the DR
1
 induced by cNGR-pQDs ranged up to approximately 0.3 
s-1, which was considerably larger than the intrinsic variation in 
pre-contrast tumor R
1
 of 0.1 s-1. Furthermore, the range in DR
1
 was 
relatively large compared with the pre-contrast tumor R
1
 of 0.8 
s-1. Administration of unlabeled pQDs resulted in a 3-fold lower 
response range (DR
1
 < 0.1 s-1) compared with cNGR-pQDs.
Subsequent investigation by TPLSM allowed localization of 
cNGR- and unlabeled pQDs at a subcellular resolution. cNGR-
pQDs were found to colocalize approximately three times more 
often with tumor VECs than unlabeled pQDs (Figure 2). cNGR- and 
unlabeled pQDs were also found in the vessel lumen, albeit that 
cNGR-pQDs were approximately three times more prevalent than 
unlabeled pQDs. Both contrast agents were only sparsely found to 
have extravasated into the tumor interstitium. Although cNGR was 
previously reported to be an internalizing peptide,32 cNGR-pQDs 
were not detected inside VECs with TPLSM.
Further evidence for the specificity of cNGR was provided by 
DR
1
 in hind limb muscle. Here, average DR
1
 upon administration of 
cNGR-pQDs was considerably lower than in the tumor and ranged 
up to 0.05 s-1. TPLSM did not display colocalization of cNGR-
pQD with VECs of muscle vasculature. However, the incidence 
of cNGR-pQDs in the muscle vascular lumen was almost two-fold 
higher than for unlabeled pQDs (Figure 2D).
   
S
0
-effect
For both cNGR- and unlabeled pQDs, changes in the scaling factor 
S
0
 colocalized strongly with DR
1
 (Figure 2B). The S
0
-effect is likely 
caused by field inhomogeneities (T
2
* effect) in the vicinity of  the 
contrast agent, induced by the magnetic properties of QDs33 and the 
dense gadolinium concentration on the particle. Analogous to iron 
oxide particles, such properties result in a locally reduced transverse 
relaxation times T
2
 and T
2
*, a shift in local resonance frequency and 
a broader water resonance line, which is reflected by a decrease in 
S
0
, i.e., a reduced proton visibility.27,34 Therefore, DR
1
 and DS
0
 both 
represent contrast agent presence.
   
Spatial heterogeneity
To explore the absolute differences between tumor rim, tumor core 
and muscle, QC
R1
 and QC
S0
 were determined for each tissue type 
for cNGR- and unlabeled pQDs (Figure 3A/B). Administration of 
cNGR-pQDs resulted in an approximately 50-fold increase in QC
R1
 
in the angiogenic rim compared with tumor core or muscle tissue. 
For unlabeled pQDs, significant differences were also found between 
tumor rim and core, and tumor rim and muscle tissue, although the 
net increase in QC
R1
 was lower than for cNGR-pQDs. The decreases 
Figure 2 A-B) T
2
-weighted anatomical images with color overlay of ΔR
1
 
(A) and ΔS
0
 (B) for tumor (T) and muscle (M) tissue of mice injected with 
cNGR- or unlabeled pQDs. Changes in R
1
 were most pronounced at the 
tumor rim for cNGR-pQDs. Although an R
1
 increase in the tumor rim was 
also observed for unlabeled pQDs, the average response was 3-fold lower 
when compared with cNGR-pQDs, indicating a high specificity of cNGR 
for angiogenic tumor endothelium. This is further supported by the low 
changes in R
1
 found in muscle tissue. Changes in S
0
 (B) colocalized almost 
completely with changes in R
1
 (A). Representative TPLSM images of tumor 
(C) and muscle tissue (D) showing pQD signal in red and endothelial 
cell specific αCD31-FITC in green. cNGR-pQDs accurately colocalized 
with tumor endothelial cells, indicating binding of the contrast agent to 
the tumor endothelium (C). cNGR-pQDs were also detected in muscle 
tissue with TPLSM (D, arrows), although to a much lesser extent than in 
tumor tissue. cNGR-pQDs did not display any colocalization with muscle 
endothelial cells and were only found intraluminally. Unlabeled pQDs were 
not or only sparsely detected in both tumor and muscle tissue. Bar: 50 μm.
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in S
0
 showed the same trend as the increases in R
1
 (cf. Figure 3A/B).
   
For each of the three tissue types, no significant differences in 
QC
R1
 or QC
S0
 were found between cNGR- and unlabeled pQDs. Since 
DR
1
 and DS
0
 were shown to accurately colocalize (Figure 2), QC
R1
 
data were combined with QC
S0
 to a summary measure as described 
above. This resulted in a statistically significant difference between 
cNGR- and unlabeled pQDs for the tumor rim only (Figure 3A/B).
To further investigate the spatial distribution of angiogenic 
activity in the tumor, the percentage of significantly enhanced 
voxels was calculated as a function of the distance to the tumor rim 
(Figure 3C). Although the highest signal increase was found at the 
tumor rim for both contrast agents, more than twice as many rim 
voxels were enhanced for cNGR-pQDs than for unlabeled pQDs. In 
the tumor core, similar enhancements were found for both contrast 
agents. These findings qualitatively concur with previous findings 
showing that angiogenic activity is most pronounced at the tumor 
Figure 3 Spatial distribution of angiogenic activity. A-B) Quantitative 
contrast as derived from changes in R
1
 (QC
R1
, A) and from changes in S
0 
(QC
S0
, B) for tumor rim, tumor core, and hind limb muscle tissue. Data 
are shown for cNGR-pQDs (n = 7), unlabeled pQDs (n = 7), and the 
competition experiment of cNGR-pQDs with excess unconjugated cNGR 
(n = 4). C) Percentage of enhanced voxels at a certain distance versus 
distance from the tumor rim for cNGR-labeled and unlabeled pQDs. 
Although enhanced voxels were mostly found at the tumor rim for both 
contrast agents, more than twice as many rim voxels were enhanced for 
cNGR-pQDs than for unlabeled pQDs. In the tumor core, similar values 
were found for both cNGR-labeled and unlabeled pQDs. Values are 
presented as median ± standard error. *, P < 0.05; #, P < 0.05 for the 
O’Brien- Läuter summary measure of QC
R1
 and QC
S0
 (see text).
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rim for this tumor model.7,35
   
Subsequently, half-value-depths were calculated for both cNGR- 
and unlabeled pQDs. High values indicate a more homogeneous 
distribution of enhanced voxels over the entire tumor and thus a 
low spatial heterogeneity, whereas low values indicate a high spatial 
variation. For cNGR- and unlabeled pQDs, the half-value-depths 
were 0.6 and 1.1 mm, respectively, indicating a stronger contrast 
between tumor rim and core for cNGR-pQDs, which suggests that 
cNGR-pQDs allow a better differentiation between tumor rim and 
core than unlabeled pQDs.
   
Competition experiment
Intravenous injection of a 1000-fold excess of unconjugated cNGR 
10 minutes after administration of cNGR-pQDs resulted in a 
statistically significant decrease in QC
R1
 and QC
S0
 for the tumor rim 
(Figure 3A/B). With TPLSM, cNGR-pQDs were barely detected in 
the tumor rim, which confirmed the MRI results (data not shown). 
These results therefore indicate that binding of cNGR-pQDs to 
tumor VECs is specific, reversible and can be competed with 
Figure 4 Biodistribution of cNGR- and unlabeled pQDs. A) Post 
mortem T
1
-weighted MRI results. Signal intensities were normalized to 
hindlimb muscle signal and subsequently averaged. No CA: no contrast 
agent administration. Both cNGR- and unlabeled pQDs were found to 
accumulate mainly in the spleen, liver and kidneys. Values are represented 
as median ± standard error. B) Representative TPLSM images of spleen, 
liver, lung and kidney. Since a similar biodistribution was found for cNGR- 
and unlabeled pQDs, no differentiation was made for the TPLSM results. 
Red: pQDs, Green: αCD31-FITC, Blue: autofluorescence, Bar: 50 μm.
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unconjugated cNGR.
   
Biodistribution
Figure 4 shows the relative MRI signal intensities for the blood 
and major organs recorded approximately one hour after the 
administration of cNGR-pQDs, unlabeled pQDs or no contrast 
agent. No differences were found between cNGR- and unlabeled 
pQDs. Both contrast agents accumulated mainly in the spleen, 
liver and kidneys (Figure 4), which was confirmed by TPLSM 
and corresponds to previous findings.36 Due to the intravenous 
administration, pQDs were also expected to accumulate in the lung. 
However, MRI has only limited signal sensitivity in the lung due to 
inherent low signal intensity and air-tissue interfaces. With TPLSM, 
pQDs could be clearly detected in the lung (Figure 4), although 
imaging was hampered by tissue movement caused by heating of 
the sample during excitation, resulting in expansion of air in the 
pulmonary alveoli.
   
Contrast agent relaxivity
The ionic T
1
 relaxivity of cNGR-pQDs, i.e., per Gd ion, was 7.1 
± 0.4 mM-1s-1 at 7 T and 20 °C, which lies in the expected range 
for macromolecular contrast agents and is in correspondence with 
previously reported values for Annexin A5 conjugated pQDs.37
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Discussion
Current findings
In this study, the ability of cNGR-labeled paramagnetic QDs to 
visualize and quantify angiogenic activity in LS174T tumors was 
evaluated using two complementary imaging modalities: in vivo MRI 
and ex vivo TPLSM. To our knowledge, this study shows the first 
results of the application of cNGR for molecular MRI. First, cNGR-
pQDs were found to have a 3-fold higher quantitative MRI contrast 
in the tumor rim, i.e., the tumor region with the highest angiogenic 
activity, compared with unlabeled pQDs. Second, cNGR-pQDs were 
barely detectable in muscle tissue, indicating a high specificity of 
cNGR-pQDs for angiogenic vessels. Third, ex vivo TPLSM showed 
colocalization of cNGR-pQDs, but not unlabeled pQDs, with VECs 
in tumor vasculature. Fourth, cNGR-pQDs allowed a more accurate 
assessment of the rim-core heterogeneity in tumor angiogenic activity. 
Fifth, the competition experiment indicated that the binding of cNGR-
pQDs to tumor VECs is specific, reversible and can be competed 
with excess unconjugated cNGR. Finally, no qualitative differences 
in biodistribution were found between cNGR- and unlabeled pQDs 
with MRI and TPLSM. For a full quantitative biodistribution 
assessment, positron emission tomography (PET) would be better 
suited since the local relaxivity of the MRI contrast agent, which is 
required to convert R
1
 to concentrations, is unknown. Taken together, 
the presented results designate cNGR as an effective ligand for 
discriminating between quiescent and activated endothelium and for 
quantifying the extent of tumor angiogenic activity.
In correspondence with other studies,7,35 our results indicate that 
angiogenic activity is highest at the tumor rim, which was reflected 
by a high QC
R1
 and a strongly negative QC
S0
 for cNGR- pQDs. This 
was supported by the statistically significant difference between 
cNGR- and unlabeled pQDs found using the summary value. 
Unlabeled pQDs also showed differences between tumor rim versus 
core and muscle, albeit smaller than for the cNGR-pQDs. This is 
likely due to the tumor rim’s intrinsically higher vascular density 
and corresponding blood pool fraction, resulting in a larger amount 
of circulating contrast agent compared with tumor core or muscle 
tissue.35 Additionally, heterogeneous blood flow and long wash-
in and -out times of macromolecular contrast agents, previously 
described for dendritic agents,38 may have contributed to prolonged 
retention of unlabeled pQDs in the tumor rim.
Methodological considerations
Non-linear fitting of the IR-signal over a range of inversion times 
provided a sensitive and reliable method for detecting R
1
 changes 
induced by contrast agent binding. Compared to signal intensity 
measurements, it is relatively independent of technical settings, e.g., 
repetition time, echo time and flip angle, thereby allowing objective 
comparison between different subjects, both spatially and temporally. 
A disadvantage of the quantitative approach is the lengthy acquisition 
time since an adequate number of data points is required for accurate 
fitting of the IR curve. Although prolonged pre- and post-contrast 
acquisition of a single image at a fixed inversion time may also allow 
accurate detection of changes in signal intensity, this will not provide 
quantitative information on R
1
 and S
0
. In our quantitative approach, 
coregistration of these parameters ensured increased sensitivity 
to detect differences between cNGR- and unlabeled pQDs and is 
therefore preferred over acquisition of a single image.
Theoretically, the measured longitudinal relaxation rates and 
contrast agent relaxivity allow estimation of local contrast agent 
concentration and might be used to gain insight in the density of the 
molecular target. However, the conditions under which the relaxivity 
was determined differ strongly from the in vivo situation. Not only is 
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the relaxivity affected by the particle’s chemical environment, i.e., 
aqueous buffer versus blood plasma,39 specific binding to vascular 
endothelium reduces its tumbling rate, thereby increasing the 
relaxivity. Taken together, this would lead to an overestimation of the 
local concentration in vivo. Unfortunately, accurate measurements 
of in vivo relaxivity are currently unavailable.
Contrast agent
Quantum dots were chosen as scaffold to enable bi-modal, i.e., 
MRI and TPLSM, visualization of tumor angiogenic activity, 
which is an essential step in the characterization and validation of 
cNGR as a targeting ligand. Furthermore, streptavidin-coated QDs 
provide a suitable and versatile research scaffold to identify and test 
other potential targeting ligands. In addition, QDs show minimal 
extravasation, both from healthy and hyperpermeable tumor 
vasculature (unpublished observations), which is beneficial for 
VEC targeting. However, QDs may pose serious health limitations 
due to the potential release of toxic cadmium ions. Although this 
can be prevented by effective shielding of the core,40,41 QDs are not 
cleared from the body and accumulate in spleen, liver and kidneys. 
Cadmium-based QDs will therefore not be approved for clinical 
application. Recently developed non-toxic and renally excretable 
QDs may provide a potential solution for this problem.42,43 
Nevertheless, once a robust MRI method has been accepted in 
clinical practice, validation with luminescent particles is no longer 
necessary and clinically more suitable particles may be applied.
The magnetic and semi-conductive properties of QDs give rise 
to field inhomogeneities when placed inside a magnetic field,33 
which likely result in a local decrease of the transverse relaxation 
times T
2
 and T
2
*. In addition, T
2
 contrast becomes more effective at 
high field strength, whereas T
1
 contrast decreases. Using a standard 
multi-slice multi-echo spin echo sequence, an average R
2
 increase of 
5.7 s-1 upon cNGR-pQD injection was detected in the tumor rim at 
a mean tumor pre-contrast R
2
 of approximately 27 s-1. However, the 
percentage of significantly enhanced voxels in the tumor rim was 
only 4%, which is considerably lower than the 42% found for R
1
. 
This demonstrates that T
2
 changes did not interfere with the effects 
on T
1
 and S
0
. Consequently, the T
1
 and S
0
 quantification was more 
sensitive in discriminating between angiogenic activity in the tumor 
rim, tumor core and muscle tissue than T
2
. 
Clinical perspectives
Regarding the potential clinical applicability, quantitative molecular 
MRI with a suitable contrast agent has a number of advantages over 
the currently used immunohistochemical methods to quantify tumor 
angiogenic activity. First, molecular MRI is non-invasive and does 
not interfere with tissue integrity. Second, it can probe the entire 
tumor, whereas immunohistochemistry requires biopsies at one 
or multiple selected locations. Third, it allows covisualization of 
angiogenic activity with local anatomy. Fourth, tumor status or 
therapeutic response may be objectively monitored over time due 
to the absolute quantification methodology. Finally, molecular 
MRI allows direct detection of activated endothelium in functional 
vasculature, while immunohistochemistry measures both perfused 
and non-perfused vessels.
With respect to the applied tumor model, a human colorectal 
adenocarcinoma, MRI is clinically important for local T-staging of 
rectal cancer and for the identification of tumors close to or invading 
the mesorectal fascia.44 On diagnostic T
2
-weighted images however, 
it remains difficult to differentiate between fibrotic tissue and viable 
tumor cells. Molecular MRI of angiogenesis may facilitate this 
demarcation, since only viable tumor cells induce angiogenesis, which 
may be visualized upon administration of the targeted contrast agent.
Besides the availability of suitable contrast agents, clinical 
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implementation of quantitative molecular MRI requires rapid 
imaging sequences, including Look-Locker,45 IR-true-FISP,46 and 
the recently described QRAPTEST.47 However, these methods are 
relatively sensitive to subject movement and field inhomogeneities, 
although the Look-Locker method was recently modified to allow 
in vivo T
1
-mapping of the heart.48 Thus, the development of fast 
quantification of relaxation rates may support future clinical 
application of quantitative molecular MRI.
In summary, we have shown that cNGR-labeled paramagnetic 
quantum dots are suitable for the non-invasive visualization 
and quantification of tumor angiogenic activity using in vivo 
molecular MRI. These results provide a promising basis for 
further developments in contrast agent design and synthesis, data 
acquisition and post-processing techniques, which may be valuable 
for future clinical applications to pathologies in which abnormal 
vessel growth plays a pivotal role.
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Neo-vascularization contributes to development and destabilization 
of atherosclerotic plaques and to growth and metastazation of solid 
tumors. The studies presented in this thesis demonstrate that the 
combination of two-photon laser scanning microscopy (TPLSM) 
and magnetic resonance imaging (MRI) allows visualization and 
quantification of microvascular morphology and angiogenic activity 
in murine models of atherosclerosis and cancer. MRI allows in 
vivo visualization and gross localization of angiogenic activity. 
Furthermore, our data indicate that MRI is able to detect differences 
in microvascular morphological quantities and localization. Ex 
vivo, TPLSM permits high resolution assessment of angiogenic 
activity and accurate visualization and quantification of microvessel 
morphology and angiogenic activity thereof at the level of the 
individual microvessel.
However, several biological and technical limitations may apply 
to the presented studies, including fluorescent labeling of vascular 
endothelial cell membranes for quantification of vasa vasorum and 
tumoral microvessels (chapter 5), the lack of an atherosclerosis mouse 
model with high vasa vasorum density (chapter 4), and the limited 
tissue penetration depth of TPLSM, relative to MRI (chapter 5 and 6).
   
CD31 for demarcation of microvessels
In the studies described in chapters 4, 5, and 6, αCD31-FITC was used to 
fluorescently label endothelial cells by in vivo injection (chapter 4) and 
ex vivo incubation (chapter 5 and 6). The former allowed visualization 
of functional, i.e., perfused vasa vasorum microvessels only, whereas 
the latter presumably allowed visualization of both functional and non-
functional tumor microvessels with TPLSM. In future experiments, 
discrimination of functional from non-functional vasculature may be 
achieved by systematic administration of fluorophores that reside in the 
blood phase1 and subsequent ex vivo incubation with spectroscopically 
distinct αCD31. Neo-vasculature may exhibit a discontinuous 
endothelial layer. Although this may have minimal effect on the 
visualization of the microvasculature, quantification of microvessel 
density may lead to underestimation. In chapter 5, this was countered 
by application of a closing and blurring filter to the acquired dataset in 
order to obtain solid cylindrical structures.
Endothelial cells of mature and angiogenic (micro-) vasculature 
express CD31.2 In addition, CD31 is expressed by endothelial cells of 
lymphatic vessels as well.3-5 Since lymphangiogenesis is associated 
with intimal thickening6 and tumor development,7 one might argue 
that the observed adventitial and tumoral vascular structures, labeled 
with αCD31-FITC, are partially lymphatic vessels. However, a recent 
FACS study showed that mouse lymphatic endothelial cells are 
only 3% positive for CD31.8 In that study, the same antibody clone 
(MEC13.3) was used as in the experiment presented in chapters 4, 5, 
and 6. These studies indicate that the differential expression pattern of 
CD31 did not overestimate microvessel density in tumors compared 
with muscle tissue and the expression of CD31 by lymphatic vessels 
is too low for imaging purposes.
   
Vasa vasorum of atherosclerotic plaques
In vivo intravenous injection of fluorophore-conjugated antibodies 
against vascular endothelial cells allowed visualization of plaque 
vasa vasorum ex vivo with TPLSM (chapter 4). Interestingly, vasa 
vasorum (an adventitial plexus of microvessels in the wall of larger 
blood vessels) were observed in the plaque region of the abdominal 
aorta of ApoE-/- mice, fed a Western type diet for approximately 20 
weeks, and not in other aortic segments. In murine atherosclerotic 
plaques, neo-vascularization and hypoxia have both been related to 
inflammatory content, however, not to intimal thickness.9,10 This 
implies that, irrespective of plaque size, angiogenic activity may be 
present in all atherosclerotic lesions, albeit at different intensities, and 
lead to the expansion of vasa vasorum and formation of intraplaque 
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microvasculature. A major future challenge in TPLSM is to extend these 
studies to specifically and sensitively detect alterations in expression 
patterns of angiogenesis markers in vivo, since this would allow 
recognition of neo-vascularization in the early stage of development.
The density of plaque vasa vasorum could, unfortunately, not be 
quantified due to the low prevalence of microvessels in this mouse 
model of atherosclerosis. In murine models of more extensive 
atherosclerosis, including long-term high fat diets, collar-induced 
intimal thickening, and ApoE-/-/LDL-/- double knockout mice, the 
vasa vasorum density will be increased.9,11 This would not only 
facilitate longitudinal and quantitative correlation of microvessel 
development to plaque growth, but also facilitate functional studies of 
these microvessels, e.g., visualization of inflammatory cell transport 
through the vasa vasorum and of their angiogenic activity. In 30% 
of the observed, axially orientated vasa vasorum, colocalization 
of cNGR-QDs with endothelial cells was observed, indicating 
significant angiogenic activity (chapter 4). Although αCD31-FITC 
and cNGR-QDs were injected in vivo, TPLSM observations were 
performed ex vivo. Tissue excision and handling may have induced 
artifacts. Furthermore, future (in vivo) experiments, will show 
whether cNGR, in addition to cRGD,12,13 is suitable for molecular 
imaging and therapy of plaque-associated angiogenesis. 
   
Neo-vasculature of solid tumors
As observed with TPLSM, tumor neo-vasculature was highly 
tortuous and displayed a wide range in radiuses (1.2 - 14.9 μm), 
whereas the microvasculature of skeletal muscle was highly 
organized (chapter 5). Using dedicated image processing, values 
were obtained for microvessel density and radius for LS174T 
tumors that are in agreement with literature.14,15 These results 
indicate that deconvolution of TPLSM data leads to reliable 
quantitative information. However, TPLSM experiments were 
performed ex vivo, whereas Leunig et al.14 and Yuan et al.15 used 
intravital microscopy to obtain the microvessel density and radius 
under physiological circumstances. Magnetic resonance vessel size 
imaging (MR-VSI) offered the ability to obtain values related to 
microvessel density and radius on a voxel-by-voxel basis (voxel 
volume of approximately 0.1 mm3). Although, TPLSM and MR-VSI 
displayed similar trends in their respective microvessel density and 
radius data when comparing tumor rim, tumor core, and muscle, MR-
VSI displayed non-physiological values for the microvessel density 
and radius (chapter 5). However, similar values were observed in 
other MR-VSI studies.16-18 These results suggest that MR-VSI is, 
at best, suitable for longitudinal assessment in detecting changes 
in microvessel density and radius during tumor growth and anti-
angiogenic therapy. In addition to the causes addressed in chapter 
5, the heterogeneity in microvascular morphology between the 
tumors observed with MR-VSI and with TPLSM and the increased 
permeability of angiogenic endothelium, causing extravasation of 
the intravascular MRI contrast agent to the interstitial space, may 
have affected the MRI results and thus may have contributed to the 
discrepancy between TPLSM and MR-VSI.
In chapter 6, cNGR-labeled paramagnetic quantum dots (cNGR-
pQDs), specific for the angiogenesis marker CD13, were used 
to visualize angiogenic activity in tumors with in vivo MRI. The 
competition of the binding of cNGR-pQDs to angiogenic endothelial 
cells with unconjugated cNGR resulted in decreased quantitative 
contrast. Moreover, observation of the excised tumor with TPLSM 
indicated colocalization of cNGR-pQDs with endothelial cells. 
These findings confirmed the presence of angiogenic activity in 
tumors. However, since tumors were excised approximately 1 hour 
after injection of the cNGR-pQDs and the binding of cNGR to the 
angiogenesis marker CD13 is reversible, detachment of cNGR-pQDs 
may have caused an underestimation in the angiogenic activity 
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observed with TPLSM, although this was not quantitatively assessed. 
Therefore, in order to prevent dynamic influences and accurately 
evaluate the obtained MRI results, TPLSM experiments should ideally 
not be performed in succession, but in parallel and in vivo under the 
same experimental conditions with a separate group of animals. 
   
Neo-vascularization: atherosclerosis versus cancer
Atherosclerosis and cancer share molecular pathways of development 
and progression, including cell proliferation, cell adhesion molecules, 
and proteolytic enzymes.19 Early atherosclerotic lesions and small 
(less than 1 mm in diameter) solid tumors are typically avascular 
and their development appears to be angiogenesis-independent.20,21 
The common denominator of advanced atherosclerotic plaques and 
solid tumors is the presence of an extensive microvascular network. 
Considering the similarity in morphology, including fragility and 
permeability, and functionality of plaque and tumor neo-vasculature, 
similar imaging approaches may be utilized for visualization and/or 
quantification of microvascular morphology and angiogenic activity. 
In chapters 4 and 6, the aminopeptidase CD13 was successfully used 
as target for molecular imaging of angiogenic activity in plaque-
associated vasa vasorum with ex vivo TPLSM and in tumors with in 
vivo MRI and subsequent ex vivo TPLSM. In addition, Buehler et 
al. and von Wallbrunn et al. showed that CD13 is a suitable target 
for optical molecular imaging of angiogenesis after myocardial 
infarction and in tumors.22,23 Although there is an increasing interest 
in the microvasculature as target for anti-angiogenic therapy in 
atherosclerosis and cancer, and for pro-angiogenic therapy after 
myocardial infarction, clinical evidence of efficacy has been 
minimal to date. Winter et al. successfully explored the feasibility 
of the α
ν
β
3
 integrin as target for molecular imaging and therapy 
of neo-vasculature in atherosclerosis and cancer.12,13,24,25 However, 
compared to cRGD, the ligand for the α
ν
β
3
 integrin, cNGR was 
shown to have a 3-fold higher tumor-homing capability.26 The use of 
cNGR as ligand for molecular imaging and therapy of angiogenesis 
in atherosclerosis is therefore promising.
Hypoxia has been accepted as the main initiator of angiogenesis 
in tumors, whereas in atherosclerotic plaques both inflammation 
and hypoxia are related to angiogenesis. Despite the similarities in 
molecular pathways during development of these diseases, differences 
in risk factors and initiators of angiogenesis may not designate 
atherosclerosis as “a cancer of the blood vessels”, as was proposed by 
Ross et al.27 
   
Future perspectives
Due to the absorption of excitation light and fluorescence by foam 
cells and extracellular lipids, the penetration depth of TPLSM in 
atherosclerotic plaques is limited (chapter 4). However, in tumors a 
penetration depth of up to 250 μm was obtained with TPLSM (chapters 
5 and 6). Penetration depth may be increased in three independent ways. 
First, narrowing of the excitation pulse width presumably increases the 
penetration depth up to 800 μm, depending on tissue composition.28 
Second, optimization of the point spread function using adaptive 
optics. To produce the smallest point spread function, a flexible 
membrane mirror may be deformed based on on the fly variations in 
refractive index within tissue and between immersion and mounting 
media.29,30 This increases fluorescence intensity and resolution, thereby 
improving the penetration depth. Third, using an optical parametric 
oscillator (OPO) laser system, operating at wavelengths 1000 - 
1500 nm, increased penetration depths can be obtained since tissue 
absorption is minimal in this spectral region. In addition, by using 
dedicated (near) infrared fluorophores, such as mCherry,31 fluorescence 
may be detected more efficiently. Which of the proposed methods or 
combinations thereof yields the greatest increase in penetration depth 
remains to be elucidated for each of the observed tissues.
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TPLSM has proven a valuable tool for visualizing and quantifying 
microvascular characteristics in atherosclerosis and cancer. Although 
TPLSM is increasingly being applied as stand-alone in vivo imaging 
modality, in vivo TPLSM evaluation of molecular MRI would 
have great benefits over ex vivo evaluation. These benefits include 
measuring under physiological circumstances and avoidance of 
artifacts induced by tissue excision. The influence of motional 
artifacts on TPLSM image resolution, induced by respiration and 
heartbeat, may be reduced by triggering methods and increasing 
the rate at which images are acquired.32 In addition, for optimal 
evaluation of molecular MRI results, multi-modal contrast agents 
should be optimized to allow efficient detection with both MRI and 
TPLSM.
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Neo-vascularization, more specifically angiogenesis, contributes 
to growth of atherosclerotic plaques and solid tumors by providing 
conduits for transport and microvasculature for exchange of 
nutrients, oxygen, and waste products to the increasing cell mass. 
The shoulders of advanced atherosclerotic plaques are characterized 
by a network of microvessels predominantly originating from the 
vasa vasorum, whereas solid tumors are provided with an internal and 
peripheral microvascular network. Visualization and quantification 
of neo-vascular morphology and of angiogenic activity would allow 
monitoring of the development of (vulnerable) atherosclerotic 
plaques and (malignant) tumors. Therefore, in this thesis, two-
photon laser scanning microscopy (TPLSM) and magnetic resonance 
imaging (MRI) were utilized to visualize angiogenic activity in 
atherosclerotic mice and in tumor-bearing mice and to quantify neo-
vascular morphology in tumor-bearing mice. The sub-micrometer 
spatial resolution of TPLSM also enables validation of the MRI 
observations.  
In chapter 2, a brief overview is provided on the mechanisms 
of angiogenesis and hypoxia as its main initiator. The processes of 
atherogenesis and carcinogenesis are shortly described, followed 
by the contribution of the vasa vasorum (VV) and intraplaque 
microvasculature to the growth and rupture of atherosclerotic plaques 
and the contribution of microvasculature to tumor growth. Animal 
models for atherosclerosis and cancer are described and methods 
to visualize morphology, permeability, and angiogenic activity are 
provided. This chapter concludes with the basic principles of two-photon 
laser scanning microscopy (TPLSM), its application to visualizing and 
quantifying neo-vasculature, and the application of TPLSM as high 
resolution imaging validation method.
Molecular imaging methods currently under development may 
contribute to future personalized medicine in treating cardiovascular 
disease. Endoscope-compatible optical techniques, including TPLSM, 
Raman microspectroscopy (RMS), optical coherence tomography 
(OCT), and photoacoustic tomography (PAT) would allow intravascular 
molecular imaging of vulnerable atherosclerotic lesions. Efficient 
optical visualization of molecular epitopes specific for vulnerable 
atherosclerotic lesions requires targeting of high quality optical 
contrast-enhancing nanoparticles. In chapter 3, a review is provided 
on current optical nanoparticles, confined to quantum dots (QDs), 
gold nanoparticles (AuNPs), diamond nanoparticles (DNPs), carbon 
nanoparticles (CNPs), and silica nanoparticles (SNPs), and targeting 
ligands for optical molecular imaging of atherosclerotic lesions. It is 
concluded that, based on the limited toxicity and favorable optical 
properties, AuNPs and SNPs provide the most promising perspective 
for future optical molecular imaging of atherosclerosis in the clinical 
environment. 
Atherosclerotic plaques are constantly evolving structures, 
which are associated with an increase in vasa vasorum (VV) density, 
as shown by several histological and micro-computed tomography 
(micro-CT) studies of ApoE-/- mice. However, these methods require 
tissue processing, thereby affecting tissue integrity and morphology. 
Therefore, in chapter 4 we investigated the feasibility of TPLSM 
to ex vivo image the VV of intact atherosclerotic aortas of ApoE-/- 
mice. Vascular endothelial cells (VECs) were fluorescently labeled 
via intravenous injection of αCD31-FITC, whereas angiogenic 
activity of VECs was assessed by in vivo targeting with QDs of 
CD13, expressed by angiogenic VECs, by binding cyclic Ans-Gly-
Arg (cNGR) to the QD surface (cNGR-QDs). VV were observed in 
the aortic abdominal bifurcation of ApoE-/- mice fed a Western type 
diet for 20 weeks, abluminal from the atherosclerotic lesion, with 
microvessels penetrating the media up to 60 μm. Interestingly, VV 
were not observed in other aortic segments of these mice. cNGR-
QDs colocalized with 30% of the ApoE-/- VV, indicating angiogenic 
activity. The sporadically observed adventitial microvessels of 
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the abdominal aorta of control C57BL/6J mice displayed no 
angiogenic activity. This study indicates a higher plaque-associated 
VV prevalence in the abdominal aorta bifurcation of ApoE-/- mice 
than of control C57BL/6J mice. TPLSM proved a practical tool in 
visualizing the VV of intact arterial segments and may be employed 
to evaluate the contribution of the VV and intraplaque microvessels 
underlying the potential destabilization of atherosclerotic lesions in 
longitudinal studies.
Non-invasive assessment of microvascular morphology and 
density would allow estimation of disease progression, i.e., 
development of vulnerable atherosclerotic plaques and tumor growth 
and metastasis formation, and the response to anti-angiogenic therapy. 
Magnetic resonance vessel size imaging (MR-VSI) non-invasively 
provides measures for the microvessel radius and fractional blood 
volume of biological tissue. In chapter 5, the validity of in vivo 
MR-VSI in assessing these measures for tumor and muscle tissue 
of mice was evaluated using ex vivo 3D TPLSM. Dedicated image 
processing was applied to the acquired TPLSM datasets to quantify 
microvessel radius, density, and length of microvasculature of 
these excised, but intact tissues. TPLSM data displayed a randomly 
oriented tumor microvasculature, whereas muscle microvessels 
were mainly oriented parallel to each other. For both MR-VSI and 
TPLSM, a larger vessel radius and fractional blood volume were 
found in the tumor rim than in the core. Compared with TPLSM, 
MR-VSI resulted in a large overestimation of the average vessel 
radius index, whereas the fractional blood volume was slightly 
lower. However, the trends for both techniques were the same: 
morphologic measures were higher for tumor than for muscle tissue, 
and higher for tumor rim than for the core. Thus, although MR-VSI 
is not suitable for absolute quantification of vessel radius and blood 
volume, it may be used to assess the heterogeneity in microvascular 
morphology within tissue. In addition, MR-VSI may be suitable to 
investigate relative inter-tissue microvascular differences and intra-
tissue effects of anti-angiogenic therapy in longitudinal studies.
In addition to the morphological characteristics of micro-
vasculature, the angiogenic activity of solid tumors provides 
information on the expansive capability of their microvascular 
network. For the study described in chapter 6, cNGR-labeled 
paramagnetic quantum dots (cNGR-pQDs) were developed and 
applied to non-invasively assess tumor angiogenic activity using 
quantitative in vivo molecular MRI. Intravenous injection of 
the cNGR-pQDs in tumor-bearing mice resulted in an increased 
quantitative MRI contrast, comprising both increased longitudinal 
relaxation and decreased proton visibility, in the tumor rim but not 
in the tumor core or control muscle tissue. Thus, cNGR-pQDs allow 
in vivo quantification and localization of angiogenic activity with 
MRI. Validation of the MRI results with ex vivo TPLSM showed 
that cNGR-pQDs colocalized primarily with the tumor VEC 
membrane, were to a lesser extent found in the vessel lumen, and 
were not internalized by VECs. In contrast, unlabeled pQDs were 
not or only sparsely detected with both MRI and TPLSM. These 
results indicate a high specificity of cNGR-pQDs for angiogenic 
tumor vasculature.
Numerous studies have established that neo-vasculature affects 
the development of atherosclerotic plaques and solid tumors and 
tentatively contributes to plaque destabilization and spread of 
metastasis. The studies presented in this thesis demonstrate that 
two-photon laser scanning microscopy (TPLSM) and magnetic 
resonance imaging (MRI), at different levels of spatial resolution 
and sensitivity, enable visualization and quantification of 
microvascular morphology and angiogenic activity in murine 
models of atherosclerosis and cancer. However, as described in the 
general discussion (chapter 7), several biological and technical 
limitations may apply to the presented studies, including the use 
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of CD31 as beacon for demarcation of VECs (chapters 4, 5, and 6), 
the relatively low incidence of VV microvessels in atherosclerotic 
mice (chapter 4), and the limited penetration depth of TPLSM 
in atherosclerotic plaques and tumor tissue (chapter 4, 5, and 6). 
Nevertheless, TPLSM has offered the ability to visualize and, with 
dedicated image processing, quantify microvasculature in associated 
with atherosclerotic plaques and tumors. Recent developments in 
endoscope-based TPLSM may widen the scope of these optical 
diagnostics to clinical applications. 
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Nieuwvorming van kleine bloedvaten (angiogenese) levert een 
belangrijke bijdrage aan de ontwikkeling van atherosclerose 
(“aderverkalking”) en kanker, de twee voornaamste doodsoorzaken 
in de Westerse maatschappij. Atherosclerotische plaques en tumoren 
kunnen namelijk groeien doordat nieuw gevormde bloedvaten het 
weefsel voorzien van voedingstoffen en zuurstof en afvalstoffen 
afvoeren. Bloedvaatjes in atherosclerotische plaques ontstaan 
voornamelijk uit de vasa vasorum, een netwerk van bloedvaten in 
de (atherosclerotische) vaatwand, terwijl tumoren door zowel een 
centraal als perifeer netwerk van bloedvaten wordt gevoed. De 
klinische relevantie van atherosclerotische plaques en tumor kan 
in kaart worden gebracht door de morfologie, denk aan de straal 
en dichtheid van de vaten, en de angiogene activiteit van deze 
bloedvaten af te beelden en te kwantificeren. In dit proefschrift 
werden twee-foton laser scanning microscopie (TPLSM) en 
magnetische resonantie beeldvorming (MRI) gebruikt om in 
atherosclerotische muizen en in tumordragende muizen angiogene 
activiteit van de nieuw gevormde bloedvaatjes aan te tonen. 
Vanwege de sub-micrometer resolutie, maakt TPLSM het mogelijk 
de MRI resultaten met grote nauwkeurigheid te valideren. Daarnaast 
werden deze technieken gebruikt om in tumor-dragende muizen de 
morfologie van de nieuw gevormde bloedvaatjes te kwantificeren. 
In hoofdstuk 2 wordt een overzicht gegeven van de mechanismen 
achter angiogenese en de rol die een lage zuurstofspanning (hypoxie) 
hierin speelt. Daarnaast wordt de ontwikkeling van atherosclerotische 
plaques (atherogenese) en tumoren (carcinogenese) beschreven en 
wordt er aandacht besteed aan de bijdrage die nieuwvorming van 
bloedvaatjes in en rond atherosclerotische plaques levert aan de 
mechanische instabiliteit van plaques en de groei van tumoren. 
Verder worden enkele diermodellen van atherosclerose en kanker 
beschreven en worden technieken gepresenteerd om morfologie, 
permeabiliteit en angiogene activiteit van bloedvaten af te beelden. 
Het hoofdstuk eindigt met de basis principes van TPLSM, de 
mogelijkheden die deze techniek biedt om nieuw gevormde 
bloedvaten af te beelden en te kwantificeren, en om als validatie van 
andere beeldvormingstechnieken te dienen.
 Detectie van moleculaire veranderingen (moleculaire 
beeldvorming) in weefsel maakt het mogelijk om ziektes in 
een vroeger stadium te diagnosticeren dan met conventionele 
middelen. Hierdoor kan mede de behandeling van bijvoorbeeld 
cardiovasculaire aandoeningen op individueel niveau worden 
aangepast. Naast de bestaande klinische beeldvormingstechnieken 
kan de verhoogde ruimtelijke resolutie en gevoeligheid van 
optische beeldvormingstechnieken hier een aanzienlijke bijdrage 
aan leveren. Met name de technieken die endoscopisch toepasbaar 
zijn zoals TPLSM, Raman microspectroscopie (RMS), optische 
coherentie tomografie (OCT) en fotoakoestische tomografie (PAT) 
zijn geschikt voor moleculaire beeldvorming van atherosclerotische 
plaques vanuit het lumen van het atherosclerotische bloedvat. Echter, 
optische moleculaire beeldvorming vereist contrastverhogende 
deeltjes (nanopartikels) die specifiek aan het pathologische molecuul 
binden. In hoofdstuk 3 wordt een literatuur overzicht gegeven van 
enkele, mogelijk klinisch toepasbare, optische nanopartikels en 
liganden, welke specifiek zijn voor atherosclerotische plaques. De 
nanopartikels zijn quantum dots (QDs), goud nanopartikels (AuNPs), 
diamant nanopartikels (DNPs), koolstof nanoparticles (CNPs) en 
silica nanopartikels (SNPs). Op basis van de minimale toxiciteit 
bij langdurige blootstelling en de gunstige optische eigenschappen 
zijn AuNPS en SNPs veelbelovend voor toekomstige optische 
moleculaire beeldvormingstechnieken in de kliniek.
Atherosclerotische ApoE-/- muizen worden veelvuldig gebruikt in 
onderzoek naar atherosclerose. In deze dieren gaat de ontwikkeling 
van atherosclerotische plaques gepaard met een toename in vasa 
vasorum dichtheid, zoals gebleken is uit studies met positron emissie 
Samenvatting
114
tomografie (PET) en histologische technieken. In hoofdstuk 4 is 
onderzocht of middels TPLSM (angiogene activiteit van) de vasa 
vasorum van intacte atherosclerotische aorta’s van ApoE-/- muizen 
afgebeeld kunnen worden. De endotheelcellen van de bloedvaten 
werden fluorescerend gelabeld door intraveneus αCD31-FITC 
toe te dienen. De angiogene activiteit van deze endotheelcellen 
werd bepaald door QDs specifiek te laten binden aan CD13 door 
middel van het cyclische tripeptide Ans-Gly-Arg (cNGR) aan het 
QD oppervlak (cNGR-QDs). Vasa vasorum werden gevonden in 
de bifurcatie van de abdominal aorta van ApoE-/- muizen die 20 
weken een hoogcholesterol dieet hadden gekregen. Enkele kleine 
bloedvaatjes, ontsprongen uit de vasa vasorum, drongen in de media 
van de vaatwand door tot een diepte van 60 μm. Vasa vasorum 
werden niet gevonden in andere slagaders van deze muizen. De 
cNGR-QDs hechtten aan de endotheelcellen bij 30% van de vasa 
vasorum, wat erop duidde dat de endotheelcellen daar angiogene 
activiteit vertoonden. Bloedvaatjes in de adventitia van bloedvaten 
waren weliswaar sporadisch aanwezig in de abdominale aorta 
van controle C57BL/6J muizen, maar vertoonden geen angiogene 
activiteit. Deze studie wijst daarmee op hogere prevalentie van 
vasa vasorum in de abdominale aorta van ApoE-/- muizen dan in 
controle C57BL/6J muizen. TPLSM is een goede techniek om de 
vasa vasorum van intacte arteriën af te beelden en kan mogelijk 
gebruikt worden in longitudinale studies ter bepaling van de 
bijdrage van de vasa vasorum aan de mechanische instabiliteit van 
atherosclerotische plaques.
Een niet-invasieve bepaling van de morfologie en dichtheid 
van bloedvaatjes zou het mogelijk maken om ziekteverloop 
te voorspellen, bijvoorbeeld de ontwikkeling van (instabiele) 
atherosclerotische plaques, tumor groei en vorming van uitzaaiing, 
en de effecten van anti-angiogene therapie vast te stellen. Met behulp 
van MRI is het mogelijk om niet-invasief een schatting te maken 
van de straal van de bloedvaten en het fractioneel bloedvolume van 
biologisch weefsel. In hoofdstuk 5 werd de nauwkeurigheid van 
deze techniek geëvalueerd door TPLSM. Hiertoe werden de straal 
en dichtheid van bloedvaten in tumoren en spierweefsel van muizen 
middels beide technieken bepaald. Digitale beeldbewerking werd 
toegepast op de verkregen TPLSM gegevens om de straal, dichtheid 
en de totale lengte van bloedvaten in intact weefsel te bepalen. 
In tumor weefsel waren de bloedvaten willekeurig georiënteerd, 
terwijl in spierweefsel de bloedvaatjes sterk parallel georiënteerd 
waren. Middels beide technieken werd een grotere straal van de 
bloedvaten en een groter fractioneel bloed volume gevonden in 
de tumor periferie dan in de kern. In vergelijking met TPLSM, liet 
de MRI techniek een sterke overschatting zien van de straal van 
de bloedvaten, maar een lager fractioneel bloed volume. Echter, 
beide technieken lieten eenzelfde trend zien: de morfologische 
grootheden in de tumor waren groter dan in de spier en groter in 
de tumor periferie in vergelijking met de kern. Uit deze studie kan 
geconcludeerd worden dat de MRI techniek niet geschikt is voor 
absolute bepaling van de straal van de bloedvaten en het fractioneel 
bloed volume, maar wel gebruikt worden ter bepaling van de 
heterogeniteit in bloedvat morfologie en relatieve verschillen tussen 
weefsels en binnen een weefsel in de tijd. 
Naast detectie van de morfologie biedt het afbeelden van de 
angiogene activiteit van tumoren de mogelijkheid om veranderingen 
in bloedvat dichtheid vast te stellen. Voor de studie beschreven in 
hoofdstuk 6 werden cNGR-QDs zichtbaar gemaakt voor MRI 
door ze paramagnetisch te maken. Deze paramagnetische cNGR-
QDs (cNGR-pQDs) werden toegepast in tumordragende muizen 
om niet-invasief angiogene activiteit te kwantificeren met in vivo 
MRI. Na intraveneuze toediening zorgden de cNGR-pQDs voor een 
verandering in contrast in de tumor periferie, maar niet in de kern van 
de tumor of in het spierweefsel. Validatie van de MRI resultaten met 
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ex vivo TPLSM liet zien dat cNGR-pQDs voornamelijk gebonden 
waren aan endotheelcellen van de bloedvaatjes, in mindere mate 
aanwezig waren in het bloed en niet door de endotheelcellen waren 
opgenomen. Controle pQDs werden nauwelijks tot niet gedetecteerd 
met MRI en TPLSM, wat wijst op een hoge specificiteit van cNGR-
pQDs voor angiogene bloedvaten in tumoren. 
Wetenschappelijke studies hebben veelvuldig aangetoond 
dat nieuw gevormde bloedvaten de groei van atherosclerotische 
plaques en tumoren beïnvloeden. Daarnaast dragen de bloedvaten 
bij aan een mechanische instabiliteit van atherosclerotische 
plaques en vergroten ze de kans op uitzaaiing van tumoren. De 
in dit proefschrift beschreven studies laten zien dat twee-foton 
laser scanning microscopie (TPLSM) en magnetische resonantie 
beeldvorming (MRI) het afbeelden en kwantificeren van de 
morfologie en angiogene activiteit van nieuw gevormde bloedvaten 
mogelijk maken in muismodellen van atherosclerose en kanker. 
Zoals beschreven in de algemene discussie (hoofdstuk 7) zijn enkele 
mogelijke biologische en technische beperkingen van toepassing 
op de opzet van de experimenten: mogelijk is er een betere marker 
voor endotheelcellen dan CD31 voor het onderscheiden van 
bloedvaten in biologisch weefsel (hoofdstukken 4, 5 en 6), moet er 
naar een diermodel gezocht worden met een hogere vasa vasorum 
dichtheid om deze te kunnen kwantificeren (hoofdstuk 4), en zal 
de doordringdiepte van TPLSM in atherosclerotische plaques 
en tumoren vergroot moeten worden (hoofdstukken 4, 5 en 6). 
Desalniettemin, TPLSM maakt het mogelijk om, in combinatie  met 
daartoe ontwikkelde beeldbewerkingssoftware, nieuw gevormde 
bloedvaten rond atherosclerotische plaques en in tumoren af 
te beelden en te kwantificeren. Recente ontwikkelingen in 
endoscopische TPLSM maakt deze techniek mogelijk geschikt voor 
toekomstige wetenschappelijke en klinische in vivo toepassingen.
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